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ABSTRACT 
Viral vector-based vaccines represent an effective means of in vivo antigen 
expression and the ensuing generation of a sustained immune response in the 
host. These new generation vaccines are deemed promising against pathogens 
for which researchers have so far failed to put forth preventive strategies 
and/or effective, accessible, treatment modalities. HIV -1 stands at the 
foremost of this list. In the CUITent study, we have evaluated the use of two 
different viral vector-based vaccines against Clade A of HIV-1, namely 
recombinant modified vesicular stomatitis virus (VSV -A V3) and Adenovirus 
serotype 5 (Ad5) expressing the Gag prote in from subtype A. These viral 
vectors, which are also inherently endowed with adjuvant properties, were 
delivered via a mucosal immunization strategy in a humanized transgenic 
mouse mode!. Transgenic mice expressing both HLA-A*0201 and HLA-
DR *0101 represent a versatile model in which HIV -specific immunogenic 
epitopes and the resulting T cell receptor (TCR) specificity can be determined. 
We show that following mucosal delivery of vaccine, there is induction of 
antigen-specific systemic T cells against epitopes which were previously 
shown to be immunogenic in humans. We next developed novel multimeric 
reagents for the detection of C04+ T cells, namely dodecameric HLA-DR1 
molecules using a murine immunoglobulin M (lgM) scaffold. These reagents 
aim at increasing the overall avidity of peptide-MHC Class II complexes to 
detect low-affinity TCRs. These multimers were able to activate in vitro a 
Jurkat T cell line in an antigen-specific manner. The identification and 
characterization of the molecular requirements boosting the qualitative and 
quantitative features of the immune response to HIV vaccines, in addition to 
the development of novel state-of-the-art immune monitoring tools, will be 
crucial in better understanding of the mechanisms of interaction between the 
virus and the host immune system, leading to rational strategies in the fight 
against the AlOS epidemic. 
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ABRÉGÉ 
Les vaccins à base de vecteurs viraux représentent un moyen efficace 
d'exprimer des antigènes in vivo et d'induire une réponse immunitaire 
persistante chez l'hôte. Cette nouvelle génération de vaccins s'avère 
prometteuse pour la prévention et/ou le traitement des maladies infectieuses 
pour lesquelles aucune stratégie thérapeutique efficace et abordable existe, le 
meilleur exemple d'une telle maladie étant l'infection par le virus de 
l'immunodéficience humaine (VIH). La présente étude porte sur l'utilisation 
de deux différents vaccins à base de vecteurs viraux dirigés contre le VIH-I de 
sous-type A, soient un virus de la stomatite vésiculaire (VSV-AV3) modifié 
recombinant ainsi qu'un Adénovirus de sérotype 5 (Ad5), exprimant la 
protéine Gag de sous-type A du VIH-l. Ces deux vecteurs viraux, qui 
possèdent des propriétés adjuvantes intrinsèques, ont été testés dans le cadre 
d'une approche d'immunisation mucosale en utilisant un modèle de souris 
transgénique humanisée que nous avons développé. Les souris transgéniques 
exprimant les molécules du complexe majeur d'histocompatibilité (CMH) 
humain HLA-A*0201 et HLA-DR*OIOI constituent un modèle idéal 
permettant l'identification d'épitopes immunogènes dérivés du VIH et la 
caractérisation qualitative et quantitative de la réponse des lymphocytes T 
contre les antigènes du VIH. Nos résultats démontrent que suite à une 
immunisation intranasale de ces souris avec les vecteurs VSV -A V3 et Ad5 
exprimant la protéine Gag, il y a induction d'une réponse immunitaire 
spécifique dirigée contre des antigènes viraux préalablement caractérisés chez 
l'humain. Nous avons ensuite développé une nouvelle forme de multimères de 
CMH de classe II (HLA-DR 1) basée sur la structure dodécamérique de 
l'immumnoglobine M (lgM) de souris. Nous avons démontré que ces 
dodécamères de HLA-DRI, lorsque chargés avec un peptide, activent une 
lignée cellulaire de lymphocytes T Jurkat possédant un récepteur de cellules T 
(TCR) spécifique à ce peptide présenté par la molécule HLA-DRI. 
L'identification et la caractérisation des déterminants moléculaires qui 
contrôlent l'induction de la réponse immunitaire par les vaccins contre le VIH, 
en combinaison avec l'émergence de nouvelles technologies permettant un 
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meilleur suivi de la réponse immunitaire, permettront de mieux comprendre 
l'interaction entre le VIH et la machinerie cellulaire de l'hôte et faciliteront le 
développement de nouvelles stratégies préventives et thérapeutiques dans le 
combat contre l'épidémie du VIH/SIDA. 
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1.1 The Immune System: an Overview 
The ability of multi-cellular organisms to defend themselves against invasion 
by pathogens de pends on their ability to mount immune responses. While ail 
metazoans have inborn defense mechanisms which constitute the innate 
immunity, jawed vertebrates, in addition, are able to mount specific defense 
mechanisms collectively known as adaptive immunity. 
1.1.1 Innate Immunity 
Through the innate immunity, pathogens are recognized by a set of receptors 
encoded in the germline. These receptors known as PRRs (pattern recognition 
receptors) have a broad specificity and recognize many related molecular 
structures called PAMPs (pathogen-associated molecular patterns). PAMPs 
are essential polysaccharides and polynucleotides that differ little amongst 
pathogens but are not found in the host. Different defense mechanisms have 
evolved for eons in eukaryotic organisms with two evolutionarily conserved 
modalities being the complement component C3 and the Toll receptor 
pathway 1,109. 
Thiolester-containing molecules with highest similarity to C3 have been 
detected to the level of the diploblastic (two-germ layer) corals and molecules 
known as TEPs (thiolester-containing proteins) capable of making covalent 
linkages to pathogens inducing opsonization have been also detected in 
mosquitoes and other insects 2,3-5. Of the three functions of the complement 
system - opsonization, direct Iysis of pathogens, and inflammation - the very 
first might be the evolutionarily oldest mechanism. The classical pathway and 
the membrane-attack complex (MAC) seem to have arisen in the jawed 
vertebrate lineage, while the alternative pathway and lectin pathways are older 
mechanisms 6. 
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Toll receptors have been observed in invertebrates and in plants. The detection 
of the signal-transduction mechanisms induced by bacterial and fungal 
pathogens in insects and the crucial involvement of this pathway in 
embryological development 7 led to the discovery ofToll-like receptors (TLR) 
in mammals, thus opening up an entirely new field of immunity 8,9 ,JO. 
On the other hand, cytokines, which are studied extensively in mammals, and 
also present in jawed vertebrates, appear to be absent in invertebrates. In the 
recent analysis of a urochordate genome, only a tumor necrosis factor (TNF) 
and IL-8 homologues were found. This argues that indeed, with the emergence 
of adaptive immunity in the jawed vertebrates, there seems to be an emergence 
of a host of supporting molecules and machinary required for function, 
maintenance, and regulation of the adaptive system Il,109. 
1.1.2 Adaptive Immunity 
A remarkable event in the evolution of the vertebrate immune system was the 
seemingly abrupt emergence of adaptive immunity at the jawed vertebrate 
stage. While every major component of the mammalian adaptive immune 
system, such as the MHC, TCR, and 19 molecules, as weil as the genes 
directly involved in somatic generation of diversity, such as RAG 1 and 2, have 
been identified in the cartilaginous fish, ail attempts to isolate these genes 
from more distant organisms to bony vertebrate than cartilaginous vertebrate 
(i.e., the jawless fish and below) have not been successful 12,109. 
Even though sorne recent results hint at the presence of an ancestral adaptive 
immune system, such as the presence of lymphocyte-Iike cells and orthologues 
to mammalian Iymphocyte-specific genes reported in lamprey 13, 14 and a 
possible proto- MHC region identified in amphioxus 1\ direct predecessors of 
any compone nt of adaptive immunity have never been identified. However, 
one should be mindful that these results were based on techniques such as low-
stringency cloning which are not infallible. A systematic search for adaptive 
immune-related genes or their precursors has not yet been possible in jawless 
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vertebrates or invertebrate deuterostomes, due to the absence of a complete 
genome sequence of a suitable organism. 
In higher vertebrates, the adaptive immune system is defined by the clonally 
distributed antigen receptors (immunoglobulins (lg) and T cell receptors), 
recombination-activating gene (RAG)-mediated gene rearrangement, primary 
and secondary Iymphoid tissues, major histocompatibility complex (MHC)-
encoded class 1 and class II molecules, and somatic hypermutation, which is 
activation-induced cytidine deaminase (AID)-dependent in every species so 
far examined. This system is further identified by the functional attributes of 
highly-diverse, clonally-distributed antigen receptors and by memory 
responses. These features are found in ail jawed vertebrates, with cartilaginous 
fish being the phylogenetically oldest group 16. 
Until recently, none of these structural, mechanistic, or functional 
characteristics were detected in invertebrates or in jawless vertebrates 
(Iamprey and hagfish). Thus, the emergence of adaptive immunity is believed 
to have been made possible by the invasion of a transposable element into an 
immunoglobulin (Ig) superfamily (st) gene sometime early during the 
evolution of the jawed vertebrates (possibly a placoderm).This initiating event 
probably resulted in a mechanism to somatically generate diversity in antigen-
receptor genes, and it was the innovation propelling the "Big Bang" that 
resulted in the emergence of adaptive system 16.104. 
1.1.3 The Major Histocompatibility Complex. 
ln order to distinguish 'self from 'non-self, the T cell receptor (TCR) on T 
cells must be presented with a relevant epitope cleaved from a given antigen. 
Class 1 and Class II Major Histocompatibility Complex (MHC) molecules 
provide the molecular cradle for peptide presentation. The MHC glycoproteins 
are encoded by a cluster of genes tirst identified due to their involvement in 
potent immune responses to transplanted tissues, thence the term Major 
Histocompatibility Comp/ex. We now know that within this region of the 
genome, in addition to those genes encoding the MHC molecules, are many 
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genes expressing accessory proteins involved in the generation of 
MHC:peptide complexes 16, 17,18. 
ln humans, the MHC genes are located on chromosome 6 and in mice, on 
chromosome 17. The organization of the MHC genes is roughly similar in 
both species with separate clusters for MHC class 1 and class II genes, 
although in the mouse an MHC class 1 gene (H-2K) appears to have 
translocated relative to the human MHC, so that the class 1 region in mice is 
split in two. The genes encoding the a chains of MHC class 1 molecules and 
the a and ~ chains of MHC class II molecules are linked within the complex; 
however, the genes for ~2-microglobulin and the invariant chain are on 
separate chromosomes (chromosomes 15 and 5, respectively, in humans and 
chromosomes 2 and 18, in the mouse). MHC loci are polygenie containing 
several different MHC class 1 and MHC class II genes, in such a way that 
every individual possesses a unique set of MHC molecules with different 
scopes of peptide-binding specificities. Moreover, the MHC is highly 
polymorphie, Le. there are multiple variants of each gene within a given 
population. In fact, the MHC genes are the most polymorphic genes known to 
date 19. 
1.1.3.1 MHC Class 1 
Class 1 MHC molecules are present on aIl nucleated ceIls, and are mainly 
involved in the recognition of 'self antigens. Aiso known as HLA class 1 
(Human Leukocyte Antigen) in humans and H-2 Class 1 Complex in mice, the 
MHC class 1 molecule consists of two polypeptide chain s, namely a variable 
heavy chain (al-a2-a3) and a constant light chain (~-2-microglobulin). An 
antigenic peptide of 9 amino acids (AA) is presented in the cleft formed by the 
heavy chain. Class 1 molecules are involved mainly in the presentation of 
endogenous antigens to C08 positive (C08+) cytolytic or NK ceIls 19,24. 
ln humans, the classical MHC class 1 consists of the highly polymorphic HLA-
A, HLA-B and HLA-C, and the so-called non-classical, class 1 - like 
molecules, which include HLA-E, F, G, and COI. In the mouse, there are also 
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3 main class 1 genes, known as H2-K, -D, and -L. Many haplotypes of the 
mouse MHC, H2, are still known through the names given to them by 
American geneticist and Nobel prize co-recipient, Dr. George Snell, starting in 
1948, including d for dilute of DBA/2, b for black of C57BL, p for pink-eyed 
of P, k for Kinky of K8, and s of A.S W, among others 20. 
1.1.3.2 MHC Class II 
The class II region (of chr. 6 in human and chr. 17 in mouse) includes the 
genes for the a and 13 chains of the classical antigen-presenting MHC class II 
molecules HLA-DR, -OP, and -DQ in the human, and H-2A and H-2E in the 
mouse. Both the a and the ~ chains of MHC II exhibit a high degree of 
polymorphism (except for the monomorphic DR a chain). In addition, both 
alleles of each locus are co-dominantly expressed, thus fully heterozygous 
individuals express 6 different MHC class II molecules 18,19. 
The non-classical MHC class II (HLA-DM, HLA-DO in human; H-2M and H-
20 in mouse), which show only limited polymorphism, are also present in this 
region. In addition, the genes for the TAPI-TAP2 peptide transporter, the 
LMP (Low molecular Mass Polypeptide) genes encoding proteasome subunits, 
and the gene for tapasin (T APBP) are also in the MHC class II region in 
humans. In the mouse, the TAPBP gene is present in the Class 1 region 21. 
The classical MHC class II molecules are involved in presenting antigenic 
peptides to CD4 positive (CD4+) T lymphocytes. They are expressed on the 
surface of professional antigen presenting cells (APC) (i.e. B cells, 
macrophages, dendritic cells); epithelial cells of the thymus (both in the 
medulla and cortex); on fibroblasts, mast cells and epithelial cells following 
induction by IFN-y; and on human activated T-cells. 
The non-classical MHC class II molecules are not found on the cell surface. 
These molecules are involved in modulating proper transport and binding of 
antigenic peptides to the classical MHC class II molecules. HLA-DM is 
expressed by the same cell types as the classical MHC molecules while HLA-
20 
DO expression is believed to be restricted to B lymphocytes, subset(s) of 
dendritic cells, and to both cortical and medullary epithelial cells of the 
thymus 22,23. 
The cJassical MHC Class II molecule is composed of two non-covalently 
associated membrane spanning glycoproteins, an alpha chain of 33kDa and 
beta chain of 28kDa. Each chain has two extracellular globular domains (a l, 
a2, pl and P2), in addition to transmembrane and cytoplasmic domains. 
Together, the al and pl domains form the peptide binding groove with open 
end s, thus being capable of binding peptides of variable length (12-30aa) 24,25. 
Antigens presented in the context of MHC cJass II molecules derive from 
extracellular proteins that access the endocytic route where they are processed 
and bind to MHC cJass II molecules. It is noteworthy however, that in normal 
circumstances, most of the proteins found in the endocytic/lysosomal 
compartments consist of membrane proteins being internalized and degraded 
as part of their due turnover. Consequently, most of the peptides eluted from 
the cell surface MHC cJass II molecules are endogenous proteins. Even in the 
presence of high concentrations of an exogenous antigen, it was observed that 
only a minor fraction of cell surface MHC cJass II proteins are loaded with 
peptides derived from that antigen. Interestingly, immature dendritic cells are 
very efficient in capturing sm ail amounts of antigen, and following 
inflammation-induced maturation, DCs can present these captured antigens at 
very high levels for a prolonged period oftime 26. 
1.1.3.3 MHC Class III 
The so-called MHC cJass III genes, which map within the MHC region, 
encode various proteins with crucial functions in immunity. These incJude 
sorne of the complement system components (e.g. C2, C4, and factor B), 
cytokines (e.g. tumor necrosis factor-a, TNF-a), and lymphotoxin (TNF-I3) 27. 
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1.1.4 Mucosal Immunity 
1.1.4.1 Overview 
Regulating a critical symbiotic environment between the host and commensal 
organisms, while acting as a tirst line of physical and immunological defense 
against pathogenic insult, the mucosal immune system, long understated, has 
gained rightful attention during recent years, especially in the context of 
mucosal vaccines. Functioning through both its innate and acquired 
components, the mucosal immune system regulates homeostasis along an 
extensive epithelial surface area, covering the oral and nasal cavities till the 
respiratory, digestive and genito-urinary tracts. 
Antigen-specific immune responses are initiated at special sites of the mucosa-
associated Iymphoid tissue (MALT). Microfold (M) cells, which are 
structurally and functionally specialized for transepithelial transport, are found 
in the epithelium overlying follicles of the MALT and deliver foreign 
antigens and microorganisms to organized lymphoid tissues within the 
mucosae of the small and large intestines, tonsils, adenoids, and airways5, 28, 29. 
Moreover, follicles localized in MALT contain a host of immune cells 
required for the generation of an effective immune response, including APC's, 
T cells, and B cells. Two major components of the MALT are the Peyer's 
patches in the gut and the nasopharynx-associated lymphoid tissue (NALT). 
The relative distribution of these secondary Iymphoid structures is however 
greatiy species-dependent. ln humans, near 1000 Peyer's patches can be found 
in the terminal ileum, while mice or rats possess 2-11 larger patches evenly 
distributed throughout the small intestine. Likewise, bronchus-associated 
secondary Iymphoid tissue is prominent in rabbits but not humans. These 
species-specitic differences have been attributed to varied environmental set-
ups which, in consequence, dictate a diverse antigen exposure in different 
species. 
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On the other hand, the Common Mucosal Immune System (CMIS) connects 
antigen exposure and inductive sites of the mucosal surfaces with effector sites 
of the lamina propria or glandular tissue. Antigen-specific T helper 2 (Th2) -
dependent IgA responses, as weil as Th 1 and cytotoxic T lymphocyte (CTL)-
dependent immune responses function as the first line of defense at mucosal 
surfaces. 
Thorough understanding of the biology, tissue genesis, and immunological 
function of different mucosal sites is critical for the appropriate manipulation 
of the MALT immune system towards the generation of much awaited for 
mucosal adjuvants and vaccines, in the context of a host of infectious diseases. 
1.1.4.2 NAL T vs GAL T Organogenesis 
Even though NAL T and gut associated mucosal tissue (GALT) demonstrate 
functional similarities as antigen encounter and mucosal inductive sites, they 
have different characteristics in terms of both kinetics and cytokine 
requirement in their programmes of Iymphoid organogenesis. Kiyono H. and 
Fukuyama S. provide an in depth review of these distinct features in the light 
ofmucosal vaccine development 30. 
Remarkably, different homing receptors are expressed in NAL T vs. GAL T. 
While high endothelial venu les (HEVs) associated with Peyer's patches 
express mucosal vascular addressin cell-adhesion molecule-l (MADCAM1), 
HEVs associated with NALT express peripheral-node addressin (PNAD). In 
terms of tissue genesis, vascular cell adhesion molecule-l (VCAM-l) 
expression was shown to be associated with the development of Peyer's 
patches at 2 weeks following coitus, while formation of mature NAL T tissue 
was completed only 5-8 weeks following birth, and the postnatal initiation of 
NAL T formation is believed to be facilitated through exposure to 
environmental antigens and mitogens. In addition, cytokine-mediated 
organogenesis mechanisms differ between NALT, Peyer's patch, and 
peripheral lymph node development. Lymphotoxin (L T), tumour necrosis 
factor (TNF), interleukin-7 (IL-7), and their corresponding receptors are 
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crucial to the development of secondary lymphoid tissue genesis, including 
Peyer's patch development. Moreover, a subset of mononuclear cells with 
IL7R+CD3TD4+CD4S+ phenotype, which also express CXCRS, has been 
implicated in the development of Peyer's patches and are known as Peyer's 
patch inducer cells. In contrast, NAL T formation seems to be independent of 
the signalling cascade which involves L T and IL-7 receptors. In addition to the 
accumulation of CD3-CD4+CD4S+ in the intestinal tract during embryonic 
stages of development, this subset of ce Ils was also observed at the site of 
NAL T formation postnatally, and their involvement in NAL T organogenesis 
was proven through adoptive transfer experiments 30. 
1.1.4.3 The Common Mucosal Immune System 
The common mucosal immune system (CMIS) is an integrated pathway which 
enables generation of antigen-specific immune responses, by concerting 
signaIs from inductive sites of MALT with the more distant effector sites 
found in the diffuse mucosal tissues. Antigens encountered in the 
nasopharyngeal or GI lumen are transported to NALT or Peyer's patches via 
M cells. Dendritic cells uptake and present these antigens to T cells of the se 
organized Iymphoid tissues, or neighbouring cervical and mesenteric Iymph 
nodes. 
Sensitized CD4+ T cells help induce IgA-committed B cell development in the 
germinal centre of Iymphoid follicles. Following IgA class switching and 
affinity maturation, B cells migrate to the mucosal effector sites through the 
thoracic duct and blood circulation. Similarly, antigen-specific activated or 
memory T cells emigrate from the initial environment via Iymphatic drainage, 
circulate through blood, and home to mucosal effector sites. Indeed, in a 
healthy human, the mucosal immune system integrates around 80% of ail 
immunocytes. In addition to the conventional CD4+ and CD8+ a~ T cells, 
mucosal tissues also contain T cells with a more Iimited repertoire diversity, 
including y8 T cells and NKT cells. 
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The presence of antigen-specific s-IgA and CTL at mucosal surfaces further 
from inductive sites where the initial antigen encounter takes place, is a 
concrete evidence of CMIS, and supports the rationale that mucosal vaccine 
administration through either NAL T or GAL T is a convenient approach to 
induce efficient immune responses in various mucosal effector tissues 30,31. 
1.1.4.4 Mucosal Effector Sites 
Mucosal effector sites include the nasopharyngeal passages and intestinal 
lamina propria, as weil as the reproductive tract and secretory glandular tissues 
such as mammary, sali vary, and lacrimal glands. These are the sites where 
IgA + B cells and plasmablasts differentiate into IgA-producing plasma cells in 
the presence of appropriate cytokine signaIs such as IL-5 and IL-6 produced 
by CD4+ Th2 cells. This in turn leads to production and secretion of dimeric 
IgA, which upon binding to polymeric Ig receptors on epithelial cells lining 
the mucosa are transported and released in the respiratory passages and 
intestinal tract. The mucosal effector sites are also a niche where antigen-
specifie T cells perform their cytotoxic or regulatory functions towards 
protection of mucosal surfaces. 
However, it is noteworthy that mucosal effector sites, which serve as a barrier 
against a host of environmental antigens and mucosal pathogens, are endowed 
with mechanisms of protection that are significantly different from that of 
inductive sites. These include increased populations of IgA + plasma cells, and 
large numbers of Band T lymphocytes in the intestinal lamina propria. In the 
mou se, several studies have observed that the CD4+ T cells of the lamina 
propria contain high numbers of IL-5 secreting Th2 type cells, indicating that 
the effector sites of mucosal immune system are biased toward a Th2 
phenotype, which is also a key component of the mechanism involved in the 
induction of 'oral tolerance'. IFN-y-producing CD4+ cells have been shown to 
be important in the mucosal immune defense, although details of their 
protective mechanism(s) need to be elucidated 31,105. 
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In addition to its barrier and mechanical cleansing function, mucosal tissues 
are endowed with different chemical antimicrobial factors, including defensins 
provided by the lining epithelial cells or underlying components of the innate 
immune system. Ali in ail, mucosal surfaces present a complex environment 
which requires well-concerted mechanisms of immune surveillance. 
1.2 HIV and Current Status of AIDS Vaccines 
1.2.1 Overview 
1.2.1.1 The HIV virus 
HIV -1 was first isolated in 1983, concurrently by three independent groups 106, 
107,108. Three years later, a genetically related virus was identified and named 
HIV -2. Both HIV -1 and -2 are known today to be related to distinct families of 
the Simian Immunodeficiency Virus (SIV), and it is believed that multiple 
zoonotic infections with SIV have led to the evolution of HIV species. HIV-l 
is a retrovirus belonging to the genus Lentivirus. Its genome consists of two 
copies of single-stranded RNA and its life cycle is dependent on a RNA-
dependent DNA polymerase, namely, the reverse transcriptase (RT). RT is a 
markedly error-prone enzyme, because it lacks the 3' exonuclease activity. 
Particular mutations resulting from this defective proofreading ability lead 
sometimes to a survival advantage of the virus in the host. This inherent 
characteristic ofRT is also responsible for the tremendous genetic diversity of 
HIV -1 within an individual, leading to a broad diversity of viral quasispecies. 
RT reverse transcribes the viral RNA into a linear dsDNA which is 
subsequently integrated into the host DNA genome in a non-site-specific 
manner. It is this integrated form of 'proviral' DNA that is later transcribed 
through the host cell machinery to generate viral particles. 
The retroviral gene products consist of structural proteins, including Gag, Pol, 
and Env, the proviral sequence being tlanked on both ends by two U3-R-U5 
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long terminal repeats (LTRs). Sequences in the LTR are responsible for the 
promoter, enhancer, and modulatory machinery, in addition to containing 
RNA regulatory sequences. Moreover, HIV -1 genome possesses nine open 
reading frames (ORFs). The gag gene encodes for a single ORF, giving rise to 
the p55 polyprotein. The latter is subsequently processed into matrix (MA, 
p 17), capsid (CA, p24), p2, nucleocapsid (NC, p7), pl and p6 proteins, 
involved in the structural association of the virion. The pol ORF yields RT and 
its RNAse H component, in addition to the integrase enzyme (which leads to 
viral DNA insertion into the host genome), and protease enzyme (which is 
crucial for processing viral polyproteins). The env gene encodes for the 
envelope gp 120 and trans-membrane gp41 proteins. gp 120 is responsible for 
viral cell-specific tropism, while gp41 assists viral fusion. 
In addition, HIV -1 contains six non-structural genes. These include tat, which 
encodes a trans-activating element crucial in viral RNA transcription and 
elongation, and rev the product of which serves as a post-translational 
transactivator involved in proper slicing, shuttling, and translation of viral 
RNA. The other non-structural genes consist of vif, vpr, vpu and nef Vif and 
Nef are particularly important in enhancing viral infectivity and immune 
evasion. The exact purpose and detailed mechanism(s) of action of the 
accessory gene products are an ongoing subject of many studies and remain to 
be fully elucidated 32. 
1.2.1.2 HIV -1 Clades and Subtype Diversity 
HIV -1 isolates are classified into three clades: M, N and O. Clade M is the 
main clade and comprises subtypes A-H and J-K. Globally, one observes a 
heterogeneous demographic and geographical distribution of individuals 
infected with different clades or subtypes of HIV -1. For example, subtype A 
and A/G recombinant variants predominate in west and central Africa, while 
subtype B has been the main species encountered in Europe and the Americas. 
However, due to increasing immigration and globalization, about 25% of new 
infections in Europe currently stem from non-B African and Asian variants. 
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On the other hand, subtype C is mainly encountered in southem and eastem 
Africa, India, and Nepal. This subtype has created the recent epicentres of the 
HIV pandemie by its uncontrolled spread through different regions of Africa 
and Asia. Subtype D is generally encountered in east and central Africa, with 
sporadic cases occurring in southern and western Africa. Subtype E manifests 
as an AIE mosaic detected in Thailand, the Philippines, China, and Central 
Africa, while subtype F has been reported in central Africa, south America and 
eastem Europe. Gand A/G recombinant viruses have been observed in 
western and eastern Africa as weil as in central Europe. H has only been 
detected in central Africa. J has been reported exclusively in central America. 
K has recently been identified in the Democratie Republic of Congo and 
Cameroon. 
Additional subtypes are constantly being discovered, and migrating 
populations are shaping new patterns of subtype distribution. HIV -1 clades C 
and A, as weil as the A/G and AIE recombinant forms, are nowadays of 
special concern, because these represent the predominant subtypes in Africa 
and Asia where HIV disease is spreading most rapidly. 
Classification of HIV -1 subtypes springs from the 20-50% discrepancy that 
exists in envelope (env) nucleotide sequences. Moreover, within the M 
subgroups, interclade env variations is around 20-30% in addition to 
intraclade variation of 10-15%. Divergence in the pol region of HIV -1 is less 
prominent th an that of env since, as mentioned above, this region encodes for 
the crucial RT, integrase, and protease enzymes. If the latter are excessively 
mutated, they affect adversely the infectivity of the virion. gag sequences are 
even less prone to mutations, since they yield the relatively stable core 
proteins. Thus, vaccines against Gag epitopes may be promising due to 
conservation of intra- and inter-clade regions 33.34. 
1.2.2 Identification of Correlates of Protection 
A hallmark of HIV -1 disease progression is CD4 T cell dysfunction. In 
primary HIV infection, there is a sharp decrease in the number of circulating 
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C04 T lymphocytes. Low C04 counts are attained by patients in chronic HIV 
infection leading eventually to Acquired Immunodeficiency Syndrome 
(AlOS). In addition, the ratio of circulating C04 to C08 T cells is inversed in 
chronic stages of HIV infection. Complex viral and host factors contribute to 
disease progression and susceptibility to AlOS. A specific group of HIV 
infected individuals known as long term non progressors (L TNP), control 
viremia for extended periods of time and do not progress to AlOS. This is 
thought to be partly related to host-factor variability, including genetic make-
up, and studies of the immunogenetic profile of the se individuals may lead to a 
better understanding of correlates of protection during the course of a natural 
infection with HIV -l, as weil as to the development of tailored therapeutic 
strategies in HIV -infected persons 35,118 • 
In chronic viral infections, virus-specific T -cells have been shown to be 
crucial for effective control of virus replication and prevention of disease. 
While EBV and CMV infections are prototypes whereby cell mediated 
immunity plays a major role in controlling infection, it is evident that HIV -1-
specific cell-mediated responses often fail in controlling infection and ensuing 
pathogenicity. Recently, and in order to better understand correlates of 
protection and heterogeneity of cellular responses, a number of phenotypic 
markers have been identified and functional readouts put forth to characterize 
virus-specific C04+ and C08+ T cell responses 10. 
These signatures of protective antiviral cellular immunity indicate that 
polyfunctional (i.e. IL-2 and INF-y secretion, and proliferation), and not 
monofunctional (i.e. IFN-y secretion alone) C04+ and C08+ T-cell responses 
represent correlates of prote ct ive antiviral immunity in chronic viral infections 
36,10 
It has also been observed that both antigen load and persistence are associated 
with functionally distinct types of T cell subsets. For instance, predominance 
of IL-2 secreting cells alone was associated with antigen clearance while IFN-
y secreting cells alone are typical during antigen persistence and elevated 
antigen levels. On the other hand, a polyfunctional IL-2 and INF-y response 
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reflects a protracted antigen exposure and low antigen load. It is noteworthy 
that in subjects with nonprogressive HIV -1 infection, virus-specific CD4 cells 
are polyfunctional. Similarly, high frequencies of monofunctional HIV-l 
specifie CD8+ cells secreting IFN-y fail to control viral replication and there is 
skewing of memory CDS+ T cells toward IFN-y secretion with impaired 
capacity to pro li ferate. On the other hand, in L TNP individuals carrying HIV-
1, as weIl as in CMV and EBV infections, the presence of antigen-specific 
CDS+ cells with the ability to proliferate and secrete IL-2 is believed to be 
associated with low viral loads and effective viral control 37. 
With regard to humoral immunity, and despite substantial research on the 
function of neutralizing antibodies, their role in conferring 'sterilizing 
immunity' and impact on the control of established, chronic HIV -1 infection 
remain to be elucidated, especially if one considers the very rapid generation 
of viral escape variants. 
Moreover, one should bear in mind that correlates of protection during the 
natural course of HIV -1 infection might not necessarily represent responses 
induced in the presence of pre-existing vaccine-related immunity. Therefore, 
rational and carefully crafted clinical trials and appropriate state-of-the-art 
immune monitoring tools are crucial to determine how pre-existing immunity 
can shape the outcome ofHIV-1 infection 4. 
1.2.3 Current HIV Vaccines 
Two major obstacles to the advancement of vaccine development are the latent 
persistence of the virus in the host genome and the high error rate of RT. 
Neutralizing antibodies block the viral entry process by binding to surface 
gp 120, however, the generation of the latter against primary viral isolates has 
been hindered due to poor accessibility of the receptor binding site and 
gp 120' s heavy glycosylation. 
Two major targets for a potential HIV vaccine involve, on one level, the virus 
entry, and on another, the replication process. Concurrent advances in our 
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understanding of the details of immune mechanisms following HIV infection, 
and the development of novel quantitative immune monitoring tools dissecting 
the Ag-specific cellular response, have assisted explore a new generation of 
vaccines which induce T cell responses. Several experimental studies have 
yielded promising results in primate models, yet these data show that, overall, 
novel T -cell-based vaccines do not pre vent, but rather control challenge. A 
potential problem in such a scenario is that of viral escape from immune 
control 38 . 
To summarize, in the course ofHIV infection, protective mechanisms ofCD8+ 
T lymphocytes include: cytolotic function against infected ce Ils, suppression 
of viral replication through soluble cellular factors, and prevention of viral 
entry by blockade of chemokine co-receptors by secretion of chemokines such 
as MIP-l a, MIP-l~, and RANTES. More than 200 HIV -1 specific T cell 
epitopes have been mapped to date and despite an overwhelming viral 
genomic diversity, there is a fair amount of intra- and inter- subtype 
conservation. The vast majority of CUITent vaccines candidates target the 
induction of cell-mediated immunity. These vaccines are now known as T cell 
vaccines. Among the se, two types of vector-based vaccines have shown 
considerable potential, and have entered c1inical evaluation, namely viral-
vector and DNA-based vectors 39. 
The viral vector-based vaccines under assessment include poxvirus (such as 
MV A and NYV AC) and adenovirus (Ad) based vaccines. In addition, 
canarypox based vaccines such as AL V AC are being tested. A variety of 
prime-boost regimens, in conjunction with heterologous viral, DNA, or protein 
based vaccines, have been widely undertaken. Results show that DNA and 
poxvirus based vaccines, when used alone, result in limited immunogenicity 
characterized by transient T ceIl responses, but are effective when used in 
prime-boost combinations 40,41,137. 
When compared to recombinant adenoviral (Ad5) based vectors, DNA and 
poxvirus vaccine candidates have shown a dominant CD4 T cell response with 
minimal CD8 T cell responses, while Ad5 based vaccines result in both CD4 
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and CD8 responses. Moreover, the latter were shown to have the highest 
immunogenicity and long-lasting cellular responses. However, a major 
drawback of adenovirus based vaccines in humans is the generation of anti-
vector antibodies or pre-existing immunity to adenovirus in the population 
(50% in the case of US population). This has been suggested to be overcome 
by immunization with higher doses of immunogen and/or priming with 
heterologous vector that is not subject to neutralizing antibodies (i.e. DNA 
vectors) 39. 
There are still several challenges which hinder the development of successful 
AIDS vaccines. Neutralizing antibodies cannot readily access their targets, 
since conserved epitopes are thermostably concealed, while exposed sites are 
highly variable. In addition, these sites are camouflaged by heavy 
glycosylation. On the other hand, latent proviral DNA establishes in niches 
early during the course of infection and has a long half-life. Moreover, and as 
described earlier, HIV has high variability, with 12 known subtypes, inter-
subtype recombinants, and high error rate RT enzyme 38. 
The complex array of the above parameters, including different viral 
pathologic and host defense mechanisms during the course of the infection, 
should be taken into account toward adopting a rational approach in the 
ongoing quest of vaccine design 42. 
1.2.4 Need for mucosal vaccines 
Perhaps the most important example to highlight the need and importance of 
targeting the mucosal immune system is the fact that over 80% of HIV 
infections occur via sexual transmission. Mucosal tissues are the primary site 
of natural HIV infection, and represent a major reservoir for viral replication. 
Enhancing immune responses at mucosal surfaces would prevent viral 
dissemination, as weIl as clear viral reservoirs of replication 79, 114. In this 
context, it has been shown that CTL cells should be present in mucosal sites to 
prevent viral transmission, while systemic CTL alone are not sufficient 38. A 
number of delivery routes have been used in experimental mucosal AIDS 
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vaccines, including intranasal, intrarectal, intravaginal, as weil as 
transcutaneous and iliac lymph no de targeted vaccines, to enhance the mucosal 
immune response 115. 
An ideal HIV vaccine should induce a broad array of cross-reactive 
neutralizing antibodies and increased levels of antigen specific effector and 
memory T lymphocytes, specifically targeting the generation of long-term 
responses at mucosal surfaces 43,110. 
1.3 Mucosal Vaccines and Immunization Strategies 
l.3.1 Mucosal Vaccines 
In the development of mucosal vaccines, it is critical to carefully select both 
an effective delivery route and vehicle. Most common strategies and routes 
target the natural encounter of mucosal sites with the antigen in question. 
Mucosal immunizations most commonly are performed through either oral or 
intranasal administration. A key and much sought-after advantage of mucosal 
immunization is the fact that this approach results in the induction of both 
mucosal and systemic arms of the immune response in the host. 
1.3.2 Intranasal Vaccines 
As described in section 1.1.4.2, NAL T is an important component of the 
organized lymphoid tissue. In rodents, NAL T is located on both sides of the 
nasopharyngeal duct and corresponds to the Waldeyer's Ring in humans, 
which includes the palatine tonsils and adenoids. Moreover, structures similar 
to NAL T, in forms of follicles, have been identified in the middle concha of 
children less than two years of age. 
Endowed with ail necessary elements for the generation of a successful 
immune response upon encounter of antigen, NAL T represents an attractive 
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target as a site for immunogen delivery and uptake. This route of vaccine 
administration has proven to elicit both humoral and cell-meditated immune 
responses. In addition, when compared to oral vaccines, intranasal (Ln.) 
vaccines require a smaller antigen dose and less adjuvant, since antigens are 
not exposed to the degrading effect of enzymes and low pH as in the digestive 
tract. Importantly, intranasal administration of the vaccine results in the 
induction ofboth mucosal and systemic antigen-specific immune responses 30. 
To increase the efficiency of NAL T targeted immunogens in stimulating 
effector cells associated with NAL T, there is a need to develop safe and potent 
mucosal adjuvants as a component of nasal vaccines. 
1.3.3 Mucosal Adjuvants 
Mucosal adjuvants have been widely studied in the context of oral vaccines. 
Among the se, the cholera toxin (CT) of Vibrio cho/erae and the heat-labile 
enterotoxin (ET) of Escherichia coli, have been successfully used in 
experimental systems with the aim of generating toxicologically acceptable 
derivatives for human use. The B subunits of these toxins act by binding to 
ganglioside GM receptors of intestinal epithelial cells, and translocate the A 
subunit into their cytosol, leading eventually to activation of adenyl cyclase 
and the subsequent elevation of cyclic adenosine monophosphate 44. 
Recombinant CTB (subunit B of CT), used in combination with different 
antigens, is able to either induce mucosal sIgA responses to pathogens or 
result in peripheral anti-inflammatory tolerance to self-antigens. Both CT and 
ET are pote nt adjuvants when administered by oral, intranasal, or even 
parenteral route. However, it is weil known that, in humans, both result in 
severe diarrhea and clinical symptoms of enteritis. Several studies have 
attempted to reduce the toxicity of these molecules while retaining their 
adjuvanticity through the generation of mutant counterparts 44,45 • 
Other mucosal adjuvants include hybrid molecules such as CTAI-DD, 
whereby the Al subunit of CT is linked to an APC-binding protein derived 
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from the bacterium Staphylqcoccus aureus (Prote in A). This molecule helps 
specifically target antigens to B ce Ils, and has been used safely in intranasal 
immunizations 45. 
On the other hand, bacterial DNA or synthetic oligonucleotides which contain 
unmethylated CpO motifs, have been also shown to act as effective mucosal 
adjuvants through the stimulation of TLR-9, thus initiating an immune-
modulatory cascade 46. 
When rationally designed, mucosal adjuvants can help successfully direct the 
mucosal system towards a desired response. Besides, mucosal adjuvants are 
needed not only to boost mucosal and systemic immunity, but also to prevent 
the generation ofmucosally induced tolerance. 
1.3.4 Mucosal Tolerance 
In addition to the induction of antigen-specific IgA and serum IgO responses 
following mucosal immunization, the introduction of proteins at mucosal 
inductive sites often results in the induction of systemic unresponsiveness or 
tolerance. This approach is useful in the context of preventing allergic 
responses to food proteins and allergens, and in the treatment of auto immune 
diseases through administration of self-antigens. 
Oral intake of a single high dose or repeated low doses of proteins was shown 
to result in peripheral tolerance along the generation of mucosal IgA 
responses. Systemic unresponsiveness was also observed following intranasal 
delivery of proteins, still the majority of the data and immune mechanisms 
involved therein emanate from studies involving oral administration of 
antigen. The major mechanisms believed to be involved in the induction of 
tolerance appear to be mediated by T ceIls, through active suppression, clonaI 
anergy or deletion. This mucosal intervention has become an increasingly 
interesting approach to prevent development of illnesses resulting from 
adverse immunologic reactions against antigens encountered or auto-antigens 
found in non-mucosal tissues 47. 
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1.3.5. Mucosal DeIivery Systems 
In addition to adjuvants, mucosal delivery systems are key vehicles which 
assist in improving vaccine efficiency. Important parameters that need to be 
considered in the design of mucosal vaccines should support the immunization 
by: 
(a) preventing degradation of antigen (i.e. due to enzymatic digestion); 
(b) enhancing antigen uptake by M cells or mucosal epithelial cells; 
(c) stimulating the innate immune system towards creating a desirable immune 
milieu for the development of antigen-specific adaptive response; and 
(d) generation of immunological memory. 
Depending on the pathogen or disease at hand, different mucosal delivery 
systems and vectors have been developed to tailor the local and systemic 
antigen-specific response. 
These include 46: 
1.3.5.1 Biodegradable Microparticles 
Biocompatible PLO polymers, long used in humans as a drug deIivery system, 
are now being tested as micropartic\e vaccine delivery vehicles. Micropartic\e 
delivery facilitates uptake of the antigen in question by M cells, and possibly 
by mucosal epithelial celIs, and enhance targeting ofPeyer's patches following 
oral intake. Microparticles are also used as a delivery vehic\e through 
intranasal route. PLO particles have been shown to result in a more protective 
Th 1 type response, as opposed to a mainly antibody-mediated, Th2-biased, 
conventional mucosal microenvironment. 
1.3.5.2 Liposomes 
Liposomes consist of a combination of different proportions of lipids and are 
combined with antigens to increase their mucosal delivery efficiency. These 
formulations protect the antigen from degradation in acidic 01 environment, 
inc\uding bile and pancreatin secretions. Liposomes used in intranasal 
formulations have also been successful in generating enhanced antibody 
36 
responses, such as in the case of the bacterial Yersinia pestis and 
Streptococcus mutans vaccines. 
1.3.5.3. Immune-stimulating agents 
Saponins (extracted from soap bark tree, Quillaja saponaria) are used in 
veterinary vaccines and function through intercalation with cell membranes. 
They form pores in the cell membrane by interacting with its cholesterol 
content and thus facilitate antigen uptake and processing by APCs. Saponins 
contain also an immunestimulatory component, which in conjunction with 
lipid ISCOMs (immunostimulating complexes), form a safe vehicle to target 
antigens to APCs. ISCOMs have been used effectively in both oral and 
intranasal formulations, leading to CDS+ and Th 1 based responses, along with 
the induction ofIL-12 production by innate immune system cells. 
1.3.5.4.Chitosan 
Derived by deacetylation of chitin, chitosan and other chitin derivatives induce 
transient openings of tight junctions of epithelial layer, and thus enhance 
mucosal absorption of prote in antigens. In addition to their mechanical action, 
these agents have been shown to stimulate non-specific immune responses to 
pathogens, such as Sendai virus and E. coli bacterium, highlighting their 
additional immunemodulatory role. 
1.3.5.5.DNA vaccines 
Over the past decade, DNA vaccines have been used to generate immunity to a 
host ofpathologic agents. Developed initially as an intramuscular formulation, 
DNA vaccines have been tested through a variety of delivery routes, including 
mucosal surfaces. Intranasal, oral, genitourinary, and ocular routes have been 
used to enhance local mucosal immunity to encoded antigens. Systemic 
responses, in addition to mucosal responses, further from the inductive site 
have been observed following mucosal DNA immunizations. Several 
techniques have been developed since to enhance efficiency of mucosal 
delivery of these formulations, including intra-oral jet injection or use of 
biodegradable microparticles, liposomes and bioadhesive polymers, such as 
macroaggregated album in complexes. 
1.3.5.6.Edible vaccines 
One promising avenue of delivering vaccines via the oral route is being 
investigated through the incorporation of antigens from pathogenic organisms 
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in transgenic plants. This would potentially allow production of antigen on a 
large scale. Studies in mice have incorporated antigens from bacteria, viruses 
or parasites in transgenic potatoes, tomatoes, and tobacco. These antigens were 
shown to result in a specific immune response without the need for adjuvant. 
However, a major obstacle yet to be overcome in this practical system, is the 
potential risk of breaching tolerance to food antigens. 
1.3.5.7.Live attenuated vectors 
Bacterial and viral vectors have been extensively explored as efficient mucosal 
delivery and/or expression systems for heterologous antigens. Among live 
bacterial vectors, there are those based on attenuated bacterial vehicles 
including Salmonella typhi or paratyphi, BCG, and Bordetella pertussis. 
Another category consists of commensal bacteria such as lactobacilli or sorne 
species of streptococci and staphylococci. In addition, several attenuated viral 
vectors have been used as vehicles of antigen delivery and expression. 
Vaccinia virus has been widely used towards this end. More recently, other 
candidate vectors among poxviruses have replaced vaccinia vectors; these 
include the canarypox virus and recombinant adenoviruses. VSV based 
vectors have been used recently as successful mucosal delivery agents and are 
endowed with inherent adjuvant features. Highly immunogenic virus-like 
particles (VLPs), also known as pseudoviruses, are also being tested as 
combined carrier/adjuvant systems. VLPs are self-assembling, non-replicating, 
recombinant viral core structures which are produced in vitro. Antigens can 
be expressed on the surface of VLPs or carried within their core, as in the case 
of DNA vaccines. Studies have shown promising data in the use of VLPs as 
mucosal delivery vehicles resulting in effective sIgA and CTL responses on 
mucosal surfaces. The safety and efficiency of sorne of the above vectors are 
currently being tested in preliminary clinical trials 46. 
1.4 Transgenic Small Animal Models 
1.4.1. 'Of Mice and Not Men' 
- inter-species differences in immune system components and correlales. 
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Over the past several decades mice have become The experimental model of 
choice for many immunologists. It is indeed undeniable the tremendous insight 
that such experimentations have brought in elucidating immune mechanisms 
involved in pathologic conditions or following immunization in murine 
models assisting in the development of therapeutic agents, vaccines or 
diagnostic tools for human application. Yet, despite genetic similarities and 
common biological mechanisms, one should bear in mind that those two 
species diverged somewhere between 65 and 75 million years ago, and since 
have obviously not shared ecological niches and face significantly different 
antigen encounters. 
Due to many similarities and paradigms that have translated successfully into 
human clinical trials, we often ignore this divergence, and tend to assume that 
what is true for mice will naturally be true for humans. The many inter-
species immunological discrepancies have been extensively described in the 
literature 48 (also Table 1), however, it is noteworthy to summarize key 
differences herein, in order to put the development of a transgenic animal 
model in the current study in better perspective and recognize the importance 
of avoiding straightforward assumptions in extrapolating immune correlates 
among species. In this regard, and though there are general structural 
similarities between murine and human immune systems, sorne significant 
differences do exist. 
It is noteworthy that, in contrast to healthy humans, mice have a considerable 
bronchus-associated lymphoid tissue. This can be explained as an adaptation 
to the higher breathable antigen load for rodents whose habitat is closer to 
ground. This difference should be kept in mind, especially in the context of the 
design of intranasaly administered vaccines and mechanisms of protection 
involved therein. Another structural difference points at the number and 
organization of various lymph nodes. Murine lymph nodes are few in number 
and organized in simple chain s, with smaller lymphatic trunks and nodes. In 
contrast, lymph nodes from larger species are numerous and organized into 
more complex chains individually draining proportionately smaller areas of 
tissue. 
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On the other hand, in rodents, Iymph nodes retain sorne residual 
haematopoietic activity which is absent in humans. With regards to the spleen, 
the periarteriolar lymphocyte sheath and marginal zone observed in mice are 
also absent in humans. Throughout the animal's life, the mouse spleen 
represents major haematopoietic activity (especially Iymphopoiesis), while in 
humans minimal activity is observed during embryonic life which is 
completely absent in adult life, except in pathologic conditions. One reflects 
upon the impact of this activity while using rodent splenic cells in an array of 
immunologic and toxicologic assays in lieu of circulating leukocytes. The 
location, size and appearance of GAL T nodules also varies, however 
corresponding functional differences have not been described yet. Mice have 
Payer's patch follicles that are uniform in size throughout the sm ail intestine 
with 6-12 follicles present in aggregates. Humans have duodenal patches with 
few follicles, these increase in size and number more distally in the gut, with 
the terminal ileal Payer's patches containing up to 1000 individual follicles. 
The human appendix contains many IgG plasma cells in its dome area, while 
mice lack an appendix, possessing instead large aggregates of Iymphoid cells 
in their cecal walls. 
On the other hand, while assessing the cellular composition of peripheral 
blood, the neutrophil to lymphocyte ratio is significantly different between the 
two species: 50-70% of neutrophils and 20-40% of lymphocytes constitute 
adult human blood, while murine blood exhibits a predominant lymphocyte 
ratio of 75-90% with only 10-25% neutrophils. 
With regards to innate immunity and Toll-like receptors (TLR), sorne species 
differences are also prominent: TLR2, which is constitutively expressed on 
murine thymus and T ce Ils, is poorly expressed on circulating lymphocytes 
except when induced by LPS. In contrast, TLR2 is not constitutively expressed 
on human thymocytes, but it is on circulating leukocytes, however this is not 
induced by LPS. Another example is TLR3, which is strongly induced on 
murine macrophages following LPS induction. In humans, TLR3 is expressed 
on myeloid dendritic ce Ils only 116. 
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Studies of the biology ofmurine NK cells show that their activity in the spleen 
and blood peaks early in life (4-10 weeks of age), while in humans NK cell 
activity is stable throughout life. In addition, in mice this activity is high in the 
lung, which is not the case in humans. Fc receptors (FcR) are readily detected 
on human, but to a lesser extent on murine NK cells. 
FcR also represent a link between the innate and adaptive arms of the immune 
system. Mice lack expression of FcRI (CD89) which is an important IgA 
receptor expressed by several types of cells in humans. It is presumed that 
mice use alternative receptors such as the transferrin receptor (CD71) which 
also binds IgM. Besides mice lack two IgG receptors expressed in humans, 
namely, FcyRIIA and FcyRIIC. Moreover, as shown in Table 1, there is a 
major difference in the expression of immunoglobulin isotypes and subtypes 
between the two species as weil as in the factors involved in the induction of 
ciass switching. Differences in B- and T-cell development and regulation have 
also been observed. For example, mature murine B cells exciusively express 
either CD5 or CD33 while hum an plasma cells express CD38. 
An important feature of adaptive immunity is often the skewing of T cells 
toward a Th 1 or Th2 phenotype. This polarization is readily observed in mice, 
yet the paradigm has not been so obvious in humans, whereby in many 
diseases both subsets can be generated simuitaneously. While in mice IL-1O is 
considered to be a Th2 cytokine, both Th 1 and Th2 cells secrete IL-1O in 
humans. In addition, in humans, IFN-a is secreted in response to viral 
infection by several cell types, leading to a Thl response through STAT4 
activation. In contrast, in mice, IFN- a does not induce Thl cells nor activates 
STAT4. 
Other major interspecies discrepancies within the adaptive immune system 
involve the costimulatory and activation pathways. One such example is the 
fact that human T cells express MHC Class II molecules upon activation while 
murine T cells don't. Another example is expression of the costimulatory 
molecule CD28. This receptor is expressed by nearly 100% of murine CD4 
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and CD8 T cells, while in humans 80% of CD4 and only 50% of CD8 cells 
express CD28. 
White it is yet early to draw global conclusions about the significance of the 
above divergences, species differences in structure and function ofthe immune 
system should be kept in mind especially when designing preclinical 
experiments to be extrapolated to humans. 
Altematively, in immunological investigation, careful selection of the 
appropriate species and strains undoubtedly enhances the value of 
experimental data and facilitates the transition from bench to bed, and 
species/strain differences can be useful in delineating immunologic 
mechanisms and therapeutic efficacy. In this context, the availability of 
various mouse stains with well-defined immunologic features, including 
knockouts and transgenics, are vital in the development of vaccines and 
immunotherapeutics and the understanding of underlying mechanisms of 
diseases pathology 48,49,50. 
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Table 1. Summary of sorne known immunological differences between mouse and human 
Mouse Human Notes 
Hemotopoiesis in spleen Active into adulthood Ends before birth 
Presence of BAL T Significant Largely absent in healthy tissue 
Neutrophils in periph. blood 10-25% 50-70% 
Lymphocytes in periph. blood 75-90% 30-50% 
Hemotopoietic stem cells c_kithi9h, fit -3' c_kitIOW, flt-3+ 
TLR2 expression on PBL Low (induced on many cells Constitutive (but not on T cells) Binds Iipopeptides 
including T cells) 
TLR3 Expressed on OC, Mac. Induced Expressed by OC. No LPS Binds dsRNA 
by LPS induction 
TLR9 Expressed on ail myeloid cells, Expressed only on B cells, Binds CpG 
plasmacytoid OC and B cells plasmacytoid OC and N 
TLR10 Pseudogene Widely expressed 
Sialic acid Neu5GC expression Widespread Absent Binds pathogens 
C033 Expressed on granulocytes Expressed on monocytes Binds sialic acids 
Leukocyte defensins Absent Present Neutrophils 
Paneth cell defensins Processed by MMP7. Stored as pro-form. Processed by 
Stored preprocessed trypsin 
Paneth cell defensins At least 20 Two 
Macrophage NO Induced by IFN-y and LPS Induced by IFN-a/I3, IL-4+ anti-C023 
C04 on macrophages Absent Present 
Predominant T cells in skin and y/ô TCR (dendritic epidermal T a/I3TCR 
mucosa cells-OETC) 
y/ô T cells respond to No Yes 
phosphoantigens 
C01 genes C01d C01a,b,c,d 
NK inhibitory Rs for MHC 1 Ly49 family (except Ly490 and H) KIR 
NKG20 ligands H-60, Rae113 MIC A, MIC B, ULBP NK activating Rs 
fMLP receptor affinily Low High 
FcaRI Absent Present 
FcyRIIA, C Absent Present 
Serum IgA Mostly polymeric Mostly monomeric 
Ig classes IgA, IgO, IgE, IgG1, IgG2a*, IgA1, IgA2, IgO, IgE, IgG1, IgG2, 
IgG2b, IgG3, IgM * absent in IgG3, IgG4, IgM 
C57BU6.110, SJL and NOD mice, 
which have IgG2c 
Ig COR-H3 region Shorter, less diverse Longer, more diverse 
BLNK deficiency IgMh'9h B cells in periphery No peripheral B cells 
Btk deficiency Normal pre-B and immature B Blocks pro-B to pre-B transition 
A5 deficiency "Ieaky" block at pro-B to pre-B Blocks pro-B to pre-B transition 
transition 
C038 expression on B cells Low on GC B cells, off in plasma High on GC B cells and plasma 
cells cells 
B cell C05 and C023 Mutually exclusive Co-expression 
expression 
IL-13 effect on B cells None Induces switch to IgE 
Thy 1 expression Thymocytes, peripheral T cells Absent from ail T cells, expressed 
on neurons 
Effect of Yc deficiency Loss of T, NK, and B cells Loss of T, NK, but B cell numbers 
normal 
Effect of Jak3 deficiency Phenocopies Yc deficiency Phenocopies Yc deficiency 
Effect of IL-7R deficiency Blocks T and B cell development Only blocks T cell development 
ZAP70 deficiency No C04+ or C08+ T cells No C08+ T but many nonfunctional Related to syk 
C04+ level? 
Caspase 8 deficiency Embryonic lethal Viable-immunodeficiency 
Caspase 10 Absent Present 
(table continues) 
~ , 
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Table 1. continued 
Mouse Human Notes 
IFN-a promotes Thl No Yes Mutant stat2 in mice 
differentiation 
Th expression of IL-l 0 Th2 Thl and Th2 
IL-4 and IFN-y expression by Either/or Sometimes both 
cultured Th 
CD28 expression on T cells On 100% of CD4+ and CD8+ On 80% of CD4+ 50% of CD8+ 
ICOS deficiency Normal B cell numbers and B ce Ils immature and severely Possibly age-
function, normal IgM levels reduced in number, low IgM related 
B7-H3 effects on T cells Inhibits activation Promotes activation 
ICAM3 Absent Present DC-SIGN ligand 
P-selectin promoter Activated by TNF and LPS Unresponsive to inflammation 
GlyCAM Present Absent 
MHC Il expression on T cells Absent Present 
Kvl.3 K+ channel on T cells Absent Present Regulates Ca flux 
MUCl on T cells Absent Present Regulates 
migration? 
Granulysin Absent Present ln CTL 
CXCRl Absent Present 
IL-8, NAP-2, ITAC, MCP-4, Absent Present Chemokines 
HCC-l, HCC-2, MPIF-l, 
PARC, eotaxin-2/3 
MRP-l/2, lungkine, MCP-5 Present Absent Chemokines 
IFN-y effects in demyelinating Protective in EAE Exacerbates MS 
disease 
DTH lesions Neutrophil-rich Lymphocyte-rich 
Constitutive MHC Il on EC Absent Present 
EC present Ag to CD4+ T No Yes Memory T only 
CD58 (LFA-3) Absent Present CD21igand 
T cell dependence on CD2- Low High 
ligand interactions 
CD2-ligand interaction Lower affinity, with CD48 Higher affinity, with CD58 
CD40 on EC Absent Present 
Vascularized grafts tolerogenic? Yes No 
Microchimerism induces graft High success rate Low success (expts. in non-
tolerance? human primates) 
Passenger leukocytes Account for graft immunogenicity Do not account for graft 
immunogenicity 
Table 1: Differences between Mouse and Human Immune System. 
Reproduced with permission from The Journal of Immunology, 2004, 172:2731-2738. 
Copyright (2004) The American Association of Immunologists, Inc. 
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1.4.2. Generation of Small Animal Models 
The discrepancy between immunogenicity and bias of T cell response among 
different vaccines is not fully elucidated. Several factors may be involved, 
including the route of delivery of the immunogen, which in tum may dictate 
the initial anatomical target and further development of ensuing immune 
response in distant lymphoid sites. Furthermore, studies have demonstrated 
that the initial antigen dose resulting from the vaccine dose, as weIl as the 
persistence of the antigen, critically influence the magnitude of the primary 
response and the subsequent development of memory response, respectively. 
The nature of the antigen and its processing and presentation mechanisms 
impact the inclination of the T cell response towards CD8 or CD4, with either 
a Th 1 or Th2 bias of the latter. Delineating these factors in vaccine 
development is key to the development of rational vaccines, however such 
studies are often hampered due to lack of practical small animal models of 
disease and immunotherapy. 
Since the first gene transfers into mice were successfully executed in 1980, 
transgenic mice have become models for studying human diseases and their 
treatment. Among the numerous genes examined for their role in disease 
development, polymorphism within MHC Class 1 and Class II loci have been 
shown to be critically involved in predisposition to certain pathologic 
conditions. This polymorphism also determines the specificity and affinity of 
peptide binding and ensuing T cell recognition. 
More specifically, the development of transgenic mice expressing human 
MHC Class II molecules has been of great value in studying the 
immunopathology of human MHC class II-associated autoimmune diseases 
including rheumatoid arthritis, multiple sclerosis, and insulin-dependent 
diabetes mellitus. These mice are useful in the identification of target antigens 
that are involved in disease initiation and provide an in vivo disease model 
since they develop aspects of the respective human disease, either 
spontaneously or following immunization with a relevant antigen. This has 
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helped in better understanding of autoimmune disease mechanisms and testing 
novel immunotherapies. 
HLA transgenic mice play a key role in the development of vaccines and the 
study of immunogenetic models of human disease. Individual haplotypes 
dictate the response to a given antigen and antigen specificity ofhuman CD4 T 
ce Ils is largely controlled by the widespread Class II HLA polymorphism. 
Hence the need to carefully define both the immunogenicity and efficacy of 
candidate vaccines in this context 138. 
To study the interactions involved between class II molecules (DQ and DR) 
and define the immunologic mechanisms in various diseases, several groups 
have generated HLA-DR and DQ transgenic mice with or without the presence 
of the endogenous class II molecules 52,53,88,89,92,111. The HLA molecules in 
these mice were shown to positively select CD4+ T cells expressing various 
Vp T-cell receptors (TCR). In addition, a peripheral tolerance is maintained to 
transgenic HLA molecules thus indicating that these molecules act as self and 
that mouse co-stimulatory and accessory molecules are able to interact with 
the HLA-peptide-TCR complex leading to efficient T-cell activation. HLA 
class II transgene-restricted T cells recognize the immunodominant antigens 
and peptide epitopes, similar to HLA class II-restricted human T cells. 
Therefore, these mice provide powerful tools to understand the role of HLA 
class II molecules in predisposition, onset, and prognosis of human diseases 51, 
52,53 
1.5 Immune Monitoring Toois 
The development of reliable, sensitive in vitro assays that allow the 
quantitation and characterization of antigen-specific T cell responses is crucial 
in monitoring the immune response both in the context of infectious or non-
infectious diseases, and in assessing outcomes of immunization strategies. 
With recent advances in our understanding of the intricacies of the molecular 
basis of the generation of adaptive immune responses, sensitive assays which 
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would dissect ensuing antigen-specific immune responses are imperative to the 
assist in depicting a clear picture of in vivo scenarios. 
Traditional assays such as thymidine incorporation, CTL, ELISpot, and 
immunoscope are being complemented or at times replaced by an array of 
novel tools, such a flow cytometry-based techniques (lCS, CBA, proliferation 
assays), HTA, and microarray analyses. Below is a summary of sorne of the 
assays that are currently used as immune monitoring tools in a variety of 
applications from basic research to clinical diagnosis and immune monitoring. 
The need of sensitive, accurate, specifie, and standardized immunologie 
monitoring is imperative towards the better understanding of often elusive 
immunepathologic and protective mechanisms. 
For example, recent advances in the methods used for the characterization of 
HIV -1-specific cellular immune responses, including quantification of 
antigen-specific IFN-y production by ELISpot assay and flow-cytometry-
based intracellular cytokine quantification, have allowed for a much more 
comprehensive assessment of virus-specific immune responses. Emerging data 
show that the regulatory and accessory proteins serve as important targets for 
HIV -l-specific T cell responses, and multiple CTL epitopes have been 
identified in functionally important regions ofthese proteins 54. 
Moreover, the use of autologous peptides have allowed for the detection of 
significantly stronger HIV -1-specific T cell responses in the more variable 
regulatory and accessory HIV-l proteins Tat and Vpr. These data indicate that 
despite the small size of these proteins, regulatory and accessory proteins are 
targeted by cellular immune responses in natural HIV -1 infection and 
contribute importantly to the total HIV -1-specific CDS+ T cell response. This 
may ultimately lead to the development of a multi-component vaccine, with 
the inclusion of these proteins plus structural proteins as a promising option 
towards an effective AIDS vaccine 55 
In recent years, CD4 and CDS T cell responses to HIV and SIV infection have 
been increasingly measured with the use of single-ce Il assays such as ELIS pot, 
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MHC-peptide oligomers, and cytokine flow cytometry. The results of the se 
assays have been compared to those obtained with traditional bulk assays such 
as lymphoproliferation (by 3H-thymidine incorporation) and cytotoxicity (by 
51Cr release). Such comparisons have led to sorne general understanding of the 
T cell responses that characterize progressive disease, long-term non-
progressors, and individuals with viral suppression achieved by anti-retroviral 
therapy. Prophylactic and therapeutic vaccine trials have also begun to use 
these assays ofT cell immunity to gauge the immunogenicity of the vaccines. 
Whether such analyses will allow us to pick the best vaccine constructs, and 
wh ether they will provide us with an improved understanding of what 
constitutes protective cellular immunity to HIV, are major questions for the 
field. Today it is becoming clearer that sophisticated multiparametric assays 
are required to sort out the factors relevant for the generation of protective 
immune responses and identification offunctional signatures 55,56. 
1.5.1. Existing Tools: 
Functional assays (ELISpot, Intracellular Cytokine Staining), detection of 
precursor cells ([3H]thymidine incorporation assay, CFSE or PKH26 
labeling), and structural assays (HT A, lmmunoscope, Class 1 and II 
Tetramers) are commonly used in a host of applications. 8elow we present an 
overview ofthese techniques and pros and cons oftheir application. 
1.5.1.1.ELISPOT 
Enzyme-linked immunospot, or ELISpot, assay allows the detection of low 
frequencies of cells secreting various molecules. ELISpot has been used in 
many areas of research and, because of its sensitivity and relative simplicity, 
has the potential to become a valuable diagnostic tool. 8ased on the same 
"sandwich" immunochemical princip les as enzyme-linked immunosorbent 
assay, ELISpot is easy to perform. At the same time ELISpot remains a 
sensitive technique that requires accuracy, thorough selection of antibodies 
and detection reagents, and an understanding of the princip les of data analysis. 
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ELIS pot appears to be 200 times more sensitive than ELISA in detecting 
secreted cytokines, with as many as 10-100 ce Ils per weil being sufficient for 
the detection of cytokine-releasing cells. Such sensitivity makes ELISpot a 
technique of choice for the detection of spontaneous and antigen-induced 
secretion of cytokines (e.g., interferon [IFN]-y, tumor necrosis factor [TNF]-a, 
interleukin [IL]-2, IL-4) from peripheral blood lymphocytes. ELISpot is 
widely used for vaccine development, AIDS research, cancer research, 
infectious disease monitoring, auto immune disease studies, and allergy and 
transplantation research 57. 
Even though the ELISpot technique has a host of advantages which incJude 
detection of cytokine secretion by Ag-specific cells at the single cell level, 
generation of results within 24hrs, performance doesn't require use of 
sophisticated equipment, can be used to assess response to a panel of peptides, 
however, it requires in vitro stimulation with Ag, and high background is often 
a problem while looking at low responders. Also, this technique will not 
distinguish CD4 from CD8 responders without prior cell separation, and ce Ils 
can not be further manipulated following the assay. Besides, production of one 
cytokine might not be the sole marker of an activated cell. As sorne of the 
other common assays, ELISpot looks only at the functional aspect of T -cells 
and fails to detect sorne subsets of cells, incJuding anergic cells. 
The performance of this assay is greatly dependent on the quality of assay 
components incJuding capture and detection antibodies, enzyme conjugates, 
chromogenic substrates, and membrane-backed plates. Careful optimization of 
ail these parameters and appropriate controls are necessary toward the best 
interpretation of results 54,57. 
1.5.1.2.1ntracellular Cytokine Staining (lCS) 
Upon treatment with inhibitors of secretion such as Brefeldin A or Monensin 
(protein transport inhibitors), T cells accumulate cytokines in their cytoplasm 
following in vitro activation. ICS is a modification of the basic 
immunotluorescence staining and tlow cytometric analysis protocol allowing 
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the simultaneous analysis of surface molecules and intracellular cytokines at 
the single-cell level. 
In this approach, following in vitro activation, cells are stained for surface 
antigens, then fixed with paraformaldehyde to stabilize the cell membrane and 
permeabilized with the detergent saponin to allow anti-cytokine antibodies to 
stain intracellularly. The in vitro stimulation of cells is usually required for 
detection of cytokines by flow cytometry since cytokine levels are typically 
too low in resting cells. Stimulation of ce Ils with the appropriate reagent will 
depend on the cell type and experimental conditions. A host of T cell 
activators have been used as positive control in ICS protocols depending on 
targeted cytokine, including a combination of PMA (phorbol myristate acetate 
- a phorbol ester / PKC activator) and Ionomycin (a calcium ionophore) or 
anti-CD3 antibodies, and in sorne cases lipopolysaccharide (LPS). 
When compared to ELISpot, intracellular cytokine measurement necessitates 
larger sample volumes, still ICS is one of the commonly used assays which 
allows the measurement of cytokine production on a single cell level along the 
simultaneous determination of the cell's phenotype using a combination of 
surface markers. Sorne of the drawbacks of ICS include: requirement of in 
vitro Ag-stimulation; background levels in staining which should be carefully 
compensated by using isotype controls; and the fact that the protocol involves 
fixation and subsequent permeabilization during staining, which prevents 
further manipulation or growth of cells 54,58. 
1.5.1.3.Cytometric Bead Array (CBA) Assay 
The recent BDTM CBA analytical tool makes use of the flow cytometry 
principal and employs a series of particles with discrete sizes and fluorescence 
intensities to simultaneously detect multiple soluble analytes from a single 
biological sample. The BD CBA, combined with flow cytometry, creates a 
powerful multiple analyte (multiplex) assay system to measure soluble 
analytes with a particle-based immunoassay. The combined advantages of the 
broad dynamic range of fluorescence detection via flow cytometry, and the 
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efficient capturing of analytes via suspended particles coated with distinct 
capture antibodies enable the BD CBA to use fewer sample dilutions to 
determine analyte concentration in substantially less time (compared to 
conventional ELISA). 
The specific capture beads are mixed with fluorochrome conjugated detection 
antibodies and then incubated with recombinant prote in standards or test 
samples to form sandwich complexes. Following acquisition of sample data 
using the flow cytometer, the sample results are generated in graphical and 
tabular format using the BD CBA Analysis Software. 
This assay allows acquisition of multiple parameters from a single small-
volume sample and avoids artifacts associated with enzyme-dependent signal 
generation. Ready-to-use kits allow generation of quantitative results with less 
time and laboT. For large volumes of experimental samples, the acquisition can 
be automated with the platebased BD F ACSArray bioanalyzer or other BD 
flow cytometers equipped with the high throughput sampler (HTS) option. 
CBA allows the measurement of secreted form of cytokines in supernatants, 
and live cells can be further analysed or cultured. However, this method 
requires Ag-stimulation in vitro (sorne populations of T-cells might have 
limited growth and division potential in vitro) and looks only at cells which 
are functional based on their cytokine secretion capacity (effector function). 
Different bioassays and immunoassays are used throughout many laboratories 
around the world for the rneasurement and report of cytokine levels in a 
variety of biological samples. Recently, the availability of international 
standard preparations of proteins has become essential to allow accurate 
analyses and comparison of results among different laboratories. These 
reagents are known as 'primary' (or aka, gold) standards and are frequently 
used to calibrate biological activities and protein concentrations between 
different secondary assay standards 59. 
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1.5.I.4.in vitro Proliferation Assays 
Assays to detect precursor T cells, which are not endowed with an effector 
function but proliferate upon exposure to antigen, include the traditional 
thymidine incorporation assay and the more recent, flow cytometry-based 
methods. 
The incorporation of radioactive eH] thymidine into the cellular DNA, gives 
an overall picture of the total amount of synthesized DNA, yet fails to indicate 
the actual frequency of specific T cells. Another approach is the use of the dye 
bromodeoxyuridine (BrdU) which is incorporated in replicating chromosomes, 
yet has limited application and sensitivity because of basal T-cell proliferation. 
Moreover, this approach does not allow further purification of Ag-specific live 
cells. 
More recent proliferation assays make use of fluorescent dyes which stain 
either the cell membrane or cytoplasm. In this protocol, ce lis are incubated in 
the presence of a fluorescent dye, such as carboxy-fluorescein diacetate 
succinimidyl ester - CFSE or PKH26 which is a long chain aliphatic dye. 
PKH26 stains the cell membrane by integrating into the lipid bilayer, while 
CFSE binds to amino groups of cytoplasmic proteins. With each division, the 
cell becomes half as fluorescent, and the number of respective cell cycles can 
thus be directly deduced from intensity of fluorescence and the initial 
frequency of precursor T cells can be calculated. CFSE (or PKH26) labelling 
can also be combined with detection of other cell surface markers or tetramer 
staining. However, anergic T cells or T cells incapable of undergoing 
proliferation cannot be detected using the above mentioned methods 54. 
1.5.1.5. HTA 
The migration of double-stranded DNA molecules through a non-denaturing 
electrophoretic gel is determined by the degree of base-pairing within the 
double helix. The heteroduplex mobility assay (HMA), also known as 
heteroduplex tracking assay (HTA), allows the comparison of PCR amplicons. 
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Amplicons comprising of exactly complementary single strands, with only A-
T and G-C base pairs, will migrate more quickly than identically sized 
amplicons that have mismatched bases. 
Due to mismatches, typical 'bubbles' in the 'rod-like' amplicons occur which 
delay their movement through the gel matrix. If one of the two strands of the 
amplicon has an insertion or deletion then a 'bulge' is formed that results in an 
even greater perturbation of the structure of the ONA and thus affects its 
electrophoretic mobility. Based on the generation of homoduplexes vs. 
heteroduplexes, HTA counters the need for extensive gene sequencing 60. 
Among their many applications, specific HT As known as T -cell receptor 
(TCR) heteroduplex mobility shift assays, are often used to analyze clonaI 
expansion of T cells and assess TCR repertoire diversity in a variety of 
infectious diseases, such as HIV infection 61. 
1.5.1.6. Immunoscope 
This technique is a reverse transcriptase-polymerase chain reaction (RT-PCR)-
based method, which subdivides any bulk population of T cells into 
approximately 2800 categories based upon different VpJp gene combinations. 
Due to the varied lengths of N (non-genomic) and 0 (diversity) insertions 
within the junctional area of the TCR gene, at least 10 discrete COR-3 lengths 
can be found within each VpJp pairing. A cONA sample for immunoscope is 
first amplified with forward and reverse primers to the variable and constant 
region segments, respectively (for the mouse this would be 24 reactions, one 
for each Vp segment). Next fluoresceinated primers to each of the joining 
segments are used for "run-off' reactions. If there is no induced T cell 
expansion within the spectra, a Gaussian distribution of COR-3 lengths is 
observed. In contrast, clonaI expansions are observed as a perturbation of this 
Gaussian distribution. For a less extensive subdivision, a fluoresceinated 
primer to the constant region can be used for the "run-off' reaction, or Vp 
primers can be designed which bind multiple Vp gene segments 62,63. 
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1.5.1.7.Genomics & Proteomics 
It is well established that to sustain health, it is critical that a vast number of 
genes is expressed in a concordant manner and at normal levels. Many 
pathologic conditions today are proved to stem from disruptions or variations 
in such expression. Recent advances, both in knowledge and technology, have 
made possible the quantitative study of gene expression and thence the 
identification of the involvement of specific genes in the pathophysiology and 
prognosis of given diseases. Importantly, the completion of the Human 
Genome Project has generated a massive amount of information regarding our 
genome, therefore facilitating the task of researchers in identifying a host of 
previously unknown genes. On the other hand, the concurrent ad van cements in 
genomic biotechnology through the 'DNA microarray technology' is allowing 
the identification and classification of the above DNA sequence information 
and assignment of functions to these new genes. 
Briefly, a microarray uses the ability of mRNA to hybridize to a DNA 
template from which it originated. By using an array of several predetermined 
DNA samples arranged in a regular pattern on a membrane or glass slide, the 
expression levels of hundreds or thousands of genes within a cell can be 
determined by measuring the amount of mRNA bound to each spot on the 
microarray. Using specially designed softwares, the amount of bound mRNA 
is measured accurately and generates a profile of gene expression in the cell at 
hand. (NeBI - http://www.ncbLnlm.nih.gov/About/primer/microarrays.html) 
The challenge currently facing scientists in this field is to find a way to 
organize and catalog this vast amount of information into a usable form 64. 
Immunotherapies for human immune-mediated diseases are proliferating 
rapidly. With these changes cornes the need to monitor patients for immune 
responses to therapy based on early surrogate markers for clinical responses. 
The development of fast and sensitive bioassays is central towards this end. 
Over the past decade, novel state-of-the-art technologies have been developed. 
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These tools allow the detection of T cells based on the Ag-specificity of their 
TCR. 
1.5.2. Oligomeric tools for detection of cellular immunity and their 
application 
The T-cell receptor (TCR) solely recognizes a specifie peptide presented in the 
context of a particular MHC molecule. This has been successfully used to 
develop technologies that allow the detection and isolation of distinct T-cell 
populations, in which aIl of the T cells carry the same specific TCR. However, 
the fairly low affinity between the monomeric MHC complex and the TCR 
does not easily permit efficient binding or detection. By the introduction of 
fluorescent-labeled multimeric MHC reagents, it has become feasible to detect 
and quantify the TCRs 65. 
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Figure 1 Schematic representations of multivalent MHC c1ass 1 molecules. 
Reprinted from the Journal of Immunological Methods, vol 268, Hugues S., 
Malherbe L., Filippi C., Glaichenhaus N., Generation and use of alternative 
multimers ofpeptide/MHC complexes, pp. 83- 92, Copyright (2002), with pennission 
from Elsevier. 
Figure 2 Schematic of a dimeric c1ass 1 MHC, MHC-Ig (BDTM Dimer X). 
Reprinted from the Journal of Immunological Methods, vol 268, Fahmy T.M., Joan 
G. Bieler J.G., Schneck J.P., Probing T cell membrane organization using dimeric 
MHC-Ig complexes, pp. 93-106, Copyright (2002), with pennission from Elsevier. 
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Figure 3 Schematic representations of monovalent and multivalent MHC 
c1ass II molecules. 
Reprinted from the Journal of Immunological Methods, vol 268, Hugues S., 
Malherbe L., Filippi C., Glaichenhaus N., Generation and use of alternative 
multimers ofpeptide/MHC complexes, pp. 83- 92, Copyright (2002), with permission 
from Elsevier. 
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1.5.2.1. Tetramers 
MHC tetramers are oligomeric forms of soluble recombinant MHC molecules 
associated with specific peptide epitopes. The recombinant MHC molecules 
are assembled into oligomers to provide multiple ligands for enhanced 
interaction with antigen-specific T cell receptors (TCRs). These multimers are 
surrogates for the MHC-peptide ligand that is expressed on the surface of an 
antigen-presenting cell during a normal immune response. By binding to the 
TCR, a labeled tetramer molecule becomes a specific marker, identifying T 
cells by virtue oftheir antigen specificity. 
The standard procedure in preparation of MHC tetramers involves production 
of recombinant soluble MHC class 1 or class II molecules bound to a specific 
peptide epitope. These molecules are later biotinylated at a specific 
biotinalation site introduced on one of the MHC chains. The biotinylated 
molecules are then incubated with fluorochrome labeled commercial 
streptavidin (or modified counterpart) to produce tetramers. Tetramers are 
used to stain CD4 or CD8 T cells expressing a TCR specific to the peptide 
epitope bound to the MHC molecule 65, 66. 
Tetramer technology has proved to be a valuable tool and has the potential to 
serve as a powerful marker for immune monitoring thereby assisting with 
patient management, therapy selection, and improved outcomes. However, 
important issues of TCR avidity require resolution, because much is still 
unknown regarding location, quantitation, and characterization of the human T 
cell responses in a host of infectious and non-infectious conditions. 
Opportunities for application of tetramer technologies would enable both 
c1inical progress and bring new insights into in vivo T cell biology. 
1.5.2.1.1. Class 1 Tetramers 
Originally described in 1996 67, MHC c1ass 1 tetramers have become widely 
used for quantitation of antigen-specific CD8+ T cell responses. MHC class 1 
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tetramers contain HLA-A or HLA-B molecules assembled with peptides from 
pathogen-associated or cellular targets, and have been used to enumerate CD8+ 
T cells to those targets, and to study CD8+ T cell specificity, avidity, and 
phenotype. The range of antigen-specific cells detected by tetramers varies 
depending both on the pathogen at hand and on the clinical setting. Indeed, 
fluctuating levels of tetramer-positive CD8+ T cells can be used as a clinical 
correlate of disease activity or immune response to administered vaccine. 
When coupled with methods that predict peptide binding to MHC class 1 
molecules, tetramer analysis can be extremely useful for identifying T cell 
epitopes 112,113. 
The application of class 1 tetramers to study self antigens has been most 
extensively developed in studies of tumor antigens. For example, peptides 
from melanoma-associated antigens loaded into HLA-A2 tetramers have been 
used for patient monitoring, phenotyping, and clinical correlations in patients 
with melanoma and in cancer vaccine trials. Insights based on the strength of 
tetramer binding have been used to infer the overall avidity of the TCR-
MHC-peptide recognition complex, information that may help direct the 
design and use of candidate vaccines for inducing tumor-specific immunity 68. 
1.5.2.l.2. Class II Tetramers 
ln contrast to many successful examples of the application of class 1 tetramers, 
success with widespread use of MHC class II tetramers has lagged. In fact, 
structural differences between class 1 and class II molecules necessitate 
different approaches to tetramer design and use. The single-chain class 1 
molecule can be efficiently renatured in the presence of antigenic peptides to 
yield a stable p2-microglobulin-associated class 1 monomer, while 
engineering a soluble form carrying a biotinylation tag allows tetramerization 
with avidin. In contrast, class II molecules are noncovalent dimers of a and p 
chains, which have a variable range of stability and solubility in solution. 
Peptides bind into the a / p chain groove of class II molecules based on 
specifie interactions with amino acid side chains, which confer specifieity, 
determining which peptides will bind which class II molecules 69. 
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Detection of individual CD4+ T cells based on their antigen specificity has 
been hampered by 2 significant barriers: the low frequency of such T cells in 
human peripheral blood and the low avidity of binding between the TCR and 
the MHC-peptide complex 70. 
To circumvent the se problems, different approaches to producing c1ass II 
tetramers have been attempted. One is the covalent synthesis of single-chain 
c1ass 11- peptide complexes, directed by engineering peptide-specific 
complementary DNA (cDNA) sequences proximal to the ~ chain cDNA. In 
this strategy, the resulting polypeptide refolds with the peptide sequence 
extended from the amino terminus of the c1ass II molecule. A tethering linker 
sequence in the peptide allows enough flexibility for the peptide to occupy the 
peptide binding groove in the mature c1ass II molecule. A presumed advantage 
ofthis methodology is that every class II molecule produced contains the same 
peptide sequence; a potential disadvantage is that a separate molecular 
construct must be produced for every c1ass II-peptide tetramer designed 69. 
The second approach that has been used is to load the biotinylated c1ass II 
dimer with exogenous peptides, followed by muItimerization with avidin . The 
principal advantage of this technique is that a single MHC molecule can be 
loaded with a large number of distinct peptides, greatly expanding the number 
of T cell epitopes that can be studied. Recombinant class II molecules that 
incorporate "leucine zipper" motifs were also produced, replacing the native 
transmembrane and cytoplasmic portion of the molecules. The addition of 
these leucine zipper sequences provides both stability and solubility to the 
complex, which is produced in stably transfected Drosophila cells and 
subsequently purified by affinity chromatography 71. 
By using fluorochrome-Iabeled streptavidin molecules, T cells that bind 
specific tetramers can be readily distinguished from those that do not, using 
flow cytometry. However, the low number of antigen-specific CD4+ cells in 
peripheral blood poses challenges for the sensitivity of flow cytometry. It is 
indeed difficult to detect cells at frequencies below 0.2% (1 :500) since 
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background staining using tetramer loaded with an irrelevant, nonspecific 
peptide may approach 0.1 % in these types of assays. To overcome this, 
tetramer-positive antigen-specific cells are expanded following in vitro 
activation leading to both the accumulation of proliferating antigen-specific 
cells and the loss of unrelated T cells 72,73. 
Furthermore, a combined technique has been set forth which allows 
determining the frequency of antigen-specific cells in peripheral blood, in 
which cell divisions and tetramer staining are determined simultaneously. In 
this system cells are labeled with CFSE, as described in section 1.5.1.4. Cells 
are then incubated with antigen-presenting cells and specifie antigen, and 
cultured in vitro for 4-7 days. Cells are stained with tetramer prior to analysis, 
and separate fluorescent wavelengths are used to detect tetramer binding and 
CFSE dye fluorescence, simultaneously. This method allows for the 
straightforward calculation of precursor frequencies of cells that respond to 
specifie antigens. This approach is particularly useful when the original 
frequency of such antigen-specific cells is exceedingly low in peripheral 
blood, below the threshold for detection in the unamplified sample 73. 
However, this requirement for in vitro amplification prior to tetramer detection 
poses sorne problems for analysis. Changes in T cell phenotype, differing rates 
of cell death, and selected expansion of higher-avidity cells are likely to occur 
during culture, potentially influencing quantitation of the tetramer-positive 
cells. Nevertheless, it is likely that sorne sort of in vitro amplification is 
necessary for routine clinical use, since direct detection of antigen-specific 
cells, both in peripheral blood and in synovial tissue, has so far yielded very 
low or absent tetramer-binding populations. By performing simultaneous 
analysis of tetramer fluorescence alongside other T cell parameters, 
information about T cell specificity and phenotype can be directly gauged, 
even within very complex samples. 
On the other hand, it has been observed that activation markers, such as CD69, 
and production of interferon-y by a clonai population of CD4 + T cells, increase 
proportionately with the addition of increasing concentrations of specifie 
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tetramer for staining. Thus, tetramer binding, which indicates a certain level of 
TCR-MHC-peptide avidity, can itself lead to T cell activation. Other recent 
studies have compared activation profiles among T cells stimulated with 
dimers (bivalent class II-peptide complexes), trimers, or tetramers. These 
studies indicate that multimerization of TCRs occurs early after interaction 
with MHC oligomers, followed by rapid T cell activation. Fluorescent staining 
with the multimers was enhanced by this activation, suggesting that clustering 
of receptors and/or endocytosis occurs, which augments the fluorescent 
tetramer signal detection. There is thus a relationship between avidity, 
activation, and tetramer binding. It appears that, while high-avidity T cells are 
readily detected using MHC tetramer fluorescence technology, detection of 
low-avidity T cells may require simultaneous measurement of activation 
markers or methods to facilitate enhanced tetramer staining by improving TCR 
1 . d/' 1" 72 73 117 c ustermg an or mterna IzatIOn .. . 
These studies highlight important issues of T cell frequency, avidity, and 
activation that have implications for analysis of rare autoreactive T cells in 
patients with auto immune disease. The CUITent methodology detects cells that 
are present in blood at frequencies ab ove 0.1 %, or 1/1 ,000. This is below the 
frequency of autoreactive CD4+ cells circulating in blood, and direct detection 
of such rare T cells remains elusive. It is reasonable to attempt direct detection 
strategies in human studies when the antigen challenge is robust, such as in, 
for instance, vaccine trials, but it is unlikely that this approach will suffice for 
studies of disease pathogenesis if peripheral blood is the only source of 
material available for analysis. 
On the other hand, avidity of the TCR-MHC-peptide interaction depends not 
only on the affinity of each TCR for its MHC-peptide ligand, but also on the 
density and clustering of TCR on the T cell surface. Together with factors 
such as the density of the MHC on the surface of the antigen-presenting cells, 
the concentration of peptide, and the type of costimulatory ligands available, 
TCR signaling leads to variable outcomes influenced by the strength of the 
interaction. 
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In c1inical studies of patients with autoimmunity, most T cell staining with 
tetramers is of low-to-moderate avidity, suggesting either that the specific 
MHC-peptides used in the tetramers are not the most avid ligands for 
autoreactive T cells (Le., we are using the wrong antigens) or, more likely, that 
circulating autoreactive T cells are indeed of low-to-moderate avidity and that 
this is intrinsic to their role in immunity. If the latter argument is correct, 
detection and monitoring of low-avidity T cells is an important challenge for 
future c1inical applications. Approaches based on enhancing the c1ustering 
and/or intemalization of TCR-tetramer complexes are one likely direction, as 
foreshadowed by the observation that higher temperatures give better staining. 
It will be worthwhile to search for additional molecular tools to facilitate TCR 
multimerization on the cell surface and increase the overall avidity of 
interaction achieved in large complexes. 
Another promising direction is to take advantage of the association between 
tetramer binding and T cell activation. Even in the absence of antigen-
presenting cells, soluble tetramers of sufficient avidity can activate T cell 
clones, as deterrnined by both surface activation markers and cytokine 
secretion. Thus, analogous to interaction with anti-CD3-activating antibodies 
such as OKT3, addition of MHC-peptide tetramers to CD4+ T cells can elicit 
partial activation responses that may be useful as markers for detection of 
specifie cells. One such tetramer-facilitated activation profile is the up-
regulation of CD4 on antigen responsive CD4+ T cells. This CD4high, CD2S+ 
population has been previously noted to include recently activated T cells, and 
is a hallmark of in vitro-stimulated antigen-specific CD4+ T cells . For 
example, in studies of autoimmune diabetes, the activated, tetramer-positive 
phenotype was correlated with recent onset of disease, suggesting that 
detection of these cells may be a useful marker for disease progression and 
response to therapy 65. 
Detection and monitoring of patients' T cell specificity and phenotype are only 
sorne of the c1inically relevant uses for tetramers. There are a multitude of 
applications for this technology in c1inical medicine and translational research. 
In addition, the ability to load the c1ass II dimer with a variety of peptide 
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antigens enables the combination of tetramer analysis with peptide array 
strategies for epitope identification. 
Peptide-MHC tetrameric complexes described above have undoubtedly many 
advantages. However, one should bear in mind that the use of tetramer 
technology depends primarily on the intimate knowledge of the individual 
peptides presented in the context of a particular MHC class 1 or class Il 
molecule and that T cells with low affinity TCR may not be detected using 
these tools. 
1.5.2.2.Novel oligomers 
The absence of natural soluble TCR molecules in the blood and the low 
affinity of the TCR-MHC peptide interaction have been the main barriers to 
developing simple detection methods. The multimerization of MHC-peptide 
complexes answers partially this latter limitation by allowing an avidity effect 
and the staining of Ag-specific T cells. However, this method, largely used for 
the detection of cytotoxic CDS+ T ceIls, has limitations. The first one of them 
is simply the geometry of display. Streptavidin is a rigid structure and the four 
biotin binding sites are positioned such that the MHC molecules are projected 
in the four cardinal directions. These structural constraints render almost 
impossible the simultaneous engagement of the four MHC molecules. 
Interestingly, a linear display of MHC molecules on synthetic polypeptides 
should lessen these steric problems. 
The second limitation of tetramers is still the low affinity or the resulting low 
avidity. Indeed, the enhancement of binding, provided by multiple binding 
sites, is highly variable and sometimes of limited impact. FinaIly, additional 
limitations come from the T cell itself and a complex set of parameters linked 
to T cell activation, such as cell cycle, membrane fluidity, microdomain 
organization, receptor density, and receptor accessibility, aIl of which 
influence tetramer binding positively or negatively. This complexity explains 
most of the unusual observations that have been made for MHC class Il 
tetramers and their low success rate. In aIl cases, systems of low functional 
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affinity cannot be detected. Thence the critical need of alternative Ag-specific 
detection systems. 
An ideal system of T cel! detection should be endowed with high specificity, 
high reproducibility, high sensitivity, and should work within the 4-25°C 
range. This association should be ideally reversible, should not result in 
activation, induce programmed cel! death, or impair long-term cell viability. 
We summarize below development alternative oligomers of peptide-MHC 
complexes (see also Figure 1-3) 74. 
1.5.2.2.1. Dimer X (BD Biosciences) 
BDTM DimerX reagents are MHC-immunoglobulin fusion proteins developed 
to detect antigen-specific CDS+ T-cells. Three extracellular domains of MHC 
class 1 molecules are fused to the N terminal of VH region of the mouse IgG 1 
through recombinant DNA technology. The expression vector containing the 
fusion protein is then co-transfected with genes containing human ~2-
microglobulin (~2m) into a myeloma cell line which is deficient in 
immunoglobulin heavy chain but retains the expression of immunoglobulin 
lambda (À) light chain. The secreted product is a three-chain complex 
molecule consisting of a recombinant heavy chain of MHC-Ig fusion chain, an 
immunoglobulin light chain disulphide-bonded to the heavy chain, and a non-
covalently associated human ~2m molecule. The bivalent nature of peptide-
binding sites of the DimerX molecules increases the avidity of MHC-peptide 
complexes to TCR and results in stable binding to antigen-specific CDS+ T-
cells. Furthermore, the hinge region in the immunoglobulin scaffold of 
DimerX provides a more flexible access for T-cell binding 75 
(www.bdbiosciences.com/pharmingen and Figure 2). 
1.5.2.2.2. Dextramers 
DakoCytomation™ MHC Dextramers consist of a dextran polymer backbone 
carrying an optimized number of peptide-Ioaded class 1 MHC and 
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fluorochrome molecules. The MHC molecules are aligned as pearls on a string 
on the dextran backbone. The biotinylated MHC moieties are attached via 
streptavidins to the dextran backbone carrying a fluorochrome of interest. 
A vidin-biotin bonds ascertain the anchoring of the MHC moieties to the 
dextran backbone that carries the fluorochromes. 
These MHC Dextramers are multimeric reagents that have an apparent higher 
TCR-binding affinity compared to single MHCs. The TCRs experience 
numerous peptide-Ioaded MHCs and an evidently higher binding affinity. The 
higher binding affinity of the MHC-Dextramers is caused by the increased 
avidity, which is the sum of the individual affinities of the multiple MHC and 
TCR interactions. To date, the standard MHC Dextramers allow only 
monitoring ofCD8+ T-cell responses 76. (http://www.dakocytomation.us) 
1.5.2.2.3. Liposomes as Artificial Antigen Presenting Cells 
Liposomes that display recombinant MHC c1ass II molecules and can bind in 
an Ag-specifie manner to CD4+ T cells have been developed in an attempt to 
track cells which could not be detected using c1ass II tetramers. As mentioned 
earlier, a strong correlation exists between binding of MHC c1ass II-peptide 
multimers to CD4+ T cells, the affinity of TCR, and the tempe rature used for 
multimer binding. Whereas low-affinity TCR can only bind MHC c1ass 11-
peptide complexes at 37°C, high-affinity TCR also stain at 4°C. Fluorescently 
labeled liposomes added to CD4+ T cells can co-Iocalize with markers for 
endocytotic compartments, indicating that the se T cells have the potential to 
internalize multimers. 
These liposomes, also known as artificial APC (aAPC) were shown to mimic 
physiological interactions with T cells by allowing migration of molecules 
whose accumulation is an essential requirement and by inducing T-cell 
activation, through formation of immunological synapse. The composition of 
these aAPC allows free movement of the MHC-peptide complexes in the 
artificial membrane leading to active c1ustering of TCR-MHC molecules at 
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the immune synapse after interaction between aAPC and T cells. To date, 
multimer based methods for the detection of antigen-specific T cells rely 
mainly on absolute affinity between the ligands and do not al10w the 
physiologic phenomenon of capping. This may limit the use of these tools to 
detection, not manipulation, of antigen-specific T cel1s 77. 
1.6 Project Rational and Research Objectives 
The pathogenesis of HIV infection is complex and multifactorial in humans, 
with genetic susceptibility, host responses, and viral factors ail playing 
significant roles. The development of small animal models addressing sorne of 
these variables is paramount in assessing the impact of different vaccine 
strategies. Such a model will also be very useful in the pre-clinical validation 
of the functionality of immune monitoring tools. 
On the other hand, to date, detection of Class II-restricted antigen-specific T 
cells by oligomeric MHC-peptide complexes has been faced with a host of 
physiological and biochemical challenges. Staining intensity being a direct 
function of T - cell receptor affinity, low-affinity TCR-bearing CD4+ T 
lymphocytes might not be recognized by existing tools, such as tetramers. In 
order to bring new insights for the quantification and dynamic studies ofCD4+ 
T cell responses, we undertook the development of novel multivalent 
molecules of peptide-MHC Class II complexes for the identification and 
stimulation of antigen-specific T cel1s. 
The specific research objectives that lead to the undertaking ofthis work were: 
1. To use double transgenic humanized mice expressing chimeric 
murine - human MHC Class 1 and Class II molecules (CHAD) as a 
small animal model for studying functional signatures of cellular 
immune responses in the context of HIV vaccines. 
II. To characterize the immunogenicity of recombinant Vesicular 
Stomatitis Virus (VSV -A V3) and Adenovirus serotype 5 (Ad5) 
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vectors expressing HIV -1 Gag A antigen inoculated in CHAD mice 
via a mucosal route. 
III. To study the specificity and potency of systemic immune responses 
following mucosal immunizations using the above viral-vector 
based vaccines. 
IV. To map epitopes within Gag subtype A in transgenic mice using 
synthetic peptide pools and matrices towards the identification of 
HLA-restricted responses and their comparison to immunogenic 
epitopes observed in HLA-A2 and HLA-DR individuals infected 
by HIV-l. 
V. To generate novel multimeric reagents with increased avidity for 
the detection and manipulation of the intensity and qua lit y of scant 
numbers of antigen-specific CD4 T lymphocytes. 
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2 Generation of a chimeric human A2DR transgenic mouse 
model: a unique platform for validation of immunization 
and immune monitoring strategies 
GENERATION OF A CHIMERIC HUMAN A2DR TRANSGENIC 
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~- SUMMARY 
ln the context of development of immune-based treatment against a variety of 
infectious or non-infectious diseases, the availability of a valid small animal 
model is crucial for the prec1inical evaluation of novel prophylactic and 
therapeutic vaccines and immunotherapies. In fact, successful progress towards a 
promising HIV vaccine has been largely hindered over the past two decades due 
to lack of one such model. We have generated a humanized, HLA transgenic 
(Chimeric Human A2DR) mouse model. These mice crossed on a DBA/2 
background express high levels of human MHC Class 1 A *0201 and MHC Class 
II DR *0101 molecules. This expression is systematically screened for by flow 
cytometry using anti-HLA antibodies on peripheral blood and by PCR on tail 
tissue using allele-specific primers. We extensively immune-characterized these 
mice using established phenotypic markers and functional assays. When 
compared to the wild type strain, these mice show comparable frequencies of 
CD3, CD4, CD8, B220, CDlib and CDllc positive cells in peripheral organs. In 
the thymus, different stages of T cell development are conserved. Naïve and 
effector T cell populations are also maintained or generated in the context of 
immunization assays. In addition, when stimulated with different polyc1onal T 
cell stimulators or antigen-specific peptide pools in the context of mucosal 
immunization experiments, splenocytes and lymph no de cells from the se mice 
show normal proliferative and functional capacity. Our data show evidence of 
HIV immunodominant epitopes, originally mapped in humans, result in antigen-
specific responses in this mouse model following mucosal immunization with two 
distinct viral vectors expressing HIV Gag from Clade A, namely VSV A V3 and 
Adenovirus serotype 5. This transgenic mouse model promises to be an important 
tool in testing novel vaccine strategies and elucidating protective mechanisms 
involved therein. Moreover, this model constitutes an excellent platform for the 
identification of new epitopes and for the validation of emerging immune 
monitoring tools in prec1inical stages. 
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INTRODUCTION 
A major limitation in advancing the study of a host of chronic viral infections, 
auto immune disorders or tumors is the lack of suitable small animal models which 
allow accurate, quantitative monitoring of candidate vaccines and therapeutic 
regimens. Deciphering putative mechanisms of immunologic events following 
immunization are difficult in human subjects and require further elucidation in 
order to define important parameters for improving vaccine design and efficacy. 
The Major Histocompatibility Complex (MHC), a set of polymorphic genes 
expressed on the surface of host cells, is involved in antigen presentation to 
immune cells. Since the discovery of HLA genes, several groups have developed 
HLA Class 1 and II transgenic mice, created to facilitate the study of HLA-
restricted CTL and helper responses that may be crucial in generation of 
therapeutic targets against viral disease, cancer and autoimmune diseases. This 
has been extensively reviewed elsewhere 1-4,21. 
CD8+ cytotoxic T cells, through their TCR, recognize MHC Class 1 molecules 
complexed with peptides derived from endogenously processed proteins. One of 
the large st common HLA Class 1 alleles, HLA-A*0201 (HLA-A2.1) represents 
28% of the Caucasians in North America, and has been used as an ideal target 
transgene for transgenic mice systems. It is now established that the a 1 and a2 
domains of the MHC Class 1 molecule restrict the ensuing response and play a 
dominant role in the generation of specific CTL repertoire across species. In the 
case of HLA Class 1 transgenic mice, and in order to improve the efficiency of 
interaction of the mouse CD8 co-receptor with the HLA Class 1 molecules, the 
third domain of the human Class 1 heavy chain was substituted by the a3 to 
cytoplasmic do main of its murine counterpart 20. These transgenic mice are 
considered the 'c1assic' A2.1/H-2 transgenics, which express heterodimeric HLA-
A2.1 molecules in an H-2 Class 1 wild-type context. Transgenics expressing 
chimeric molecules have been widely used for the study of HLA-A2.I-restricted 
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responses 5-7. On the other hand, transgenic mice expressing human MHC Class 
II molecules have also been generated and used as a model for studying HLA 
Class II -restricted patterns of immune response. More specifically, the HLA Class 
II DRB*OIOl allele displays an allelic frequency of 9.3% in the North American 
Caucasian population, and plays an important role in many infectious and non-
infectious diseases including Rheumatoid Arthritis, HIV, Hepatitis B, diabetes, 
and Goodpasture's disease. In this chimeric model, and to counter the inefficiency 
of interaction of mouse CD4 co-receptors with HLA Class II molecules, the 
peptide-binding region ofthe MHC is derived from the human HLA-DR sequence 
whereas the CD4-binding do main conserves the murine Class II sequences 8,9,10. 
It is nowadays evident that an effective and potent CD4 help is crucial both to 
priming and maintenance of CD8 mediated responses Il. In this study, we 
generated a double transgenic murine line that expresses chimeric human-mouse 
MHC Class 1 and Class II molecules by crossing transgenic HLA-A *0201 and 
HLA-DR*OIOl mi ce which co-express normal levels of endogenous murine 
MHC. This system offers a convenient small animal model for the pre-clinical 
evaluation of vaccine regimens and other therapeutic interventions in the context 
of specific aIle les without compromising the endogenous murine T cell numbers 
and other cell populations involved in antigen processing and presentation. We 
thoroughly immune-characterized these mice and validated this model in primary 
immune response scenarios using two different viral vector-based systems, 
namely a modified vesicular stomatitis virus (VSV-AV3) and Adenovirus 
serotype 5 (Ad5) expressing Clade A Gag of HIV-1. 
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MATERIALS & METHOnS 
Generation of HLA transgenic mice 
To generate HLA-HLA-A*0201/HLA-DR*0101 H-2Dd/ I_Ad double transgenic 
mlce (referred herein as HLA-A2.l/DRl), HLA-A2.1/H-2Dd transgenic mice 
were crossed with HLA-DRlII-Ad mi ce and progeny were screened for the 
presence of HLA-A2.1 and HLA-DRI chimeric transgenes until double 
transgenic animaIs were obtained. These mice express a transgenic mono chain 
MHC Class 1 molecule in which the C-terminus of the human ~2-microglobulin 
(~2m) is covalently linked to the N-terminus of a chimeric heavy chain (HLA-
A2.1 al-a2; H-2Db a3, transmembrane, and intracytoplasmic domains), and a 
chimeric MHC Class II molecule consisting of the recombinant MHC class II 
molecule in which the al and ~1 domains of mouse I_Ed were replaced by the 
corresponding do mains of human DR *0101 molecule 8, 10. PCR on tail tissue was 
performed using primers previously described 12. Flow cytometry on tail blood 
using anti-A2-FITC and anti-DR-PE labeled antibodies allowed selection of mice 
that were high expressors of transgene. In addition, these mice express a full set of 
endogenous H-2Dd and I_Ad molecules. 
Mice were bred and maintained at the Animal Care Facilities of the CHUM-
Hôpital Notre-Dame, under specified pathogen-free (SPF) conditions, and sentinel 
mice were routinely tested for absence of mouse pathogens. AlI animal 
procedures described herein were approved by the institution's ethical review 
committee CIP A. 
Harvesting of cells 
Cells from lymphoid organs were isolated by mechanical disruption, 
homogenized into single cell suspensions and treated with Red Blood Cell (RBC) 
lysis buffer (0.15 M NH4CI, 10.0 mM KHC03, 0.1 mM Na2EDTA, pH 7.4). For 
immune compartment analysis, blood was collected by heart puncture. Blood 
from tail vein was collected using EDT A containing disposable Sarstedt 
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Microvette®200 blood collection microcapillary tubes. RBC were lysed as 
described above. 
Phenotyping, immune compartments and Flow Cytometry 
1x106 cells from either the thymus, Lymph Nodes, spleen, or blood where labelled 
with a panel of fluorochrome conjugated antibodies [see Antibodies below] and 
respective isotype controls. The assessment of the levels of expression of 
endogenous and transgenic MHCs, and the phenotypic characterization of 
immune cell subsets were performed using a BD LSR II flow cytometer. Data 
analysis was performed using either CellQuest™ or DiVa™ analysis software (BD 
Biosciences, San Jose, CA). 
Antibodies 
The following antibodies from BD Pharmingen and BD Biosciences were used: 
PE-Cy7 anti-mouse CD4 (L3T4) (RM 4-5); APC anti-mouse CD3e chain (145-
2Cll); Alexa-700 anti-mouse CD3e chain (500A2); APC-Cy7 anti-mouse CD8a 
(53 - 6.7); R-PE anti-mouse CDllc (HL3); R-PE anti-mouse CDllb (MI170); 
APC anti-mouse CD25 (PC61); R-PE anti-mouse CD44 (IM7); APC anti-mouse 
CD62L (MEL-14); PE-Cy5 CD45R/B220 (RA3-6B2); R-PE anti-mouse H-2Dd 
(34-2-12); R-PE anti-mouse I_Ad (AMS-32.1); R-PE anti-HLA-DR (G46-6, 
L243); FITC anti-HLA-A2 (BB7.2). 
Viral Vectors 
VSV A V3-Gag (Consensus Subtype A) and VSV A V3-GFP control vectors were 
generously gifted by Dr J. Hiscott (McGill University, Montreal) and 
subsequently propagated and purified from vero cells in Biosafety Level 2 
laboratory. The VSV-AV3 vector has been previously described by Stojdl DF et 
al 13. 
The Clade A Gag-expressing Adenovirus serotype 5 (Ad5) vector was generated 
in our laboratory using the Clade A Gag insert of the VSV intermediary cloning 
vector. Briefly, the 1550 bp fragment of Gag Clade A (Gene Bank U51190) was 
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inserted into the EcoRI site of the Ad5 shuttle vector pDC315 (Microbix) and 
screened for correct orientation. 293 cells were co-transfected with 
pDC315GagA+ and the adenoviral genomic vector pBHGloxdelElcre (Microbix) 
(Figure SIl in Appendix) and successful recombinant viruses were picked and 
tested for production of Gag prote in (Figures S 12 & S 13 in Appendix). Positive 
clones were propagated on 293N3S cells, in spinner flasks. The recombinant Ad5 
viruses were purified by double cesium ch10ride gradient ultracentrifugation and 
concentrated by means of Centricon® centrifugaI filter devices (Millipore). Viral 
stock titration was performed by lytic plaque assays on 293 cell monolayers. 
Expression of Gag was confirmed by western blot. Control vectors in the 
immunization protocol consisted of the virus containing the empty vectors 
(Ad5CTL) and were prepared similarly. 
Immunizations 
Groups of 6 transgenic mice aged between 6-8 weeks were immunized intranasaly 
(i.n.) through both nostrils with 10 III of VSV AV3-GagA diluted to 5xl06 
pfu/mouse/l 0 III in LPS free PBS (Sigma) just prior to inoculation and kept on ice 
or with 1 x 108 pfulmouse/1 0 III of AdGag. Control mice received respective 
amounts of AV3-GFP, AdCTL, or PBS. Immunizations were carried out under 
general gas anesthesia using isofluorane/oxygen mixture. Splenocytes were 
harvested 7 days following immunization. AB immunizations were carried out 
according to animal experimentation protocols approved by the institutional 
animaIs ethics committee. Immunized animaIs were maintained under 
microisolator-barrier conditions in a Biohazard Class II (P2) -equipped facility 
and given food and water ad libitum. 
Peptides 
Peptide pools consisting of 15 amino acid (AA) length peptides, overlapping by 
Il AAs and spanning the entire sequence of HIV -1 Consensus Subtype A Gag, 
were obtained from the NIH AIDS Research and Reference Reagent Program 
(MD, USA). Individual peptides were dissolved in DMSO at 10 mg/mL, aliquoted 
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into matrix pools, and used at a final concentration of 1 J.lg per peptide per 
stimulation. 
Stimulation Assays 
Briefly, splenocytes (20x 106 /mL in PB S) were labeled with a predeterrnined 
concentration of 5-(and-6)-carboxyfluorescein diacetate-succinimidyl ester 
(CFSE; Molecular Probes, Eugene, OR) freshly diluted solution in PBS, 
incubated 8 minutes at RT in dark, washed twice with PBS supplemented with 
2%FCS to quench the dye, and plated at 2x 1 06 cells per well during 5 days in 96-
ImL-deep-well-plates (Nunc) in complete DMEM culture medium (SIGMA) 
supplemented with 10% FCS, 10 mM HEPES (Gibco), 1 % Penstrep (Gibco), and 
5xl0-5 M 2-mercaptoethanol (Sigma). CFSE-Iabeled cells were cultured ln 
medium alone for negative control (NS) or in presence of 2.5J.lg/mL of 
Concavalin A (ConA) for positive control. Peptide pools or individual peptides 
were used at a concentration of 1 J.lg per peptide per stimulation. 
MHC Class II Blocking Assay 
Splenocytes from vaccinated and control mlce were labeled with CF SE and 
cultured during 5 days (as described above) in the presence ofpurified anti-HLA-
DR L243 antibody at 1 J.lg/mL and 10 J.lg/mL. L243 antibody was added 1hr prior 
to addition of Gag peptide pool and again 48hrs following stimulation. 
HLA-A2 Tetramer Staining 
Direct ex vivo staining using HLA-A2/Gag-specific (SL YNTV ATL P 17; 
FLGKIWPSYK p15, epitopes) and CMV (GILGFVTFL epitope) control 
tetramers was perforrned as previously described 14. The tetramers were obtained 
from the Tetramer Core Facility, Canadian Network for Vaccines and 
Immunotherapeutics (CANVAC), Montreal, Canada. 
Statistical Analysis 
Probability levels and p values were calculated using two-tailed Student T -test. 
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RESULTS 
Expression of MHC endogenes and transgenes in periphery and thymus 
Blood collected from tail vein was marked with antibodies against HLA-A2 and 
HLA-DRI, as well as endogenous H-2Dd and I-Ad molecules. As illustrated in 
Figure l, CHAD mice express high levels of both chimeric human MHC Class 1 
(93.40% of cells in Ml) and Class II (43.57% of cells in Ml) molecules in 
periphery. In addition, when compared to wild-type DBA/2 mice, CHAD mice 
maintain comparable levels of endogenous H-2Dd (91.29% for CHAD vs. 99.23% 
for DBA/2 in Ml) and I_Ad molecules (49.28% for CHAD vs. 43.65% for DBA/2 
in Ml) (Fig lA). In the thymus, expression of the transgene in CHAD mice did 
not hamper expression of the endogenes as shown in Fig. lB by nearly 
overlapping histograms of H-2Dd and I_Ad expression on CHAD vs DBA/2 
thymocytes. Parallel screening through Polymerase Chain Reaction (PCR) using 
previously described allele-specific primers l2 allowed amplification of both HLA-
A2 (lane 2, band at 813bp) and HLA-DRI (lane 3, band at 315bp) from tail tissue 
(Fig IC). 
T cell maturation in the thymus 
To assess thymocyte differentiation, we looked at the phenotypic stages which 
correspond to developmental checkpoints in the mouse, namely, Double Negative 
(DN CD4-CD8-: mean2.80±0.36% vs. 2.23±0.15% of total thymocytes in CHAD 
vs. DBA/2), mouse Immature Single Positive (ISP, CD8+CD3-), Double Positive 
(OP CD8+CD4+: mean 67.73±4.61% in CHAD vs. 81.53 ± 2.06% in DBA/2 of 
total thymocytes) and Single Positive (SP, CD4+CD3+: mean 18.37±4.23% in 
CHAD vs. 9.60±0.95% in DBA/2 and SP CD8+CD3+: mean 2.80±0.26% in 
CHAD vs. 1.70±0.2% in DBAl2) populations. Furthermore, we looked at the DN 
subsets based on surface CD44 and CD25 expression, numbers indicating the 
percentage of each subset within the total DN population: DNI (CD44+2Y: mean 
17.10±0.72% in CHAD vs. 18.10±1.21% in DBA/2), DN2 (CD44+25+: mean 
9.60±0.30% in CHAD vs. 5.87±0.64% in DBA/2), DN3 (CD44-25+: mean 
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43.63±7.77% in CHAD vs. 57.70±0.72% in DBAl2), DN4 (CD44-25-: mean 
29.70±7.22% in CHAD vs. 18.33±1.24% in DBAl2, p=0.05), as shown in Figure 
2A. The total CD3+ population in the thymus was represented by a mean of 
23.70±4.71% in CHAD and 16.00±1.35% in DBAl2 of total thymocytes (p=0.05). 
The different populations described above showed normal distribution in CHAD 
and DBAl2 mice, with p values> 0.05, except in the DN4 and CD3 populations, 
whereby the p-value was equal to 0.05. 
Distribution of Lymphoid Subsets in Periphery 
Subsets of different lymphoid compartments were analyzed in peripheral tissues 
of CHAD vs. wild type DBAl2 mice using multiparameter flow cytometry. These 
compartments inc1uded: CD3+, CD4+, CD8+, DP, and CD62LhiCD44IO, 
CD62L hiCD44hi, CD62L1oCD4410, CD62L1oCD44hi populations within CD3+CD4+ 
and CD3+CD8+ cells, in Lymph Nodes (Fig 2B), Blood (Fig2C), and Spleen (Fig 
2D), in addition to the B220+ compartment (Figure S2.1 supplementary data). Our 
results indicate that the transgenic CHAD mice overall have conserved basic 
immune cell compartments and subsets relative to wild-type DBAl2 mice. Other 
compartments that were also tested inc1uded CDl1b+, CDllc+ and CD3-CDllc+ 
cells in the spleen and lymph nodes [data not shown]. The p-values were > 0.05 
unless otherwise specified, indicating that there was no considerable statistical 
difference between the studied cell populations in CHAD vs. wild type mice. 
Peripheral Lymph Nodes. In the LN the relative distribution of the following 
subsets was observed in CHAD vs. DBAl2. 78.l0±3.41 % vs. 82.l0±1.08% of 
cells were CD3+. Within the CD3+ compartment, 22.83±2.95% vs. 24.27±1.62% 
of cells were CD8+, 69.50±2.52% vs. 67.77±1.52% were CD4+, and 5.27±0.96% 
vs. 6.27±0.58% were CD4+CD8+ (Fig 2B). Of the CD3+CD8+ cells 68.57±6.00% 
h' 1 
vs. 66.17±6.55% were CD62L 'CD440; 18.70±3.66% vs. 18.33±3.61% were 
CD62LhiCD44hi ; 7.20±4.16% vs. 9.80±4.33% were CD62L1oCD441o; and 
1.97±O.55% vs. 3.33±1.45% were CD62L1oCD44hi . Similarly, of the CD3+CD4+ 
cells 49.87±9.65% vs. 55.77±10.29% were CD62LhiCD44Io; 34.63±5.02% vs. 
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24.30±6.61 % were CD62LhiCD44hi ; S.17±1.9S% vs. S.S3±0.71 % were 
CD62L10CD441o; and 6.S0±0.17% vs. Il.43±4.S8% expressed a CD62L1oCD44hi 
phenotype (Fig 2B, p>O.OS). B220+ cells in peripheral lymph nodes were 
represented by 33.20±4.83% in CHAD vs. 24.83±l.S8% in DBA/2 mice (p=O.OS) 
(Fig. S2.1 supplementary data). 
Blood. Blood was collected through heart puncture and displayed the below 
distribution following RBC lysis. 41.23±12.06% in CHAD vs. 31.67±S.20% of 
DBA/2 blood cells were CD3+. Within the CD3+ compartment, 21.80±2.88% vs. 
18.93±0.96% of cells were CD8+, and 68.S3±2.S2% vs. 67.77±l.S2% were CD4+ 
(Fig 2C). Of the CD3+CD8+ cells 78.30±S.79% vs. 72.10±2.80% were 
CD62LhiCD441o; 16.23±4.31% vs. 1S.S3±1.70% were CD62LhiCD44hi ; 
2.10±0.70% vs. S.33±2.02% CD62L1oCD441o; and 0.73±0.3S% vs. 2.20±0.30% 
CD62L1oCD44hi . On the other hand, of the CD3+CD4+ blood cells, 80.43±2.86% 
vs. 78.43±3.S7% were CD62LhiCD441o; 12.33±1.76% vs. 9.27±2.17% were 
CD62LhiCD44hi ; 3.03±0.64% vs. 2.80±1.4S% were CD62L1oCD441o; and 
2.00±1.08% vs. 8.07±3.SS% expressed a CD62L1oCD44hi phenotype (Fig 2C). 
The p values were greater than O.OS except for the CD4+ CD62L1oCD44hi 
(p=O.OS) and the CD8 CD62L1oCD44hi (p=0.01) populations. 42.07±9.0S% of 
CHAD vs. 4S.60±4.11 % of DBA/2 blood cells expressed B220 (p>O.OS) (Fig. 
S2.1 suppl. data). 
Spleen. In the spleen 22.S7±S.67% vs. 16.43±1.38% of cells were CD3+. Within 
the CD3+ compartment, 19.83±2.06% vs. 26.20±0.40% of cells were CD8+ 
(p=O.Ol), 69.97±3.91% vs. 60.63±1.27% were CD4+ (p=0.02), and 3.77±0.3S% 
vs. 3.20±0.44% CD4+CD8+ (Fig 2D). In CD3+CD8+ splenocytes 49.93±4.70% vs. 
42.97±4.77% were CD62LhiCD441o; 41.47±6.31% vs. 47.90±4.33% were 
CD62LhiCD44hi ; 3.03±1.19% vs. 3.10±1.21% CD62L1oCD441o; and 3.67±O.2S% 
vs. 3.90±O.10% CD62L1oCD44hi • In the CD3+CD4+ compartment 49.07±3.4S% 
vs. 49.93±6.S1% were CD62LhiCD441o; 31.93±3.69% vs. 28.S0±4.S8% were 
CD62LhiCD44hi ; 6.07±2.01% vs. 7.40±0.69% were CD62L1oCD441o; and 
1 hO 10.S0±O.S3% vs. 11.S0±2.91% expressed a CD62L °CD44 1 phenotype (p>O.OS). 
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B220+ cells constituted 51.00±3.30% of CHAD vs. 62.37±2.40% of DBA/2 
splenocytes (p=O.OI) (Fig. S2.l suppl. data). 
Gag-specifie primary CD4+ and CDS+ responses following VSV A V3-GagA 
and Ad5GagA mucosal immunizations 
To detennine whether transgenic CHAD mice represent a useful model in testing 
vaccine strategies, their immune competency was tested in two separate viral 
vector based mucosal immunizations. Groups of 5 to 6 mice were inoculated 
intranasaly (i.n.) with either VSV-AV3/Gag or Ad5/Gag (derived from consensus 
subtype A) and corresponding viral vector controls (CTL). Splenocytes from 
immunized mice were tested using an in vitro CFSE proliferation assay against 
pools of Gag Clade A peptides. Immunization of CHAD mice with viral 
constructs expressing Clade A Gag led to significant and reproducible 
proliferative CD4 responses against Gag peptides from a previously tested pool of 
10 immunodominant peptides in the VSV -A V3/Gag immunized group (Fig 3A, 
Fig 4A, and 4B, Gag pool). Following 5 days of in vitro stimulation with the 
above-mentioned peptide pool, 17.6% of CD3+CD4+ splenocytes were CF SElo 
over a background of 0.5% CF SElo cells in negative control samples (i.e. 
unstimulated, NS), while splenocytes from mice immunized with VSV A V3 
vector alone immunized group showed a 4.5% of CD3+CD4+ CFSElo cells 
following stimulation with the peptide pool (Fig 3A). CD3+CD8+ splenocytes 
proliferated concomitantly implying shared CD4 and CD8 epitopes among the 15-
mer Gag peptide pool used in stimulations. 32.3% of CD3+CD8+ cells were 
CFSElo in VSV -A V3 Gag group following 5-day in vitro stimulation compared to 
a vector-induced 6.1 % CD3+CD8+ CFSElo cells (Fig 3B). Similarly, Ad5/GagA 
immunized mice showed antigen-specific CD4+ cell proliferation in the spleen 
following in vitro stimulation with Gag peptide pool. 13.5% of CD3+CD4+ 
splenocytes were CFSElo compared to 5.2% in the Ad5 vector immunized group, 
over a background proliferation of 0.2% for Ad5Gag vs. 3.6% for Ad5 vector 
control in media control samples (Fig 4C, Gag pool NS samples). Furthennore, a 
specific CD4 proliferative response was observed when individual Gag peptides 
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constituting the above pool were tested in a similar stimulation assay (Fig 3C and 
S2.2A in suppl. data). Gag peptides G066, G065, G057 and G042 yielded the 
strongest response, resulting in 7%, 4.6%, 4.5% and 3.8% of CD3+CD4+ CFSElo 
cells (Fig 3C). A similar response was also observed when individual mice from 
each group were tested against individual peptides (Fig. S2.2B in suppl. data). 
Low levels of background proliferation were detected after control vector 
immunization, however this was significantly lower than the response in 
immunogen immunized groups. Splenocytes from aIl groups did respond strongly 
to a polyclonal stimulation with concanavalin A (Con A) (Fig 3A, 3B and Fig 4B, 
4C, Con A). 
In vitro bloc king of HLA-DR molecules results in a reduction of antigen-
specifie CD4+ proliferation 
Based on the observation that mucosal immunization of CHAD mice with Clade 
A Gag expressing viral vectors resulted in significant proliferation of peptide-
specific CD4+ T ceIls, we next tested whether this response was restricted to the 
transgenic human MHC Class II molecules. As described in Materials and 
Methods, we performed peptide stimulations of splenocytes from vaccinated vs. 
control mice in the presence of two concentrations of anti-HLA-DR (L243) 
antibody at 1 Ilg/mL/2x 106 vs. 10 Ilg/mL/2x 1 06 splenocytes. A second aliquot of 
L243 was further added following 48hrs of culture to block de novo expression of 
Class II molecules on the surface of APCs as much as possible. Proliferative 
CD4+ cell responses were considerably reduced following the addition of 10 Ilg of 
L243 (twice during a 48hr interval) and to a lesser extent following the addition of 
1 Ilg of L243 (Fig 4A). The following blocking effect was observed in VSV -A V3 
Gag immunized group, 16.4% of CD3+CD4+ cells were CFSElo following 
stimulation with Gag peptide pool without any blocking antibody, this number 
decreased to 13% and 9.7% following the addition of 1 Ilg and 10 Ilg of L243, 
respectively (Fig 4A and 4B). In the Ad5 Gag group, the numbers of CD3+CD4+ 
CF SElo cells were 13.5%, 8.2% and 5.6% when no amount of antibody, or 11lg, 
and lOllg of L243 were added, respectively (Fig 4A and 4C). The residuallevel of 
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proliferation observed in the se stimulations might be attributed to endogenous lAd 
presentation as weIl as, on sorne level, to background activation observed due to 
reactivity to viral vector (5.6% in VSV -A V3 CTL and 4.2% in Ad5 CTL control 
vectors in 10 J.lg/mL L243 samples, Fig 4B and 4C). These ce Ils were also 
brighter in CFSE, suggesting blockade at early stages of proliferation. On the 
other hand, the proliferation of CD8 cells was also impaired to sorne extent 
following addition of anti-HLA-DR antibodies (data not shown), implying a role 
of CD4 help for effective CD8 T cell proliferation. This involvement in promoting 
the quality of CD8 response, their clonaI expansion and survival, as weB as 
possible mechanisms involved therein have been addressed elsewhere Il,15. 
Primary HLA-A2-restricted CD8 T cell response following VSV -A V3/Gag 
immunization 
We measured HLA-A2-restricted CD8+ T cells responses by direct ex-vivo HLA-
A2 Class 1 Tetramer staining of splenocytes from vaccinated and control animaIs, 
7 -days post immunization with VSV -A V3/Gag, using HLA-A2 tetramers 
recognizing either Gag p 15 (FLGKIWPSY[S]K), Gag p 17 (SL YNTV ATL) or 
control pp65 CMV (GILGFVTFL), which are previously described epitopes in 
humans (Fig. 5). 1.3% of CD8+ cells were HLA-A2/ p15 Tetramer positive, 
implying that epitopes previously identified in humans and restricted by HLA-A2 
are presented and recognized in the CHAD model. Tetramer staining on 
splenocytes from groups that received vector alone or PBS controls was below 
0.2% with sorne values lower than background levels. We did not observe any 
response to the Gag p17 epitope through A2 p17 Tetramer staining. Lack of 
staining with HLA-A2 tetramers in HLA-A*0201 mice has been observed 
previously and attributed to the relatively poor interaction between muCD8+ 
receptor and the a3 domain of the tetramer Class 1 heavy chain. This has been 
circumvented through the generation and use of chimeric murine-HLA-A2 
tetramers 16,19. 
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DISCUSSION 
ln the present study, we developed a chimeric human HLA-A2.1/DRI MHC 
transgenic mouse model and validated it as a platform for testing vaccine 
strategies using two separate viral vector based mucosal vaccines against HIV -1, 
namely, recombinant VSV-AV3 and Adenovirus serotype 5 expressing Clade A 
Gag. Although MHC transgenic mouse models expressing A2.1 and/or DRI have 
been developed previously, to our knowledge, this is the first study testing the 
immunogenicity of mucosal HIV vaccines in such a model. We demonstrate here 
that mucosal immunization with either VSV - or Adenovirus-based vectors results 
in primary antigen-specific CD4+ and CD8+ systemic T cell responses that could 
be detected directly from the spleen 7 days post-immunization. The use of in vitro 
stimulation assay of CFSE labeled splenocytes in combination with synthetic 
HIV -1 de ri ved peptide pools allowed mapping of T -cell epitopes which were 
previously identified as being immunogenic in HIV -1 infected humans. Moreover, 
sorne of these epitopes are conserved across HIV -1 clades (A, B, and C), 
indicating that these mucosal vaccines can be important in eliciting cross-clade 
systemic cell mediated responses. Whether these vaccines induce mucosal 
immune responses and lead to protection against challenge in this transgenic 
model remains to be tested. 
First, we de scribe the expression of endogenous and transgenic MHC molecules 
in this model. We then look at the difIerent developmental stages of T cells in the 
thymus and immune compartments in the periphery of naïve CHAD mice, using 
wild type DBA/2 mice as parental control for endogenous MHC expression. Our 
results show that CHAD mice express high levels of transgenic Class 1 and Class 
II molecules in periphery, and that expression of the endogenous H-2Dd and I-A d 
molecules is conserved both in periphery and thymus (Figure 1). In addition, we 
studied the different thymocytes differentiation stages, including DN 1 to DN4 
populations which showed a normal distribution (Figure 2A) as did the different 
cell subsets in periphery including cells of the lymph nodes, blood and spleen 
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(Figure 2B, C, & D), including CD3, CD4, CDS populations and subsets 
delineated by the CD44 and CD62L markers. Therefore, the presence of human 
MHC molecules did not cause abnormal immune cell differentiation and 
distribution in these mice. 
Next, in order to study primary immune responses elicited in mice vaccinated 
intranasaly with either recombinant VSV -A V3 or Ad5 vectors expressing Gag 
from Clade A HIV -l, we used several pools of 15-mer Gag peptides overlapping 
by Il amino acids. We identified a pool of 10 peptides (Table 1) which resulted in 
considerable systemic CD4+ and CDS+ responses and used this pool in further 
stimulation assays. These experiments did validate the concept that T -cell 
epitopes previously defined in HIV-l-infected HLA-A2 or HLA-DR humans 
induce significant antigen-specific T cell responses in HLA-A2/DRl transgenic 
mice. This in tum infers the likelihood of identifying important epitopes through 
epitope mapping in the CUITent transgenic model, which might be immunogenic in 
humans. 
We quantitated the pnmary response to these peptides through an in vitro 
proliferation assay alongside CFSE labeling of bulk splenocytes (Figures 3 & 4). 
Mice from either VSV -A V3/Gag or Ad5/Gag immunized groups showed antigen-
specifie proliferation of CD4+ and CD8+ cells. Remarkably, in the VSV -A V3/Gag 
immunized group, and after 5 days of in vitro stimulation, 17.6% of CD3+CD4+ 
and 32.3% of CD3+CD8+ ceUs were CF SElo, while vector alone immunized group 
did not show any significant response. Background levels of proliferation of 
splenocytes cultured in media alone were negligible (Figures 3A & 3B, NS). We 
further stimulated splenocytes with individual peptides constituting the above 
pool which led to the identification of single Gag epitopes (Figure 3C & suppl. 
Fig. S2.2A). Stimulation with individual peptides in sorne cases resulted in up to 
7% CD4+CFSElo cells, such as with the G066 epitope previously identified in 
humans l7 • The above data were reproduced in subsequent independent 
experiments undertaken in parallel to adenoviral immunizations, whereby 16.4% 
85 
of CD3+CD4+ cells were CFSElo in the VSV -A V3/Gag immunized group (Figure 
4A & 4B). In addition, 13.5% of CD3+CD4+ cells were CF SElo in the Ad5 Gag 
counterpart (Figure 4A & 4C). Vector alone immunized groups displayed a 
proliferation of 4.3% and 5.2% of CD3+CD4+ cells in VSV-AV3 CTL and Ad5 
CTL groups, respectively, while cells cultured in media alone (NS) showed a 
background proliferation of 1.5% and 0.2%, respectively (Fig. 4B & C). Our 
results demonstrate that HLA double transgenic mice mount potent systemic 
antigen-specific T cell responses following mucosal immunization with viral 
vectors expressing HIV antigens. 
To study HLA-DR restriction of antigen presentation in the se mice, we further 
performed the in vitro stimulation assays in the presence of anti-DR antibodies 
(Fig 4A, B & C). The addition of anti-HLA-DRI L243 antibody, one hour prior to 
- and 48 hours post- stimulation, resulted in a significant reduction of the number 
of CD4+CFSElo cells. As expected, this effect was more significant when a higher 
concentration of antibody was added. No consistent effect was observed in wells 
where splenocytes from vector alone immunized groups were cultured (A V3 
CTL, Ad5CTL) and background levels of proliferation (NS) were minimal (Fig. 
4A, 8, C). The demonstration of antigen-specific HLA-DRI-restricted responses 
in our study suggests that a putative murine MHC Class II restricted response did 
not prevent generation of systemic CD4+ responses to epitopes presented through 
the chimeric murine-human Class II molecule. 
Previous studies have demonstrated that the co-expression of murine MHC genes 
can hinder development of HLA-A2-restricted T cell responses in HLA-A2 
transgenic mice and this might be compounded by the immunodominance of the 
H-2Dd-restricted epitopes 18. Here we used two HLA-A2 Gag tetramers, namely 
Tet-A2/pI5 and Tet-A2/pI7, to demonstrate HLA-A2 restricted primary 
responses in the VSV -A V3/Gag immunized groups (Fig. 5). Direct ex-vivo 
staining was performed on splenocytes 7 days post-mucosal immunization. We 
observed Gag pl5 specific CD8+ responses, but not Tet-A2/pI7 staining. The 
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absence of the latter could be either due to low frequency of pl 7 restricted CD8 T 
cells in the absence of in vitro expansion of splenocytes by peptide stimulation, 
and/or due to the inherent biochemical characteristics of the HLA-A2 tetramers. 
To circumvent the problem of low affinity of interaction between muCD8 cells 
and a3 domain of HLA-A2, other groups have developed chimeric murine-HLA-
A2 reagents 16,19. Staining with negative control Tet-A2/CMVpp65 and staining 
of splenocytes from vector immunized group yielded equivalent or lower values 
to background levels of fluorochrome-Iabeled streptavidin staining. 
To date, a substantial focus of immunization studies in mice has been dedicated to 
the delineation of murine CD8 responses while murine CD4 responses and 
subsets remain poorly defined. We are confidant that double transgenic mouse 
models such as this will be an important tool in identifying T cell subsets and 
mechanisms involved in correlates of immunity and shed light on the generation 
of memory T cells. In addition, this model can be a valuable instrument in the 
quality control and assessment of diagnostic tools, such as MHC Class II 
tetramers and epitope mapping through synthetic peptide matrices. Our results 
reinforce the advantages of using pools and overlapping peptide matrices 
alongside CFSE labeling, as this allows unbiased screening of either HLA-A2.1 
and DR1 or murine MHC Class 1 and II restricted responses. 
On the other hand, it is well established nowadays that the mucosal route of 
vaccine administration is an important consideration in the development of a 
prophylactic HIV -1 immunization regimen. The two viral vectors used in this 
study represent excellent candidates for prime-boost approaches in HIV vaccine 
development. Pre-existing immunity to vaccine vectors, such as Adenovirus based 
vectors, is a major concem. Since there is little seroprevalence to VSV in the 
human population, it would be interesting to use these vectors in combination, as 
heterologous prime-boost strategies. lt is clear that further exploration of the T 
cell responses against the herein identified peptides is required in this mouse 
model, as the current study did not look at the faith of these antigen-specific cells 
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longitudinally. Currently, different prime-boost regimens using these viral vectors 
are underway to track these cells, and study the generation, maintenance, and role 
of memory ceUs in conferring protection. 
The generation of relevant smaU animal models, which preserve the ability of 
generation of primary and memory immune responses without compromising 
endogenous CD4 and CD8 T cell numbers, would undoubtedly facilitate the 
development and pre-clinical evaluation of much awaited for vaccines and 
therapeutic strategies in a host of disease scenarios. 
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LEGENDS TO FIGURES 
FIGURE 1. Surface expression of endogenous and transgenic MHC Class 1 
and Class II molecules in CHAD vs DBA/2 mice. Peripheral blood cells 
following RBC lysis (A) and bulk thymocytes (B) were stained with anti-HLA 
DR PE, anti-HLA A2 FITC, anti-H2Dd PE, and anti-IA d PE antibodies, followed 
by flow cytometry analysis. White histograms with black contour represent 
DBAl2, grey histograms represent expression in CHAD mice. Data representative 
of several routinely performed screening results. Ml depicts region positive 
relative to negative isotype control. (C) Screening by PCR amplification of HLA 
transgenes from tail tissue. Lane 2: HLA-A2 amplicon, expected band size 813bp, 
Lane 3: HLA-DR amplicon, expected band size 315bp. Products were analyzed 
on a 1 % agarose gel against a Lambda DNA Pst! digest ladder (Lane 1). 
FIGURE 2. (A) T cell maturation in thymus. Anti-CD3, CD4, CD8, CD25, and 
CD44 antibodies were used in multi-parameter flow cytometry to delineate 
different maturation stages of T cells in the thymus. (SP single positive, DP 
double positive, and DNI-4 double negative populations). (B-D) Distribution of 
T cell subsets in periphery. Anti-CD3, CD4, CD8, CD62L, and CD44 antibodies 
were used to assess the relative distribution of peripheral lymphoid cell 
populations. Surface staining was performed on freshly isolated single cell 
suspensions from peripheral tissues, namely, Lymph Nodes (B), Blood (C), and 
Spleen (D). White bars correspond to CHAD, dark bars to DBAl2 mice. The 
results represent the geometrical mean of 3 mice, and y-error bars represent 
standard deviation within a group. 
FIGURE 3. T cell proliferation assay. Splenocytes from mice immunized i.n. 
with 5xl06 pfu of either VSV AV3 Gag or AV3 Vector control were harvested 7-
days post-immunization and stimulated in vitro with 15mer individual Gag 
peptides or peptide pools for a period of 5 days following CF SE labeling. 2.5ug 
(per 2xl 06 cells) of ConA was used as a positive control; negative control samples 
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were cultured in medium alone (NS). (A) Antigen-specific proliferation of CD4+ 
cells following stimulation with a pool of 10 Gag peptides in VSV A V3 Gag 
immunized group (17.6% CD4+CFSE1o cells) vs. vector control group (4.5%). (D) 
Antigen-specific proliferation of CD8+ cells following stimulation with above 
Gag pool in VSV AV3 Gag immunized group (32.3% CD8+CFSE1o cells) vs. 
control group (6.1%). (C) Antigen-specific proliferation of CD3+CD4+ cells 
following stimulation of splenocytes with individual Gag peptides constituting 
above Gag pool (the vertical y-axis represents the percentage of 
CD3+CD4+CFSE1o cells). All above results are representative of 3 independent 
immunization experiments. These data were also reproduced using samples from 
individual mi ce in lieu of pooled samples from a group of mice (Fig. S2.2B). 
FIGURE 4. HLA DR bloc king assay. Splenocytes from mi ce immunized i.n. 
with 5xl06 pfu of either VSV AV3 or lxl0s pfu of Adenovirus (Ad5) vectors 
expressing Gag or respective control vectors were harvested 7-days post-
immunization and stimulated with Gag pool in the absence or presence of anti-
HLA Class II DR antibody (L243) at a concentration of either l/lg or 
1 0/lg/mL/2xl 06 cells. A second aliquot of the same concentration was added to 
wells 48hrs following stimulation to block de novo surface expression of DR 
molecules. The percentage of CD3+CD4+ CFSE10 cells was analyzed by flow 
cytometry as described in Materials & Methods and the blocking effect of anti-
DR antibody on proliferation is represented hereby in bar graphs (4A) and dot 
plots (4B & 4C). 
FIGURE 5. Direct ex-vivo HLA A2 tetramer staining. Splenocytes from mi ce 
immunized i.n. with 5x 1 06 pfu of either VSV A V3 Gag and respective control 
vector, or from mice that received endotoxin-free PBS solution, were harvested 7-
days post-immunization and stained with HLA-A2 Tetramers bearing either HIV 
Gag p 17 or P 15 peptides and control CMV peptide, in an direct ex-vivo assay. 
(*) values below background levels. 
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Table 1. Amino Acid sequence of HIV-1 
Consensus A Gag 15mer peptides used 
in stimulation assays. 
Peptide Sequence 
G034 PIVQNAQGQMVHQSL 
G042 SPEVIPMFSALSEGA 
G044 SALSEGATPQDLNMM 
G054 DRLHPVHAGPIPPGQ 
G057 PGQMREPRGSDIAGT 
G065 PVGDIYKRWIILGLN 
G066 IYKRWIILGLNKIVR 
G072 IKQGPKEPFRDYVDR 
G076 FKTLRAEQATQDVKN 
G083 DCKSILRALGAGATL 
CHAPTER 2 SUPPLEMENTARY DATA 
Table S 2.1: T Cell Maturation in the Thymus, data from individual mice. 
A2DR-A A2DR-B A2DR-C A2DRMean SD DBA/2-D DBA/2-E DBA/2-F DBA/2 Mean SD 
CD3 18.80 28.20 24.10 23.70 4.71 16.40 17.10 14.50 16.00 1.35 
SPCD8 2.50 3.00 2.90 2.80 0.26 1.70 1.90 2.80 2.13 0.59 
SPCD4 14.70 23.00 17.40 18.37 4.23 10.20 15.30 8.50 11.33 3.54 
DN % of total Thy 2.70 3.20 2.50 2.80 0.36 2.20 2.40 2.10 2.23 0.15 
DP CD4+CD8+ 79.50 63.30 67.40 70.07 8.42 81.30 79.60 83.70 81.53 2.06 
DNI CD25-CD44+ 15.90 16.50 17.90 16.77 1.03 19.40 17.90 17.00 18.10 1.21 
DN2 CD25+CD44+ 9.90 6.60 9.30 8.60 1.76 6.60 5.50 5.50 5.87 0.64 
DN3 CD25+CD44- 45.10 54.10 35.60 44.93 9.25 57.10 57.50 58.50 57.70 0.72 
DN4 CD25-CD44- 29.10 22.80 37.20 29.70 7.22 16.90 19.10 19.00 18.33 1.24 
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Table S 2.2: T Cell Subsets in Peripheral Lymph Nodes, data from individual mice. 
A2DR-A A2DR-B A2DR-C A2DRMean SD DBA/2-D DBA/2-E DBA/2-F DBA/2 Mean SD 
CD3 76.60 75.70 82.00 78.10 3.41 83.00 82.40 80.90 82.10 1.08 
CD3+CD8+ 23.90 25.10 19.50 22.83 2.95 22.40 25.10 25.30 24.27 1.62 
CD3+CD4+ 69.10 67.20 72.20 69.50 2.52 69.40 67.50 66.40 67.77 1.52 
CD4+CD8+ 4.40 5.10 6.30 5.27 0.96 6.60 5.60 6.60 6.27 0.58 
CD4 CD62LhiCD4410 52.10 58.20 39.30 49.87 9.65 66.90 46.60 53.80 55.77 10.29 
CD4 CD62LhiCD44hi 35.90 29.10 38.90 34.63 5.02 17.10 30.10 25.70 24.30 6.61 
CD4 CD62L1oCD4410 3.80 4.30 7.40 5.17 1.95 4.90 5.40 6.30 5.53 0.71 
CD4 CD62L1oCD44hi 6.60 6.60 6.30 6.50 0.17 9.20 16.70 8.40 11.43 4.58 
CD8 CD62LhiCD4410 68.30 74.70 62.70 68.57 6.00 72.80 59.70 66.00 66.17 6.55 
CD8 CD62LhiCD44hi 22.90 17.00 16.20 18.70 3.66 18.00 22.10 14.90 18.33 3.61 
CD8 CD62L1oCD4410 4.70 4.90 12.00 7.20 4.16 5.20 10.40 13.80 9.80 4.33 
CD8 CD62L1oCD44hi 2.00 1.40 2.50 1.97 0.55 1.90 4.80 3.30 3.33 1.45 
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Table S 2.3: T Cell Subsets in Peripheral Blood, data from individual mice. 
A2DR-A A2DR-B A2DR-C A2DRMean SD DBAl2-D DBAl2-E DBAl2-F DBAl2 Mean SD 
CD3 45.60 27.60 50.50 41.23 12.06 35.70 33.50 25.80 31.67 5.20 
CD3+CD8+ 21.30 24.90 19.20 21.80 2.88 19.80 19.10 17.90 18.93 0.96 
CD3+CD4+ 72.40 62.20 71.00 68.53 5.53 69.70 71.70 69.60 70.33 1.18 
CD4 CD62LhiCD4410 80.20 77.70 83.40 80.43 2.86 77.00 75.80 82.50 78.43 3.57 
CD4 CD62LhiCD44hi 13.30 13.40 10.30 12.33 1. 76 8.90 Il.60 7.30 9.27 2.17 
CD4 CD62L1oCD4410 2.30 3.40 3.40 3.03 0.64 1.30 2.90 4.20 2.80 1.45 
CD4 CD62L1oCD44hi 1.70 3.20 1.10 2.00 1.08 11.60 8.10 4.50 8.07 3.55 
CD8 CD62LhiCD4410 73.20 77.10 84.60 78.30 5.79 74.90 72.10 69.30 72.10 2.80 
CD8 CD44hiCD62Lhi 19.30 18.10 Il.30 16.23 4.31 13.80 15.60 17.20 15.53 1.70 
CD8 CD441oCD62L1o 2.90 1.60 1.80 2.10 0.70 6.40 6.60 3.00 5.33 2.02 1 
~D8 CD44hiCD62L1~ 1.10 "---- 0.70_ ~.40 _ ,--~.73 _ ~3~ _2.20_ 1.90 2.50 2.20 0.30~ 
--- ---
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Table S 2.4: T Cell Subsets in Spleen, data from individual mice. 
A2DR-A A2DR-B A2DR-C A2DR Mean 1 SD DBA/2-D DBA/2-E DBA/2-F DBA/2 Mean SD 
CD3 29.10 19.00 19.60 22.57 5.67 15.40 15.90 18.00 16.43 1.38 
CD3+CD8+ 18.40 22.20 18.90 19.83 2.06 26.20 25.80 26.60 26.20 0.40 
CD3+CD4+ 72.80 65.50 71.60 69.97 3.91 61.60 61.10 59.20 60.63 1.27 
CD4+CD8+ 3.40 4.10 3.80 3.77 0.35 3.40 3.50 2.70 3.20 0.44 
CD4 CD62LhiCD4410 52.50 45.60 49.10 49.07 3.45 43.20 50.40 56.20 49.93 6.51 
CD4 CD62LhiCD44hi 31.00 36.00 28.80 31.93 3.69 33.50 27.50 24.50 28.50 4.58 
CD4 CD62L1oCD4410 4.20 5.80 8.20 6.07 2.01 8.20 7.00 7.00 7.40 0.69 
CD4 CD62L1oCD44hi 10.10 10.30 11.10 10.50 0.53 12.20 14.00 8.30 11.50 2.91 
CD8 CD62LhiCD4410 48.80 45.90 55.10 49.93 4.70 45.10 37.50 46.30 42.97 4.77 
CD8 CD62LhiCD44hi 43.90 46.20 34.30 41.47 6.31 44.60 52.80 46.30 47.90 4.33 
CD8 CD62L1oCD4410 2.20 2.50 4.40 3.03 1.19 4.40 2.90 2.00 3.10 1.21 
CD8 CD62L1oCD44hi 3.40 3.70 3.90 3.67 0.25 3.90 4.00 3.80 3.90 0.10 
104 
8220+ 
LN Blood SDleen 
Figure S 2.1: B lymphocyte (B220+) population in Iymph nodes (LN), blood, and spleen 
of A2DR (c1ear bars) vs. DBA/2 (black bars) mice. 
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Figure S 2.2A: Dot plot representation of stimulations 
presented in Fig. 3C of Chapter 2. 
Figure S 2.2B: Representative stimulation of splenocytes from 
individual mice using individual peptide. 
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3 Activation of human CD4+ T cells by dodecameric human 
MHC Class II chimeras and their implication in vaccine 
development and immune therapy 
In an era where most therapeutic modalities and immunization strategies have 
become highly disease-specific, the concurrent development of targeted and 
sensitive immune-monitoring tools, and their subsequent standardization becomes 
imperative. Soluble peptide-MHC oligomers have been used in our laboratory and 
elsewhere for detection and tracking of antigen-specific CDS+ and CD4+ T 
lymphocytes in a ho st of applications. Despite the increased sensitivity of these 
reagents, it has been however observed that low-affinity TCR-bearing T 
lymphocytes are often undetected and that staining intensity reflects the overall 
avidity of these oligomeric molecules towards their respective TCR. In an attempt 
to increase the overall avidity of these reagents to seant numbers of CD4+ T cells, 
we undertook the design of multimeric MHC Class II molecules using murine 
immunoglobulin M lacking the joining (J) chain as a molecular scaffold. These 
novel reagents are targeted both towards the detection and ex-vivo expansion of 
antigen-specific CD4+ T lymphocytes. 
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SUMMARY 
ln the past decade, the qualitative and quantitative assessment of antigen-specific 
cellular immune responses has proved to be of utmost importance in 
understanding the clinical outcome in several diseases, specifically in tumors, 
acute and chronic viral infections, such as AIDS and hepatitis, and in the 
evaluation of immunization strategies. Many of the commonly used assays, 
starting with the conventional chromium release to ELIS POT or intracellular 
cytokine staining, are somehow biased relying mainly on the effector function of 
the cells to be detected. More recently, oligomeric tools (such as MHC Class 1 and 
Class II Tetramers) have been successfully developed in our laboratory and 
elsewhere and attested to be valuable tools in assessing antigen-specific cellular 
immune responses. These versatile tools are sensitive and specific, allowing direct 
ex-vivo analysis of T cells without the need of an in vitro amplification in most 
cases, and without being limited by the functionality of the cell, thus allowing 
visualization of all specific cells, whether precursors or effectors, functional or 
anergized. These reagents can be further combined with functional or phenotypic 
assays. Seeking to augment the overall avidity of these tools to scant numbers of 
antigen-specific T -lymphocytes, and thus improve the overall sensitivity of the 
reagents, we engaged in the development of novel MHC ClassII-chimeras of 
higher oligomerizing capacities, namely the dodecavalent MHC Class II 
DRl *IgM multimer. Here we describe the production of these reagents using an 
insect expression system. We then demonstrate the capacity of these molecules to 
activate Jurkat CD4+ T cell line in an antigen-specific and HLA-DRl restricted 
manner. 
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INTRODUCTION 
The recognition of antigenic peptides bound to MHC molecules (PMHC) at the 
surface of antigen presenting cells (APCs) by T lymphocytes bearing specific T-
cell receptors (TCRs) is a central event in the development of the adaptive 
immune response. After the initial priming, the pathogen-specific T cell 
population undergoes a series of characteristic processes including proliferation, 
up-/down-regulation of adhesion and co-stimulatory molecules as well as 
acquisition of effector functions such as cytotoxicity and/or cytokine production. 
Several reports have shown that sorne features of CD4+ T cell activation, 
including activation marker (CD25 and CD69) up-regulation and TCR 
intemalization, can be triggered by soluble reagents that multivalently engage 
TCRs, including anti-TCR antibodies1 and oligomeric pMHC complexes 2,3,4 . 
For soluble MHC class II oligomers, it appears that di mers are sufficient to initiate 
signalling in CD4+ T cells but that higher valency MHC oligomers, such as 
trimers and tetramers, are more potent than di mers at inducing CD4 T -ce Il 
activation 2,4. These data suggest that higher order oligomeric forms of soluble 
pMHC molecules might prove useful at inducing potent antigen-specific CD4+ T 
cell activation in the context of immunotherapeutic strategies. 
CD4+ T cells are at the center of immune responses. After being activated, naive 
CD4+ T cells differentiate into functional subsets called T helper type 1 (THl) and 
T helper type 2 (T H2) cells, based on their production of cytokine interferon 
(IFN)-y and interleukin (IL )-4, respectively 5. TH 1 cells secrete pro-inflammatory 
cytokines and are essential for protection against a variety of intracellular 
pathogens and viruses, whereas T H2 cells promote the generation of high affinity 
antibody responses and can be protective against extracellular pathogens. In 
addition, CD4+ T cells are an essential component of effective CD8+ T cell 
responses, being involved in both the development and maintenance of memory 
CD8+ T cells 6-10. Therefore, the elaboration of methods to activate and exp and 
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antigen-specific CD4+ T cells ex vivo is crucial for the development of effective T 
cell-based immunotherapies. 
Current immunotherapeutic strategies against various diseases, like cancer, 
involve the adoptive transfer of antigen-specific T cells (mostly CD8+) that have 
been expanded ex vivo Il. However, given the recognized role of CD4+ T cells in 
the generation of optimal immune responses against viruses and tumours, 
strategies to activate and expand CD4+ T cells in an antigen-specific manner are 
much needed, and might significantly improve the efficiency of T cell-based 
immunotherapies. The approaches currently used to expand the se T cells include 
culturing T cells in the presence of allogeneic feeder cells, EBV -transformed B 
cells or autologous dendritic cells in the presence of antigens (in the form of 
whole prote in or peptide). However, these techniques are time-consuming, 
necessitate the culture of allogeneic or virally-infected cells for antigen 
presentation and, especially in the case of dendritic cells, require a large number 
of allogeneic cells. Moreover, the use of co-culture systems might greatly limit the 
reproducibility and consistency of T cell expansion over time and over multiple 
donors. 
In this paper, we describe the development of novel human MHC Class II 
chimeras of higher oligomerizing capacities: the dodecavalent MHC Class II 
DRI *IgM multimers. We demonstrate that the se chimeric molecules are 
conformationally active when expressed in Drosophila 52 cells and that they have 
the capacity to potently stimulate human CD4+ T cells in an antigen-specific 
manner. 
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MATERIALS AND METHODS 
Generation of expression vectors 
The constant regions of murine IgM (mIgM) heavy (~) and light (K) chains were 
amplified from cDNA library by PCR using forward 5' CCG CTC GAG GCT 
AGC GAG AGT CAG TCC TTC CCA AAT 3' (~Ct), 5' CCG GAA TTC GCT 
AGC GCT GAT GCT GCA CCA ACT GTA 3' (K Ct) and reverse 5' CCC AAG 
CTT TGG TCA ATA GCA GGT GCC GCC TGT 3' (~Ct), 5' CCC AAG CTT 
GGA CCT TTG TCT CTA ACA CTC ATT CCT GTT GAA 3' (K Ct) primers, 
respectively. The amplicons were inserted into the intermediate pGEM-T 
(Promega, Madison, WI) and pBS KS(+) (Invitrogen) vectors to generate 
subc1ones. The C terminus alpha-linker-~ chain and the C terminus beta-linker-K 
chain segments were then c10ned into the custom made, methallothionine 
inducible (pMT), double promoter insect cell expression pCV vector. This vector 
contains the extracellular portion of the DRA 1 *0101 (DRa) and DRB1 *0101 
(DR~) chains, with their respective leader sequences, as well as a constitutively 
expressed eGFP gene. The heavy chain (~) ofmIgM was fused in frame at the C-
terminus of the HLA-DRa gene via a GGGSAS linker. Similarly, the light chain 
(K) of mIgM was fused in frame at the C-terminus of the HLA-DR~ gene via a 
GGGSAS linker. In the parental vector pCVDR1-HA306-31S the N-terminus of the 
HLA-DR~ gene is in tum covalently linked to the hemagglutinin (HA) peptide 
(HA306-31S:PKYVKQNTLKLAT)-encoding sequence via a flexible linker 
(GGGGSLVGGGSGGGGS). The generated vector was designated pCV -MHC-
DR1/HA306-31S IgM and was later modified to generate pCV-MHC-DR1/p24-5 
IgM expression vector by peptide encoding sequence substitution with Gag 
peptide p24-5 (WIILGLNKIVRMYS) of HIV -1. The sequences of fusion genes 
were confirmed by DNA sequencing. 
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Transfection and selection of S2 cells 
Drosophila melanogaster S2 cells were seeded (5x106/mL) ovemight in 25cm2 
vented cell culture flasks in 4ml of S&S medium (Shields and Sang M3 Insect 
Medium, Sigma-Aldrich) supplemented with 1 % FCS and 1 % antibiotic-
antimycotic reagent (Gibco). The transfection mixture consisted of 51lg of 
expression vector and 0.51lg of the selection vector pCOhygro in a final volume of 
100111 of S&S medium. Subsequently, 100111 of S&S containing 20111 of 
Lipofectin reagent (Invitrogen) was added to the transfection mixture and 
incubated for 15-20 minutes at room temperature. 1.8ml of S&S medium was then 
added and the final volume of 2ml transfection mixture was carefully overlaid on 
the S2 cells from which the ovemight culture media was aspirated. No FCS was 
added at this stage. After an ovemight incubation at 26°C, 8ml of fresh S&S 
containing 10% FCS was added to the flasks. To establish stable expression, cells 
were treated with 315U ofhygromycin B (Calbiochem, San Diego, CA) 48 hours 
following transfection. Culture medium was subsequently replaced once a week 
until stable clones were established. The cells were maintained at 26°C in S&S, 
10% FCS medium containing hygromycin B for 1-2 weeks until clones could be 
spotted and expanded in the flasks. Constitutive eGFP expression was monitored 
by flow cytometry from this point onward. The cells were then adapted to and 
transferred into a serum free Baculo Gold MAX XP medium (BD Biosciences) for 
expansion and heavy metal induction of prote in expression. 
Expression and purification of HLA-DR*OlOl IgM multimers 
Stable transfectants were expanded in Baculo Gold MAX XP containing 3 .15U of 
hygromycin B (Calbiochem) per ml, up to a maximum volume of 400mL in IL 
Coming sterile bottles at 26°C, on a rotary shaker at 140 rpm. Once a density of 
2.5 x 107 cells/ml was reached, cells were split at a ratio of 1:2 and induced with 1 
mM CUS04 for 4 days. Cells and debris were removed by centrifugation at 4 oC, 
3500rpm for 20 minutes in conical bottles. Supematants were passed through 
0.81lm followed by 0.21lm low protein binding filter (Millipore, Billerica, MA). 
The clarified medium was passed through a monoclonal L243 anti-HLA-DR (BD 
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Biosciences) or rabbit anti-IgM heavy chain (Jackson ImmunoResearch 
Laboratories) affinity column, at a flow rate of Iml/min at 4°C. The column was 
then washed with at least 10 bed volumes of phosphate-buffered saline (PBS), pH 
7.4. The HLA-IgM multimer was eluted with O.lM Glycine HCI, O.l5M NaCl 
elution buffer (pH 2.5), and immediately neutralized with lM Tris-HCl buffer, pH 
7.5. Fractions containing proteins were determined using the Bio-Rad Protein 
Detection Reagent (Bio-Rad). The fractions with higher density were pooled, 
buffer-exchanged with 20mM HEPES, 0.5M NaCl buffer (pH 8.1), and 
concentrated till 1-2 mg/ml by centrifugation through a 30-kDa molecular weight 
cutoff Centricon Plus-20 device (Millipore, Bedford, MA). 
Western Blot analysis 
Following induction, 10ml of culture supematant from each transfection was 
immunoprecipitated with IOIJ1 of LB243 monoclonal or rabbit anti-IJ chain 
antibody-conjugated CNBR-activated Sepharose-4B beads (Amersham 
Biosciences, Piscataway, NJ), by head-to-head rotation ovemight at 4°C. The 
beads were then washed with PBS and resuspended in 30~1 of sample buffer 
containing p-mercaptoethanol. The samples were incubated at 100°C for 2 
minutes and pelleted by brief centrifugation. Twenty ~l of sample was loaded on a 
5-10% Tris-glycine SDS-polyacrylamide gel and separated in running buffer (25 
mM Tris, 192 mM Glycine, 0.1 % SDS) by electrophoresis. The separated proteins 
were transferred onto a Hybond-C super nitrocellulose membrane (Amersham 
Biosciences) and blocked with 5% skim milk ovemight at 4°C. The membrane 
was incubated for Ihr at room temperature in 10ml 5% milk-PBS-0.05% Tween-
20 containing anti-~ chain (Jackson ImmunoResearch Laboratories) and anti-K 
chain (PharMingen) monoclonal antibodies conjugated to peroxidase, then 
washed three times with PBS 0.05% (v/v) Tween-20, and once with PBS alone. 
Bands were revealed and detected using the ECL Plus chemiluminescence reagent 
(Amersham Biosciences). Expression of HLA-DRI a and p chains was detected 
using rabbit polyclonal anti-DRa and anti-DRp primary antibodies, followed by 
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addition of goat anti-rabbit peroxidase-conjugated (GARP) secondary antibody 
(Molecular Probes). 
Gel Filtration analysis 
A Superose 6 HRIO/30 gel filtration column (Amersham Pharmacia) was used to 
determine the valance of purified MHC-IgM. The sample was passed at a flow 
rate of O.2ml/min through an HR-IO cell pre-equilibrated with PBS, connected to 
a GP-250 Programmer Plus FPLC instrument (Amersham Biosciences). 
T celllines 
Immortalized hum an T lymphoid Jurkat Al4 (generously gifted by Dr. Oreste 
Acuto, Institut Pasteur, Paris, France) and E6.1 (ATCC: TIB-152™) lines were 
used in the stimulation experiments. Al4 cells specifically recognize the HA 
peptide in the context ofDRI molecules, through expression ofHA-specific TCR, 
in addition they express CD28. E6-1 cells express an irrelevant TCR and CD28. 
LG-2 (DRlIDRI) B lymphoblastoid cell line (B-EBV) was provided by Larry 
Stem (Massachussets Institute of Technology) and was used as APC for activation 
control of JKT Al4 cells in the presence ofthe HA peptide. 
T cell activation assays 
96-well u-bottom microtiter plates (Falcon) were coated in wells designated for 
positive control samples with IlJg of anti-human CD3 (OKT3) antibody in 200/l1 
PBS and incubated ovemight at 4°C. Jurkat Al4 and E6.1 cells were seeded at 
IxIOs/well, in duplicate. Stimulations were performed with 200ng of MHC.IgM 
multimer per well, for 16hr at 37°C. 2.5/lg of soluble CD28 was added per 
stimulation. 
Staining and Flow Cytometry 
CD3 Alexa700, TCR FITC, CD25 PE and CD69 APC (BD Biosciences, San Jose, 
CA) antibodies were used to detect activation status of Jurkat cells. Briefly, 
following stimulation, cells were transferred to v-bottom 96-well plates, washed 
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once with PBS-2% FCS, and stained for 30min at 4°C for surface markers with 
corresponding fluorescent antibodies, followed by 2x wash with 200l-li of PBS-
2%FCS. Events were acquired on a BD LSR II and analyzed by Flow Jo software. 
Antibodies 
anti-HLA-DR clone L243 (BD Biosciences, San Jose, CA) and affiniPure rabbit 
antÎ-mouse IgM I-l chain specifie (Jackson ImmunoResearch Laboratories, West 
Grove, PA) were used in immunoprecipitation reactions and affinity columns. 
Peroxidase-conjugated rabbit anti-mouse IgM I-l chain specifie (Jackson 
ImmunoResearch Laboratories, West Grove, PA), HRP-conjugated rat anti-mouse 
Ig, K light chain monoclonal antibody (Pharrningen, San Diego, CA), rabbit 
polyclonal anti-DRa, rabbit polyclonal anti-DR~ sera (in-house production), and 
goat anti-rabbit peroxidise-conjugated (GARP) secondary antibody (Molecular 
Probes, Eugene, OR) were used in Western Blot experiments. CD28 pure, clone 
L293 (BD Biosciences, San Jose, CA) and purified anti-human CD3 (OKT3) were 
used in stimulation assays. For control murine IgM (K chain): purified mouse 
IgM, K isotype control (anti-TNP) (Pharrningen, San Diego, CA) and purified 
mouse IgM CDS7 (HNK-l) (Pharrningen, San Diego, CA) were used. 
RESULTS 
Vector generation and protein expression 
To produce dodecameric complexes of the human MHC class II prote in (soluble 
extracellular domain), the latter was covalently linked to a murine 
immunoglobulin M (IgM) molecular scaffold lacking the variable regions of both 
the heavy and light chains (Figure ! B). In the absence of the secretory J chain, 
IgM tends to produce higher levels of hexamers in lieu of its physiologie 
pentameric structure 12,13 . Using a short GGGSAS linker, the heavy chain of 
mIgM was fused in frame at the C-terrninus of the MHC DR! a gene, while the 
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/"-- light chain was fused in frame at the C-terminus of the MHC DR1 ~ gene (Figure 
1). The N-terminus of the HLA-DR~ gene was covalently linked to the 
hemagglutinin (HA) peptide (HA306-318: PKYVKQNTLKLAT) encoding 
sequence via a flexible linker (GGGGSL VGGGSGGGGS). The pCV -MHC-
DR1/HA306-318 IgM was later modified to generate pCV -MHC-DRl/p24-5 IgM 
expression vector by substituting the HA peptide encoding sequence with that of 
Gag p24-5 peptide from HIV -1. 
To verify whether the insect expression system supports production of MHCII-
IgM multimers, stable transfectants of Drosophila S2 cells were generated under 
Hygromycin B selection. The constitutive expression of GFP protein under the 
control of a pCopia promoter was used to screen for high expressors (Figure 2). In 
addition, western blot analysis of expression was performed on small scale culture 
supernatants to select positive clones. Cultures were then upscaled on an 
optimized shaker culture system, and expression of protein of interest was induced 
using CuS04 which targets the double methallothionine promoters (PMT) of the 
pCV vector (Figure lA). 
Biochemical assessment of MHC-IgM multimer 
Supernatants cleared from debris by centrifugation followed by filtration were run 
through affinity columns (either L243- or anti-IJ- coupled Sepharose matrix). To 
determine whether the expressed protein exhibited the expected molecular weight, 
the purified protein was run on a 10% SDS-PAGE under reducing conditions. 
Coomassie staining of purified samples demonstrated a shi ft in molecular weight 
corresponding to the expected molecular weight of chimeric chains (Figure 3A). 
To assess the conformational quality of the purified protein, equal amounts of 
culture supernatant were purified concurrently with L243 vs anti-IJ coupled beads 
followed by western blot analysis. Figure 4C demonstrates that both anti- IJ or 
conformational L243 antibodies were capable of efficiently binding and purifying 
the prote in at hand. To determine the oligomeric valence of the molecule of 
interest, a gel filtration assay on Superose 6 column showed a peak corresponding 
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to a molecular size of > 1400 kDa when compared to pentameric murine IgM and 
run against a panel of controls (suppl. Figure S3 & S4 in Appendix and data not 
shown ). 
T cell activation by MHC-IgM multimer 
Jurkat A14 (expressing HA- peptide-specifie TCR and CD28) and irrelevant 
Jurkat E6.1 (expressing an irrelevant TCR and CD28) cell lines were used to 
assess the ability of the MHC-IgM multimer to activate T cells. Activation of T 
cells was evaluated by measuring the upregulation of the early T cell activation 
marker CD69 and upregulation of the low-affinity IL-2 receptor CD25. The 
multimeric MHC-HA-DRl-IgM induced upregulation of both CD69 and CD25, 
as measured by flow cytometry (Fig. 4). CD69 and CD25 upregulation was 
measured 16 br following stimulation. MHC-HA- DR1- IgM complexes did not 
result in any significant activation in the E6.1 clone, and expression of activation 
markers were comparable to those observed at basal level. For positive control 
wells, anti- CD3 (+/-) CD28 were immobilized on plastic microtiter plates. 
Upregulation of CD69 and CD25 by Jurkat Al4 cells following stimulation 
with HA-DRl IgM but not p24-5-DRl-IgM mutimer. 
Stimulation assays were performed concurrently on A14 cells using specifie MHC 
HA-DRl-IgM and non-specifie p24-5-DRl-IgM multimers (Figure 6). p24-5-
DRl-IgM multimers did not result in any specifie stimulation of JKT A14 cells 
beyond background stimulation levels when 100 king at the CD69 and CD25 
activation profiles, implying that activation resulting from HA-DRl-IgM 
multimers in the presence of soluble CD28 is inherent to MHC restriction of the 
HA peptide multimerized on an immunoglobulin M scaffold, and that the latter Ig 
backbone does not result in non-specifie activation of cells. 
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DISCUSSION 
Several methods have been described for the detection of antigen-specific T cells 
over the past two decades. Most of the se essays rely on the functional 
characteristics of T cells, including proliferation and lytic activity. More recently, 
soluble MHC multimers have been used successfully in the detection and 
enumeration of both CD4+ and CD8+ T cells. Sorne reports have also described 
the involvement of these molecules in activation of antigen specifie T cells in 
vitro. It is well known that T cell receptors have transient and low binding affinity 
to peptide-MHC complexes. To this end, several groups have developed different 
forms of multivalent peptide-MHC complexes to study T cell specificity, and to 
increase the overall avidity of these tools to respective TCRs. The most widely 
used multimeric molecules include the Class 1 and Class II tetramers which use 
streptavidin as a molecular scaffold. In addition, immunoglobulin fusion 
proteins, using mainly IgG, have been used to produce multimeric MHC 
molecules. These have been reviewed extensively elsewhere 14,15. 
It has been previously shown that Drosophila cells possess a homologue (hsc72) 
of the immunoglobulin binding chaperone prote in (BiP) and are capable of 
efficiently secreting physiologically active IgG with substrate binding activity 
indistinguishable from that produced from vertebrate cell lines 16. In addition, 
results from our laboratory and other groups have supported the Drosophila 
expression system as feasible for the production of conformationally active MHC 
Class II molecules. Moreover, in the absence of the joining (J)-chain, IgM 
assembles into hexamers in lieu of its physiologie pentameric structure 12,13. 
In this paper we described the generation of a novel multimeric MHC Class II 
fusion protein, namely the dodecameric MHC Class II-IgM (Figure lB). We 
showed that Drosophila cells were capable of secreting multimers of MHC DRl 
molecules which were conformationally active as evidenced by 
immunoprecipitation and affinity purification using the anti-DRI confomational 
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antibody L243 (Figure 3 and 4). By Western Blot analysis we confirmed the 
presence of Ig heavy chain - IJ - DRa and Ig light chain - 1<; - DRp chimeric 
polypeptides, using monoclonal anti- Il and anti- K, or polyclonal anti-DRa and 
anti- DRp antibodies (Figure 3 and 4). These blots showed the expected shift in 
molecular weight of the polypeptides due to respective fusion of DRa and DRp 
chains with immunoglobulin domains when compared to the position of control 
murine IgM Il and K, chains. This was also observed on Coomassie stained 
polyacrylamide gels of purified samples. In addition, we tested the 
multimerization of the chimeric molecule, by Superose 6 Gel Filtration. 
ln the context of other oligomeric reagents (dimers, trimers, tetramers), studies 
have shown that even in the absence of antigen-presenting cells, soluble 
molecules of sufficient avidity activate T cell clones 17. Indeed, DRI-lgM 
multimers bearing an epitope from the HA antigen of influenza virus resulted in 
the activation of Jurkat A14 T cellline which expresses a TCR that recognizes the 
above epitope in the context of DRI molecules. This was evidenced by the 
upregulation of surface activation markers such as CD25 and CD69, following 
incubation with HA-DRI-lgM multimers. We observed that this activation 
necessitated the concurrent addition of soluble anti-CD28 antibody 18. In addition, 
we showed that this interaction was specific, since neither the addition of an 
irrelevant p24-5-DRI-lgM multimer on A14 cells, nor the stimulation of 
irrelevant Jurkat E6.1 cells by HA-DRI-lgM resulted in any significant 
upregulation of activation markers. 
The overall increased functional avidity and the stability of the complex formed 
with corresponding TCR's are key factors in identifying specific populations ofT-
cells in clinical as well as basic research laboratories. These properties are also 
crucial for improving the qualitative and quantitative value of multimer-based 
molecular monitoring of clinical trials of vaccination with ClassII-defined 
immunogens, and the isolation of those populations for further phenotypic and 
functional assays. However, the avidity of the TCR-MHC-peptide interaction 
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depends not only on the affinity of each TCR for its peptide-MHC ligand, but also 
on the density and clustering of TCR on the T ceIl surface. Thus, approaches that 
enhance the clustering and/or intemalization of TCR-peptide/MHC complexes are 
prime towards the ex-vivo manipulation of scant number and/or low affinity 
antigen-specific T ceIls 21. 
In its physiologic milieu IgM is known to 'staple' upon antigen binding 19,20. In 
contrast to rigid Streptavidin moieties in multimerization of MHC monomers, 
using IgM as a molecular scaffold offers a more flexible access for TCR binding 
due to the inherent characteristics of the immunoglobulin hinge region. Moreover, 
preliminary Fluorescence Microscopy studies using the multimeric DRI-IgM 
molecules showed evidence of TCR capping. Further experiments are underway 
to delineate the specific molecular mechanisms involved therein and the impact of 
experimental conditions, such as temperature, on staining. These novel reagents 
are promising as a multivalent system for identification, stimulation, and ex-vivo 
expansion of T cells, ultimately allowing the manipulation of the intensity and 
quality of T cell responses. 
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LEGENDS TO FIGURES 
FIGURE 1. A. Insect Expression Vector. pCV DR1 IgM is a methallothionine 
inducible (pMT), double promoter in sect cell expression vector. This vector 
contains the extracellular portion of the DRA1 *0101 (DRa) chain covalently 
linked to the heavy chain (~) of mIgM via a GGGSAS linker; and the 
ORBI *0101 (DR~) chain covalently linked to the light chain (K) of mIgM. The 
vector also contains the constitutively expressed eGFP gene. In the parental vector 
pCVOR1-HA306--31s the N-terminus of the HLA-DR~ gene is covalently linked to 
the hemagglutinin (HA) peptide (HA306--31S:PKYVKQNTLKLAT) encoding 
sequence via a flexible linker. B. Cartoon of the dodecameric IgM*MHCII 
fusion protein, without the immunoglobulin variable domain. In the absence 
of J chain, immunoglubin M molecules tend to assemble into hexamers. Here, the 
MHC DRl alpha chain was covalently linked via a GGGSAS linker to the 
constant Cfll domain of the IgM heavy chain, while the MHC DRI beta chain, 
carrying an antigenic peptide of interest, was covalently linked to the constant 
do main of the IgM K. light chain. 
FIGURE 2. Constitutive eGFP expression in transfected Drosophila in sect S2 
ceUs. Efficiency of transfection and selection of positive clones is monitored by 
assessing the constitutive expression of the egfp gene. Autofluorescence from 
untransfected S2 cells alone serves as negative control and in-house pCV DRI 
HA WT clones established for production of MHC Class II tetramers serve as 
positive control for MHC Class II DRI *IgM construct transfection. 
FIGURE 3. Biochemical assessment of purified protein. A. Following L243 
affinity column purification, the purity of the MHC II DRI *IgM fusion prote in 
was assessed through Coomassie Blue staining of proteins separated on a 10% 
SOS PAGE. Lane 1. 0.2flg BSA; Lane 2. 0.5flg BSA; Lane 3. Iflg BSA; Lane 4. 
0.5flg control mIgM; Lane 5. 0.5flg control mIgM; Lane 6. Iflg HA-DRI-IgM; 
Lane 7. 2flg HA-ORI-IgM; Lane 8. Sample 'flow through' after affinity column 
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elution. B. Following transfer on nitrocellulose membrane, samples were blotted 
with primary rabbit polyclonal anti-DRa and anti-DR~ antibodies, followed by 
secondary goat anti-rabbit HRP antibody. 
FIGURE 4. Immunoprecipitation and Western Blot analysis of fusion 
protein. To assess protein conformation following production in insect S2 cells, 
culture supernatants were tested by immunoprecipitation using either the 
conformational anti-DR L243 or anti-IgM heavy chain antibody-coupled 
Sepharose beads followed by Western Blot. A. Supernatant from S2 cells were 
immunoprecipitated (IP) with L243, beads were washed, boiled in sample buffer 
and mn on SDS-PAGE. Following transfer, membrane blotted with monoclonal 
anti-I< light chain antibody. Lane 1. Control mIgM; Lane 2. Untransfected induced 
S2 negative control; Lane 3. DRI-IgM-p24-5 (51lg of transfected DNA); Lane 4. 
DRI-IgMp24-5 (7.5Ilg of transfected DNA); Lane 5. DRI-IgM HA (7.5Ilg of 
transfected DNA). Kappa light chain originating from the L243 Ab used in 
immunoprecipitation is visible at 25KDa in lanes 3,4, and 5, due to loading of 
Sepharose beads coupled to L243 antibody (IgG 1<) . B. L243 IP. Blot by rabbit 
polyclonal anti-DR~ antibody (upper panel), and monoclonal anti-IgM Il and anti-
IgM 1< chain antibodies (lower panel). Lane 1. Control mIgM; Lane 2. DRI-IgM-
p24-5 (51lg of transfected DNA); Lane 3. DRI-IgM-p24-5 (7.5Ilg of transfected 
DNA); Lane 4. DRI-IgM-HA (7.5Ilg of transfected DNA). C. Comparison of 
Immunoprecipitation with anti-mouse IgM heavy chain vs. anti-DR L243 
antibodies. Membrane blotted with monoclonal anti-Il chain antibody. Lane 1. 
Control mIgM; Lane 2. Untransfected induced S2 negative control; Lane 3. DR1-
IgMp24-5; Lane 4. DRI-IgMp24-5 Lane 5. DR-I-IgM HA (7.5Ilg oftransfected 
DNA). Lane 6. untransfected induced S2 negative control; Lane 7. DRI-IgMp24-
5; Lane 8. DRI-IgMp24-5; Lane 9. DRI-IgM HA (7.5Ilg oftransfected DNA). 
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FIGURE 5. 
SA. Upregulation of CD69 and CD2S activation markers and blast formation 
following stimulation of A14 cells with DRI-IgM-HA multimer. A14 cells 
expressing HA-specifie TCR and CD28 were stimulated in vitro for 16hr in the 
presence of HA-DRI-IgM multimer and soluble anti-CD28 antibody. Stimulation 
with anti-CD3/anti-CD28 was used as positive control. Jurkat A14 cells did not 
display any significant basal level of CD69 and CD25 expression when cultured 
in medium alone. Following stimulation with HA-DRI-IgM, in addition to 
upregulation of CD69 and CD25 markers, blast formation characterized by 
increased si de and forward scatters could also be observed (cells delineated by an 
oval in SSC/FSC dot plot). 
SB. Absence of CD69 and CD2S upregulation following stimulation of E6.1 
ceUs with DRI-IgM-HA multimer. Control Jurkat E6.1 cells expressing an 
irrelevant TCR and CD28 were concurrently stimulated in vitro for 16hr in the 
presence of HA-DRI-IgM multimer and soluble anti-CD28 antibody. Stimulation 
with anti-CD3/anti-CD28 was used as positive control. E6.1 cells had minimal 
basal levels of CD69 and CD 25 expression when cultured in medium alone, 
which was more significant when soluble anti-CD28 was added to the medium 
(Figure 7). 
Sc. Background control. A14 and E6.1 cells were stimulated with soluble anti-
CD28 alone, to determine the effect of the latter on non-specifie expression of 
CD25 and CD69. There was no effect of addition ofanti-CD28 to A14 cells, since 
the expression levels were comparable to basal levels of expression as observed in 
Figure 5A. However, the addition of soluble anti-CD28 to E6.1 cells increased 
CD69 expression to levels comparable to that observed in stimulation with HA-
DRl-IgM + CD28 stimulation, indicating that the latter expression is due to CD28 
and hence non-specifie. 
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FIGURE 6. Irrelevant peptide MHC*lgM multimer does not stimulate A14 
cells. A14 cens were stimulated with either HA-DR1-IgM (panel B) or p24-5-
DR1-IgM (panel C) multimer, in conjunction with soluble anti-CD28, to 
determine the effect of non-specifie activation of HA specifie T cens due to an 
irrelevant MHC IgM multimer. Stimulation of A14 cens with HA-DR1-IgM alone 
(panel A) failed to result in significant activation, indicating the need of soluble 
CD28. 
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4 Original contribution to scientific knowledge 
The results presented in this thesis contribute original!y to scientific 
knowledge in several aspects: 
The mucosal immunizations carried out in the humanized mouse model in 
Chapter 2 set forth a unique model for pre-c1inical evaluation of new 
generation T cel! vaccines. We showed that mucosal administration of viral 
vector based vaccines results in antigen-specific, systemic primary T cel! 
responses. Moreover, we demonstrated that the presentation of epitopes from 
the HIV -1 subtype A Gag immunogen was restricted by the human MHC 
transgene. Previously identified epitopes in HIV -1 patients were found to be 
immunogenic in these mice. Therefore, we propose this model as a platform 
for mapping and identification of novel T-cell epitopes restricted by human 
MHC Class 1 and Class II molecules as weil as the delineation of functional 
signatures following mucosal immunization using viral vector based mucosal 
T cell vaccines. 
The reagents developed in Chapter 3 are pioneering in the attempt to generate 
conformationally active multimers of human MHC Class II DR 1 molecules 
covalently linked to antigenic epitopes. We showed that these molecules 
assemble indeed into higher valence multimers in an insect expression system 
without the need of further in vitro multimerization steps. We further tested 
the production of these molecules in mammalian systems. We demonstrated 
that these reagents were capable of the in vitro activation of Jurkat T cells in 
an antigen-specific manner. The development of su ch reagents for the 
detection and ex-vivo expansion of low-avidity T cell receptor (TCR) bearing 
T lymphocytes has critical implications in the context of such conditions as 
autoimmune diseases. 
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5 Discussion 
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5.1 Current status of HIV vaccine research 
The UNAIOS '2006 Report on the Global AlOS Epidemie' stated that in 2005 
nearly 39 million people worldwide were living with HIV, including 4.1 
million new cases, and that an estimated 2.8 million lost their lives to the 
disease that year (www.unaids.org). 
Since it was first identified over 20 years ago, the HIV/AIOS epidemic has 
undoubtedly exceeded ail anticipations of severity of global demographic, 
social, and economic impact 78. In addition, the inefficacy and inaccessibility 
of retroviral treatment regimens in areas worst hit by this expanding epidemic, 
highlight the imperative need of tangible progress toward a vaccine. In this 
respect, the 'XVI International AlOS Conference' 2006, joining over 24,000 
stakeholders of the field in Toronto, Canada, ri ghtfu Il y adopted the slogan 
'rime 10 De/iver' . 
Until recently, approaches to vaccine development for a range of different 
infectious diseases have been mainly empirical. Identification and delineation 
of the intricate immune correlates of protection during the natural course of an 
infection or following vaccine administration are becoming vital to the design 
and development of new generation vaccines against emerging as weil as 
existing diseases, such as AlOS 4,42,124, 125. 
The transmission of HIV -1 occurs primarily at mucosal surfaces. The mucosa 
is also possibly involved in the initial selection of the genotypic and 
phenotypic minor variants found during acute phases of infection 79, 80. To 
prevent dissemination of the virus to draining Iymph nodes and systemic 
Iymphoid tissue, and thwart the establishment of local and systemic reservoirs, 
generation of protective humoral and cell-mediated immune responses at 
mucosal sites of initial viral encounter must be targeted through the rational 
design of mucosal vaccines. Vaccines intended to prevent mucosal 
transmission of HIV should ideally be able to induce multiple immune 
effectors in the host including antibodies and cell-mediated immune responses 
both at mucosal and systemic sites 80,81. 
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The pathogenesis of HIV infection is complex and multipronged, with genetic 
susceptibility, host responses, and viral factors ail playing important roles in 
disease prognosis. The development of small animal models addressing sorne 
ofthese variables, including genetic background, is paramount in assessing the 
impact of different therapeutic, immune-intervention, and vaccine strategies. 
5.2 Rationale for mucosal delivery 
Recent understanding of the mechanisms involved in mucosal HIV 
transmission and the role of immune modulators, such as integrins and 
chemokines, in mucosal trafficking can aid the tailoring of new strategies to 
enhance AIDS vaccine efficacy 80,82. The stimulation of a mucosal response 
can be achieved through the administration of immunogens at mucosal 
inductive sites, where specialized, organized Iymphoepithelial follicular 
infrastructures exist. Subsequently, the corn mon mucosa-associated system 
regulating and coordinating immune responses at mucosal surfaces helps in the 
generation of responses at distal mucosal effector sites 83. This system, called 
the mucosa-associated Iymphoid tissue, is based on primed T and B 
lymphocytes that leave the original site of antigen presentation through the 
Iymphatics and blood, and selectively home to Iymphoid tissue at distant sites 
in gastrointestinal, respiratory, genitourinary, and other mucosa-associated 
regions. Furthermore, it has been observed that immunization by mucosal 
delivery of a host of live-attenuated or recombinant viral vectors expressing 
the antigen of interest, results in significant humoral and cellular responses 
both mucosally and systemically 84,85. 
5.3 Development of the transgenic CHAD model 
Over the years, transgenic animal models have contributed greatly to the 
progress made toward understanding the pathogenesis and immune 
mechanisms involved in many diseases. The Major Histocompatibility 
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Complex (MHC), a set of polymorphic genes expressed on the surface of host 
cells, is involved in antigen presentation to immune cells. The Class 1 HLA-
A*0201 and Class II HLA-DRBl*0101 alleles coyer nearly 40% and 10% of 
the human population, with sorne groups having frequencies as high as 56% 
and 31 %, respectively (source: www.allelefrequencies.net). 
Moreover, it has been previously demonstrated that in the generation of HLA 
transgenic models, the substitution of the CD8-binding a3 domain of A2.1 
with its murine counterpart leads to the effective generation of murine CTL 
responses to HLA-A2.1 restricted epitopes previously identified in humans 86, 
87. Similarly, the substitution of a2 / p2 CD4 biding domains of DR with a 
murine counterpart enhanced interaction with murine CD4, resulting in more 
potent responses 88,89,90. 
Taken the above into account, and in conjunction with Dr. D.B. Weiner's 
laboratory at the University of Pennsylvania, we generated a humanized 
chimeric A2DR (CHAD) transgenic mouse mode\. These mice concurrently 
express MHC Class 1 A*0201 and Class II DR*0101 molecules. Over the past 
3 years, we undertook careful derivation and selection of progeny to establish 
a colony of animais which are high expressors of the chimeric transgenes. 
Our study in Chapter 2 exploits this model to study HLA-A2-restricted 
cytotoxic T lymphocyte (CTL) and HLA-DRI-restricted CD4 helper 
responses following immunization with viral vectors expressing Gag. We 
observed that epitopes in Gag that serve as the dominant HLA-A2.1 or DR 1-
restricted determinant in the equivalent human response were also dominant in 
these mice. The use of synthetic peptide matrices covering the complete Gag 
sequence can further reveal similarities between the murine and human 
response repertoire and be crucial in the identification of novel 
immunodominant epitopes following immunization. 
When considering T cell responses by different species, our results confirm 
earlier results that the al and a2 domains of HLA-A2.1 and the a 1 and pl 
domains of HLA-DRI play a dominant role in determining the ensuing CD8 
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and CD4 repertoire, despite the chimeric murine regions of the molecules. Our 
results therefore support previous studies which have used HLA transgenic 
system for the delineation of HLA-Class 1 and Class II -restricted responses, 
providing a rational animal model for the design and assessment of new 
generation vaccines. 91,92,93. 
Interestingly, a recent study de scribes that the use of the HLA-A2IKb 
transgenic mice allowed the definition of an HLA-A *0201 binding peptide 
epitope that would have been rejected on the basis of predicted major 
histocompatibility complex binding affinity. This peptide was shown to bind 
to HLA-A *0201 but not murine Db or Kb molecules on the cell surface. 
Furthermore this peptide was shown to be immunogenic in vitro to human T 
cells from HLA-A2 healthy don ors 94. 
Altogether, this model emerges as a versatile small animal system (in lieu of 
non-human primates or human subjects) for the study of the correlates of 
protection and immune mechanisms involved in a multiplicity of vaccines in 
development and corresponding preclinical strategies. This transgenic mouse 
model also constitutes a unique system and platform in validation of the 
functionality of immune monitoring tools in preclinical stages, including novel 
multimeric tools, which following proof-of-concept, can be extrapolated to 
non-human primate or human samples. 
Still, species differences in structure and function of the immune system 
should be remembered and vigilance must be practiced wh en designing 
strategies and regimens, and extrapolating data to humans. Successful 
approaches in mice and even primates have often disappointingly failed when 
tested in humans. Results should always be considered with great care before 
applying to human disease especially if new concepts for therapy are 
concemed. Thus, animal models of HIV immunizations are relevant for 
primate or human trials, as long as the limitations of this approach are kept in 
mind. 
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5.4 Use of viral-vector vaccine delivery systems 
Live recombinant vesicular stomatitis viruses (rVSV) expressing foreign viral 
proteins have been used successfully in animal models, in immunizations 
against a variety of viral pathogens such as HIV, Influenza virus, Measles 
virus, Papillomavirus, Rabies virus, etc 95. rVSV vaccines administered 
mucosally induce pote nt systemic humoral and cellular immune responses, 
thus making this vector a promising candidate in the design of HIV 
primelboost immunization strategies. In addition, attenuated VSV -vectors 
have a major advantage of low-Ievel seropositivity in the human population. 
This makes VSV -based vaccines candidates for heterologous prime-boost 
protocols 96,97,98. Similarly, recombinant adenovirus based vaccines have been 
used recently in a variety of prime-boost regimens and have yielded promising 
data 84,41. Adenoviral vectors are limited however by pre-existing 
seropositivity in the population 99. 
We based our choice of vaccine vector and delivery regimen on preliminary 
data obtained from collaborating two CANY AC research laboratories and on 
results from the litterature. As described in Chapter 2, we adapted a mucosal 
vaccination protocol involving two viral vectors, namely rVSV and 
Adenovirus serotype 5, expressing HIV Gag from Subtype A. These vectors 
are also endowed with inherent adjuvant properties, thus dispensing the need 
for mucosal adjuvant co-delivery. The efficacy of this strategy, as weil as the 
generation and dissection of the ensuing cellular immune response was 
investigated. 
Our main interest lies in the identification and characterization ofHIV-specific 
T cell subsets both in the CD4 and CDS compartments following 
immunization, and the generation of long-term memory. To this end, thorough 
and multiparameter immune monitoring tools set forth in our laboratory and 
protocols carefully adopted to murine samples are employed. These allow the 
meticulous assessment of the phenotype, functional signature, and epitope 
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specificity of CD4+ and CD8+ T lymphocytes at different time points 
following immunization. 
Proliferation assays, class 1 and class II tetramer staining, ICS, and a panel of 
phenotypic markers are cUITently used through multiparameter flow cytometry 
to characterize the phenotype, receptor specificity, and functionality of the 
generated T cell subsets both at the acute and memory phases following 
vaccine administration. Phenotypic subsets of CD4+ T cell compartment are 
not fully elucidated in the mou se. In this report, we showed that i.n. route of 
immunization using two different viral vector based vaccines resulted in the 
generation of significant systemic antigen-specific CD4+ T -ce Il responses in 
the primary phase of the immune response. Our objective is to dissect the 
exact nature of this response. 
On the other hand, ev en though in the CUITent study we did not investigate 
specifie mucosal immune responses following vaccine administration, 
previous studies have shown that i.n. immunization with an adenoviral vector 
expressing HIV -1 Gag resulted in enhanced IgA responses in body secretions 
84. Further experiments for longitudinal analysis of these responses are 
discussed below, in Section 5.7. 
5.5 Development of multimeric MHC Class II molecules 
Immunotherapies for human immune-mediated diseases are proliferating 
rapidly. With these changes cornes the need to monitor patients for immune 
responses to therapy based on early surrogate markers for clinical responses. 
The development of fast and sensitive bioassays is central towards this end. 
As reviewed in Chapter l, over the past decade, novel state-of-the-art 
technologies for detecting cellular immunity have been developed. These tools 
allow the detection of T cells based on the antigen-specificity of their TCR. 
Concurrently, many of the new immunotherapeutic approaches and vaccine 
strategies that are currently being developed - in infectious disease, 
autoimmune disorder, or tumor models - are highly targeted and disease 
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specific. Thus careful assessment of the quantitative and qualitative nature of 
antigen-specific T cell response is critical in the validation of the efficacy of 
such treatments and immunizations, especially in clinical studies. 
In this context, optimization of multimeric reagents which characterize 
specific cellular immune responses is an ongoing process and of utmost value 
as a mean of detecting and tracking the fate of antigen-specific T lymphocytes 
as surrogate markers of clinical trials. For long, many attempts to ligate the T 
cell receptor to prote in substrates failed. This led to the assumption that the 
affinity of the T cell receptor was too low. 
Following the unravelling of the molecular structure of MHCs and antigen 
presentation of peptides to TCR, Mark Davis and John Altmann pioneered the 
development of oligomeric MHC reagents through the realization that by 
increasing the avidity of MHC molecules one could Iigate the corresponding 
TCR 67. Since, MHC Class 1 and Class II Tetramers have been developed and 
tested in identification of antigen specific T cell responses in a variety of 
disease models and their impact in the field of immunology has been 
significant in elucidating many specificities of the immune response. 
Our objective is to develop a novel, multimeric, versatile tool and ultimately 
assess its functionality within a specific HIV - immunization framework. 
Staining intensity being a direct function of T- cell receptor affinity, low 
affinity TCR's might not be recognized by existing tools such as tetramers. 
These low-affinity interactions, which are involved in processes such as 
autoimmunity, may often be missed. The elaboration of methods to efficiently 
activate and expand antigen specific CD4+ T cells ex vivo is crucial for the 
development of effective T cell based immunotherapies. 
On the other hand, it is established that the avidity of the TCR-MHC-peptide 
interaction depends not only on the affinity of each TCR for its MHC-peptide 
ligand, but also on the density and clustering ofTCR on the T cell surface. lt is 
important to state that the higher binding affinity of the MHC-multimers is 
caused by the increased avidity, which is the sum of the individual affinities of 
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the multiple MHC and TCR interactions. Moreover, together with factors such 
as the density of the MHC on the surface of the antigen-presenting cells, the 
concentration of peptide, and the type of costimulatory ligands available, TCR 
signaling leads to variable outcomes influenced by the strength of the 
interaction. 
Recent studies have compared activation profiles among T cells stimulated 
with dimers (bivalent class II-peptide complexes), trimers, or tetramers. These 
studies indicate that multimerization of TCRs occurs early after interaction 
with MHC oligomers, followed by rapid T cell activation. Fluorescent staining 
with the multimers was enhanced by this activation, suggesting that clustering 
of receptors and/or endocytosis occurs, which augments the fluorescent 
tetramer signal detection. There is thus a relationship between avidity, 
activation, and tetramer binding. It appears that, while high-avidity T cells are 
readily detected using MHC tetramer fluorescence technology, detection of 
low-avidity T cells may require simultaneous measurement of activation 
markers or methods to facilitate enhanced tetramer staining by improving TCR 
clustering and/or internalization 72,100,101. Researchers have exploited this 
association between tetramer binding and T cell activation, since even in the 
absence of antigen-presenting ce Ils, soluble tetramers of sufficient avidity can 
activate T cell clones, as determined by both surface activation markers and 
cytokine secretion 70,72,101 
On the other hand, while low-affinity TCRs were shown to only bind MHC 
class II-peptide complexes at 37°C, high-affinity TCR stained at 40C 102. 
Fluorescently labeled liposomes added to CD4+ T cells co-localized with 
markers for endocytotic compartments, indicating that these T cells have the 
potential to internalize multimers. 
In the present report, and in order to increase the overall avidity of soluble 
MHC Class II reagents, we used the murine immunoglobulin M (lgM) as a 
molecular scaffold to multimerize HLA-DRI molecules. As demonstrated in 
Chapter 3, this system allows the identification (through stimulation) of 
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antigen-specific T ceIls, offering a new tool to study and manipulate the 
intensity and quality of the T ceIl responses 117. 
It is noteworthy that the hinge region in the immunoglobulin scaffold provides 
a flexible access for T-ceIl binding in contrast to the conventional rigid 
Streptavidin moieties used in monomer oligomerization in the generation of 
class 1 and class II tetramers. Similarly, IgM takes a characteristic 'staple' 
conformation upon binding to antigen in physiologic conditions, and this 
structural tendency would ultimately assist the concurrent ligation of multiple 
TCRs. 
Approaches based on enhancing the clustering and/or internalization of TCR-
tetramer complexes are desirable and additional molecular tools which 
facilitate TCR multimerization on the ceIl surface and increase the overaIl 
avidity of interaction achieved in large complexes may lead to new avenues in 
the better characterization of low-affinity T lymphocytes and the isolation of 
those populations. 
5.6 Rationale for insect expression 
S2 Drosophila cells have conserved a homologue (heat shock cognate protein: 
hsc72) of the immunoglobulin binding chaperone protein (BiP). Hsc72 was 
shown to chaperone the secretion of mature and conformationaIly active IgG, 
with a production efficiency of 1 )lg/ml (by ELISA) 103. In addition, our 
laboratory and others have used insect expression systems for the production 
ofMHC Class II monomers 69. 
We based our hypothesis on the above observations, and undertook expression 
of IgM based multimers in the Drosophila expression system. Since, we have 
introduced several modifications to support and optimize production of a 
dodecameric molecule that measures over 1400 kDa. 
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5.7 Future Directions and Conclusion 
5.7.1 Prime-boost immunization strategies and immune monitoring. 
Studies are currently underway in mice, which include the study of T cell 
repertoire diversity following different combinations of prime/boost strategies 
using the vectors characterized in primary responses in Chapter 2, namely 
VSV -A V3 and Adenovirus serotype 5 expressing Gag A from HIV -1. 
Furthermore, we have adapted our multiparameter functional assays to murine 
samples, and functional signatures following immunization will be explored 
using a combination of proliferation and intracellular staining assays. 
In addition, we have established the protocol and necessary logistics and 
ethical requirements to be able to perform vaccinia challenge in immunized 
HLA A2DR mice to assess ensuing protection. Other studies that are planned 
include the longitudinal study of memory generation (including adoptive 
transfer of antigen-specific cells into naïve transgenics) and the delineation of 
different murine CD4 memory subsets, an area that so far has not been fully 
ventured. 
This mouse model is also being exploited as a model to validate immune 
monitoring tools, such as HLA-DRI tetramers presenting different epitopes 
from HIV. Given the fact that these mice responded to common 
immunodominant epitopes indentified in human subjects, we are in the process 
of establishing immortalized clones from splenocytes of Gag immunized 
groups, for quality control of our in hou se MHC Class II tetramer production. 
These clones will also be useful in the validation of the novel multimeric 
reagents developed in Chapter 3, namely the p24-5 DRI *IgM dodecamer. The 
efficacy of these reagents will be tested versus conventional MHC Class II 
tetramers. 
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5.7.2 Large-scale production and validation of multivalent MHC*IgM 
As mentioned above, the HLA-A2DR mou se model will be of valuable use in 
the validation and optimization of the multivalent MHC reagent developed in 
Chapter 3. 
Since its development and production in insect Drosophila system, we have 
generated an array of constructs incorporating both variants of the murine 
immunoglobulin, that is in the presence or absence of the variable domains of 
the heavy and light chains of IgM. We have further tested these constructs in 
several systems, including a Bacu/ovirus expression system, and eukaryotic 
293T and 293E expression systems, using vectors such as pcDNA3 (Figure S8 
and S9 in Appendix) and SRalpha (Figure S6-S 1 0 in Appendix). 
A visual summary of these approaches is presented in the subsequent 
Appendix section ofthis thesis. 
Briefly, in collaboration with BD Biosciences, Pharmingen, we have cloned 
the respective chimeric chains into the Baculovirus 2plO expression vector, 
which similarly to the Drosophila system, incorporates both chains within a 
single vector. We have successfully up-scaled production of the chimeric 
protein in the BD in-hou se high-throughput Baculovirus system (Figure S5 in 
Appendix). On the other hand, in the mammalian expression system we have 
adopted an approach of co-transfection using dual vectors, each expressing 
either the chimeric DRa-IgMIl or pep-DRp-IgMI\ chains (Fig. S6-S 10 in 
Appendix). 
The reagents developed through the different systems above are yet to be 
evaluated for their valency, conformation, stability, and function. The 
biochemical complexity of this biomolecule requires fine control along each 
step of production and purification. Furthermore we are in the process of 
testing, standardizing, and optimizing direct staining protocols of IgM-MHC 
class II oligomers on T cell lines and primary cells. In collaboration with BD 
Biosciences we are also considering approaches for direct coupling of this 
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multivalent molecule to tluorochromes to allow performance of single step 
direct visualization assays. 
In conclusion, the MHC multimeric tools developed in the framework of this 
project will permit the identification and characterization of antigen-specific 
CD4 T cells bearing low affinity TCR against peptidelMHC complexes, the 
characterization of peptide epitopes derived from cDNA library targeted by 
major histocompatibility complex (MHC)-restricted CD4 T cells of unknown 
specificity, and the ex-vivo tailoring of the quality and ofT cell responses. 
Once established, we would test these novel multimers in the context of acute 
antiviral immune responses and adapt conditions for use in the analysis of 
mouse or human samples. 
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Figure 51. 5chematic presentation of mlgM*MHCII dodecamer 
51a. Cartoon of MHCII*IgM constant construct (without variable-domain) 
51b. Cartoon of MHCII*IgM construct including variable domain 
51c. Western Blot with monoclonal anti-IgM heavy chain 
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Figure 54. Gel Filtration Chromatography (FPLC 5uperose6) on 
mouse IgM-MHC II DR1 Chimera 
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Figure 55. Coomassie Blue staining of mIgM*DRl 
expressed in Saculovirus expression system. 
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Figure 56. Clones of IgM*DRl chimeric chains in 5Ralpha mammalian expression system. 
The SRalpha promoter is composed of SV40 early promoter/enhancer & the R-US' of the L TR of the HTLV-1. 
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Figure 510. Western Blot using monoclonal anti-IJ chain Ab on 293T cell Iysates 
following 24hr, 48hr, and 78hr of transfection by 5Ralpha vectors of 
either constant or variable constructs. 
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ID VOIJS avez répondu le 8/25/2006 à 10:48. 
Lina lI<alfayan 
De: 
À: 
Cc: 
Objel: : 
Pièce:s jointes : 
Smith, Stephanie (ELS-OXF) [ST.Smith@elsevier.com] 
Lina Kalfayan 
RE: Obtain Permission 
Date: ven. 8/25/2006 5:45 
We hereby grant you permission to reproduce the material detailed below in 
your thesis at no charge subject to the following conditions: 
1. If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another 
source, permission must also be sought from that source. If such permission 
is not obtained then that material may not be included in your 
public:ation/copies. 
2. Suitable acknowledgment to the source must be made, either as a 
footnote or in a reference Iist at the end of your publication, as follows: 
"Reprinted from Publication title, Vol number, Author(s), Title of 
article, Pages No., Copyright (Year), with permission from Elsevier". 
3. Reproduction of this material is confined to the purpose for which 
permission is hereby given. 
4. This permission is granted for non-exclusive world English rights 
only. For other languages please reapply separately for each one required. 
Permi:ssion excludes use in an electronic form. Should you have a specifie 
electronic project in mind please reapply for permission. 
5. This includes permission for the Library and Archives of canada to 
supply single copies, on demand, of the complete thesis. Should your thesis 
be published commercially, please reapply for permission. 
Yours sincerely 
Steph Smith 
Rights Assistant 
Elsevier Ltd 
The Boulevard 
Langl'ord Lane 
Kidlington 
Oxford OX5 1GB 
-----Original Message-----
From: lina.kalfayan@mail.mcgill.ca [mailto:lina.kalfayan@mail.mcgill.ca] 
Sent: 25 August 200602:10 
To: permissions@elsevier.com 
Subject: Obtain Permission 
This Email was sent from the Elsevier Corporate Web Site and is related to 
Obtain Permission form: 
Page 1 sur 2 
https://exchange.mcgill.calexchange/lina.k. .. :%200btain%20Pennission-2.EML?Crnd=ope 2006-08-28 
Product: Customer Support 
Component: Obtain Permission 
Web server: http://www.elsevier.com 
IP address: 10.10.24.148 
Client: Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1) 
Invoked from: 
bttR.;,l /www.elsevier.com/wps/find/obtainpermissionform .cws home?isSubmitted=y 
es&navigateXmIFileName=/store/prod_webcache_act!framework_supportjobtainperm 
ission.xml 
Request From: 
Ms Lina Kalfayan 
McGili University 
4000 de maisonneuve w. #3106 
H3Z1.J9 
Montreal 
Canada 
Contact Details: 
Telephone: 15148650025 
Fax: 
Email Address: lina.kalfayan@mail.mcgill.ca 
To use the following material: 
ISSN/ISBN: 
Title: 
Author(s): 
Volume: 
Issue: 
Year: 
Pages: 
Article title: 
Journal of Immunological methods 
Hugues S et al 
268 
1 
2002 
83 - 92 
generation and use of alternative multimers 
How much of the requested material is to be used: 
Figure 1 and Figure 2 
Are you the author: No 
Author at institute: No 
How/where will the requested material be used: In a thesis or dissertation 
Details: 
PhD thesis, Litterature review section 
Additional Info: 
- end -
For further info regarding this automatic email, please contact: 
WEB APPliCATIONS TEAM (esweb.admin@elsevier.co.uk) 
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Lina Kalfayan 
De: Smith, Stephanie (ELS-OXF) 
[ST.Smith@elsevier.com] 
Date: ven. 8/25/2006 5:42 
À: Lina Kalfayan 
Cc: 
Objet: RE: Obtain Permission 
Pièces jointes: 
We hereby grant you permission to reproduce the material detailed below in 
your thesis at no charge subject to the following conditions: 
1. If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another 
source, permission must also be sought from that source. If such permission 
is not obtained then that material may not be included in your 
publication/copies. 
2. Suitable acknowledgment to the source must be made, either as a 
footnote or in a reference Iist at the end of your publication, as follows: 
"Reprinted from Publication title, Vol number, Author(s), Title of 
article, Pages No., Copyright (Year), with permission from Elsevier". 
3. Reproduction of this material is confined to the purpose for which 
permission is hereby given. 
4. This permission is granted for non-exclusive world English rights 
only. For other languages please reapply separately for each one required. 
Permission excludes use in an electronic form. Should you have a specifie 
electronic project in mind please reapply for permission. 
5. This includes permission for the Library and Archives of Canada to 
supply single copies, on demand, of the complete thesis. Should your thesis 
be published commercially, please reapply for permission. 
Yours sincerely 
Steph Smith 
Rights Assistant 
Elsevier Ltd 
The Boulevard 
Langford Lane 
Kidlington 
Oxford OX5 1GB 
-----Original Message-----
From: Iina.kalfayan@mail.mcgill.ca [mailto:lina.kalfayan@mail.mcgill.ca] 
Sent: 25 August 2006 01:58 
To: permissions@elsevier.com 
Subject: Obtain Permission 
This Email was sent from the Elsevier Corporate Web Site and is related to 
Obtain Permission form: 
https://exchange.mcgi ... :%200btain%20Pennission.EML?Cmd=ope 2006-08-28 
Product: Customer Support 
Component: Obtain Permission 
Web server: http://www.elsevier.com 
IP address: 10.10.24.149 
Client: Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1) 
Invoked from: 
Page 2 sur 2 
http://www.elsevier.com/wps/find/obtainpermissionform.cws home?isSubmitted =y 
es&navigateXmIFileName=/store/prod_webcache_act/framework_support/obtainperm 
ission.xml 
Request From: 
Ms Lina Kalfayan 
McGiII University 
4000 de maisonneuve w. #3106 
H3Z1J9 
Montreal 
Canada 
Contact Details: 
Telephone: 5148650025 
Fax: 
Email Address: lina.kalfayan@mail.mcgill.ca 
To use the following material: 
ISSN/ISBN: 
Title: 
Author(s): 
Volume: 
Issue: 
Year: 
Pages: 
Article title: 
Journal of Immunological Methods 
Fahmy TM et al 
268 
1 
2002 
93 - 106 
Probing T cell membrane 
How much of the requested material is to be used: 
figure 1 
Are you the author: No 
Author at institute: No 
How/where will the requested material be used: [how_used] 
Details: 
PhD thesis, Litterature Review 
Additional Info: 
- end-
For further info regarding this automatic email, please contact: 
WEB APPUCATIONS TEAM (esweb.admin@elsevier.co.uk) 
https://exchange.mcgi ... :%200btain%20Permission.EML?Cmd=ope 2006-08-28 
AFTERWORD 
Looking forward to getting this degree - once rightfully known as Doctor of 
Philosophy - and which, in our CUITent day realities, has shrunk to a mere 
Ph.D., in my bewilderment, l allow myselfto end this phase ofmy life with this 
afterword, inviting aIl modem-day scientists, doctors of philosophy, 
philosophers, thinking minds, and whoever might one day come across this 
manuscript, to take a moment to reflect upon the following quote from the Il th 
century Sufi poet Hakim Sanai: 
"If, my love, 1 had to describe to you the way, 
1 would say clearly: 
Turn to Life for the Truth 
And not to empty truths for Life ... " 
From the 'Walled Garden of Truth' -
'Hadiqat ul-Haqiqat', Hakim Sanai. 
